data_5x3l_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 5x3l _Structure_validation_residue.Date_analyzed 2017-02-10 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.52 -0.203 0 CA-C-O 121.523 0.678 . . . . 0.0 109.519 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.413 ' CG1' ' CD1' ' A' ' 9' ' ' LEU . 9.2 t -79.31 -30.02 13.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 114.814 -1.084 . . . . 0.0 110.638 179.599 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . 0.458 ' CD2' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -42.14 -25.38 0.07 Allowed 'General case' 0 CA--C 1.528 0.13 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.752 179.942 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.458 ' N ' ' CD2' ' A' ' 6' ' ' PHE . . . -66.02 -38.61 94.25 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.725 -0.75 . . . . 0.0 111.605 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.409 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -80.8 -51.99 8.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.67 0.272 . . . . 0.0 110.41 179.41 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.42 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 2.9 mp -51.96 -38.47 56.64 Favored 'General case' 0 CA--C 1.529 0.156 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.897 179.766 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.515 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -50.75 -21.45 1.64 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.183 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.47 ' O ' ' N ' ' A' ' 15' ' ' ARG . 1.7 ptm180 -88.77 -41.39 12.56 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.551 -179.183 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.467 HG13 ' N ' ' A' ' 13' ' ' LEU . 3.7 pt -54.62 -35.46 32.38 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.178 0 C-N-CA 120.369 -0.533 . . . . 0.0 110.817 -179.637 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.515 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.05 -26.98 67.75 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 177.879 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.641 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -93.96 -17.02 42.33 Favored Glycine 0 N--CA 1.444 -0.806 0 CA-C-N 115.187 -0.915 . . . . 0.0 111.532 178.273 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.47 ' N ' ' O ' ' A' ' 11' ' ' ARG . 2.5 mpt_? -100.35 26.58 6.46 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 120.956 0.408 . . . . 0.0 110.716 179.718 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.464 HG13 ' O ' ' A' ' 13' ' ' LEU . 7.3 p -112.19 -50.42 5.9 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.02 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 179.67 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.415 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 40.4 mm -150.15 83.82 5.97 Favored Pre-proline 0 N--CA 1.425 -1.703 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 174.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.641 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.8 Cg_endo -91.37 -179.18 1.34 Allowed 'Trans proline' 0 N--CA 1.422 -2.684 0 C-N-CA 124.904 3.736 . . . . 0.0 109.808 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.55 -29.46 70.72 Favored 'General case' 0 C--N 1.299 -1.604 0 CA-C-N 115.152 -0.931 . . . . 0.0 111.001 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.5 t . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.287 -0.863 . . . . 0.0 111.092 179.908 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.518 -0.253 0 CA-C-O 121.577 0.703 . . . . 0.0 109.398 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.464 ' O ' ' N ' ' A' ' 8' ' ' ARG . 5.5 t -76.47 -30.0 19.09 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.448 0 CA-C-N 114.658 -1.155 . . . . 0.0 110.394 179.406 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . 0.451 ' CD2' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -41.56 -25.61 0.05 Allowed 'General case' 0 C--O 1.232 0.138 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.738 179.936 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.451 ' N ' ' CD2' ' A' ' 6' ' ' PHE . . . -68.89 -42.01 80.18 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.359 179.045 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.464 ' N ' ' O ' ' A' ' 5' ' ' VAL . 2.0 mpt_? -71.03 -54.36 11.46 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 179.088 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.411 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 2.3 mp -50.58 -33.57 22.47 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 120.966 0.412 . . . . 0.0 110.71 179.646 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.474 ' HA ' HD23 ' A' ' 13' ' ' LEU . . . -49.61 -21.44 1.01 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.917 -0.583 . . . . 0.0 112.076 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.521 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.2 ptm180 -88.73 -42.43 11.95 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.326 -179.265 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.452 HG13 ' N ' ' A' ' 13' ' ' LEU . 3.8 pt -54.19 -34.38 27.07 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.181 0 C-N-CA 120.376 -0.529 . . . . 0.0 110.927 -179.685 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.474 HD23 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.39 -28.89 68.99 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 178.023 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.648 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.67 -15.95 44.33 Favored Glycine 0 N--CA 1.445 -0.76 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.59 178.271 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.521 ' N ' ' O ' ' A' ' 11' ' ' ARG . 9.1 mpt_? -100.71 26.69 6.55 Favored 'General case' 0 N--CA 1.465 0.316 0 C-N-CA 122.768 0.427 . . . . 0.0 110.642 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.437 HG13 ' O ' ' A' ' 13' ' ' LEU . 7.2 p -111.77 -50.41 6.05 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.994 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.427 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 42.4 mm -150.2 83.51 6.04 Favored Pre-proline 0 N--CA 1.425 -1.685 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 174.61 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.648 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.5 Cg_endo -91.35 -179.15 1.34 Allowed 'Trans proline' 0 N--CA 1.423 -2.653 0 C-N-CA 125.002 3.802 . . . . 0.0 109.95 178.782 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.01 -26.95 69.09 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 115.135 -0.939 . . . . 0.0 111.135 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 18.6 t . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.279 -0.867 . . . . 0.0 111.174 179.951 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.52 -0.193 0 CA-C-O 121.467 0.651 . . . . 0.0 109.483 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 9.3 t -78.04 -30.33 16.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 114.827 -1.079 . . . . 0.0 110.47 179.389 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . 0.448 ' CD1' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -41.8 -25.28 0.05 Allowed 'General case' 0 CA--C 1.529 0.138 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.78 -179.978 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.448 ' N ' ' CD1' ' A' ' 6' ' ' PHE . . . -64.18 -40.25 97.85 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.721 -0.752 . . . . 0.0 111.476 179.124 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -79.72 -51.14 9.59 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.751 0.31 . . . . 0.0 110.364 179.277 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.414 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 1.4 mp -51.32 -38.28 52.16 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-O 121.09 0.471 . . . . 0.0 110.507 179.515 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.503 ' HA ' HD23 ' A' ' 13' ' ' LEU . . . -48.7 -21.12 0.55 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.949 179.567 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.481 ' O ' ' CD ' ' A' ' 15' ' ' ARG . 1.3 ptm180 -88.17 -42.31 12.41 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.235 -179.394 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.464 HG13 ' N ' ' A' ' 13' ' ' LEU . 5.1 pt -55.53 -34.68 35.66 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.17 0 C-N-CA 120.329 -0.549 . . . . 0.0 110.734 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.503 HD23 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.38 -27.25 67.72 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 178.053 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.636 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.06 -16.74 43.15 Favored Glycine 0 N--CA 1.443 -0.834 0 CA-C-N 115.276 -0.875 . . . . 0.0 111.303 178.197 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.481 ' CD ' ' O ' ' A' ' 11' ' ' ARG . 1.7 mpt_? -100.22 26.91 6.04 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.004 0.43 . . . . 0.0 110.528 179.602 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.489 HG13 ' O ' ' A' ' 13' ' ' LEU . 9.1 p -111.45 -49.82 6.22 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.038 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.437 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 40.5 mm -150.2 83.27 6.12 Favored Pre-proline 0 N--CA 1.424 -1.738 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 174.514 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.636 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.1 Cg_endo -91.39 -179.05 1.31 Allowed 'Trans proline' 0 N--CA 1.424 -2.616 0 C-N-CA 124.916 3.744 . . . . 0.0 109.801 178.696 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.39 -30.24 69.96 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.006 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 17.2 t . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.234 -0.889 . . . . 0.0 111.283 179.892 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.518 -0.281 0 CA-C-O 121.587 0.708 . . . . 0.0 109.354 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.461 ' O ' ' N ' ' A' ' 8' ' ' ARG . 5.5 t -74.64 -30.08 24.43 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.428 0 CA-C-N 114.621 -1.172 . . . . 0.0 110.279 179.237 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -42.78 -25.45 0.09 Allowed 'General case' 0 C--O 1.232 0.141 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.375 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -69.77 -40.67 75.57 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.816 -0.707 . . . . 0.0 111.388 178.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.461 ' N ' ' O ' ' A' ' 5' ' ' VAL . 1.0 OUTLIER -72.43 -54.14 10.19 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.772 0.32 . . . . 0.0 110.389 179.262 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.409 ' O ' ' CG1' ' A' ' 12' ' ' ILE . 1.7 mp -53.8 -35.03 60.95 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 121.057 0.456 . . . . 0.0 110.718 179.623 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.536 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -47.72 -21.6 0.41 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.759 -0.655 . . . . 0.0 112.209 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.458 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.2 ptm180 -89.1 -41.54 12.23 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-N 116.603 -0.272 . . . . 0.0 111.469 -179.574 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.445 HG13 ' N ' ' A' ' 13' ' ' LEU . 4.9 pt -54.87 -34.73 31.57 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.234 0 C-N-CA 120.497 -0.481 . . . . 0.0 110.82 -179.7 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.536 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -65.3 -27.16 68.43 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.811 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.612 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -93.65 -19.38 34.9 Favored Glycine 0 N--CA 1.444 -0.768 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.506 178.166 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.458 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.7 mpt_? -100.16 26.28 6.64 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 120.863 0.363 . . . . 0.0 110.638 179.571 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.473 HG13 ' O ' ' A' ' 13' ' ' LEU . 7.5 p -112.07 -49.63 6.0 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.064 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.406 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 38.7 mm -149.74 83.19 6.4 Favored Pre-proline 0 N--CA 1.424 -1.748 0 N-CA-C 106.51 -1.663 . . . . 0.0 106.51 174.823 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.612 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.0 Cg_endo -91.58 -178.94 1.24 Allowed 'Trans proline' 0 N--CA 1.423 -2.618 0 C-N-CA 125.048 3.832 . . . . 0.0 109.746 178.692 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.92 -30.56 68.0 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.845 179.786 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.189 -0.91 . . . . 0.0 111.182 179.984 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.521 -0.153 0 CA-C-O 121.398 0.618 . . . . 0.0 109.798 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.432 ' O ' ' N ' ' A' ' 8' ' ' ARG . 15.0 t -72.82 -23.81 20.83 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.425 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.282 179.323 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -41.54 -25.24 0.04 OUTLIER 'General case' 0 C--N 1.333 -0.132 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.633 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.417 ' N ' ' C ' ' A' ' 5' ' ' VAL . . . -67.22 -41.03 92.33 Favored Glycine 0 N--CA 1.45 -0.423 0 CA-C-N 115.577 -0.738 . . . . 0.0 111.68 179.217 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.432 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -73.62 -54.74 7.46 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 179.251 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.429 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 2.8 mp -52.44 -34.53 49.17 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 120.982 0.42 . . . . 0.0 110.741 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.515 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -50.28 -21.51 1.41 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.989 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.501 ' O ' ' N ' ' A' ' 15' ' ' ARG . 3.1 ptm180 -88.68 -42.78 11.77 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.392 -179.311 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.47 HG13 ' N ' ' A' ' 13' ' ' LEU . 4.8 pt -53.39 -35.89 25.71 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.194 0 C-N-CA 120.364 -0.534 . . . . 0.0 110.823 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.515 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -65.03 -28.73 69.69 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 178.133 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.638 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.6 -16.16 43.75 Favored Glycine 0 N--CA 1.445 -0.763 0 CA-C-N 115.269 -0.878 . . . . 0.0 111.672 178.412 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.501 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.8 mpt_? -100.46 26.69 6.4 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 122.721 0.408 . . . . 0.0 110.733 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.422 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 7.1 p -111.92 -50.22 6.01 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.015 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.422 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 42.6 mm -150.21 83.5 6.04 Favored Pre-proline 0 N--CA 1.424 -1.731 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 174.715 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.638 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.9 Cg_endo -91.36 -179.09 1.32 Allowed 'Trans proline' 0 N--CA 1.423 -2.629 0 C-N-CA 124.98 3.787 . . . . 0.0 109.754 178.774 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.61 -29.54 70.78 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.983 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 20.8 t . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.297 -0.859 . . . . 0.0 111.195 179.95 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.519 -0.242 0 CA-C-O 121.53 0.681 . . . . 0.0 109.507 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.464 ' O ' ' N ' ' A' ' 8' ' ' ARG . 6.2 t -75.53 -29.2 20.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.402 179.384 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -41.53 -25.67 0.05 Allowed 'General case' 0 C--N 1.333 -0.121 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.661 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -65.18 -40.55 96.86 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.383 179.179 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.464 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -75.85 -52.55 10.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.789 0.328 . . . . 0.0 110.14 179.136 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.42 ' O ' ' CG1' ' A' ' 12' ' ' ILE . 5.1 mp -52.43 -38.53 59.39 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.006 0.431 . . . . 0.0 110.618 179.609 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.481 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.3 -21.18 0.78 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.981 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.519 ' O ' ' N ' ' A' ' 15' ' ' ARG . 2.2 ptm180 -88.13 -42.08 12.59 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.338 -179.311 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.445 HG13 ' N ' ' A' ' 13' ' ' LEU . 4.5 pt -55.36 -34.79 34.83 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.218 0 C-N-CA 120.35 -0.54 . . . . 0.0 110.838 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.481 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.45 -27.73 68.04 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 178.089 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.637 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.7 -17.22 39.35 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.303 178.014 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.519 ' N ' ' O ' ' A' ' 11' ' ' ARG . 9.2 mpt_? -100.87 26.41 6.94 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 122.693 0.397 . . . . 0.0 110.866 179.816 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.429 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 8.2 p -112.34 -50.32 5.85 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.059 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.429 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 44.4 mm -150.29 83.78 5.91 Favored Pre-proline 0 N--CA 1.424 -1.743 0 N-CA-C 106.517 -1.66 . . . . 0.0 106.517 174.816 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.637 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.0 Cg_endo -91.24 -179.28 1.39 Allowed 'Trans proline' 0 N--CA 1.422 -2.702 0 C-N-CA 124.836 3.691 . . . . 0.0 109.569 178.662 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.23 -28.73 69.56 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 115.116 -0.947 . . . . 0.0 111.051 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 20.1 t . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.245 -0.883 . . . . 0.0 111.232 179.881 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.517 -0.304 0 CA-C-O 121.65 0.738 . . . . 0.0 109.357 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.445 ' O ' ' N ' ' A' ' 8' ' ' ARG . 4.8 t -74.34 -32.19 30.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 114.652 -1.158 . . . . 0.0 110.315 179.352 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -42.14 -26.0 0.09 Allowed 'General case' 0 CA--C 1.528 0.112 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.583 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -71.72 -41.65 55.98 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.742 -0.742 . . . . 0.0 111.595 179.339 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.445 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -71.69 -52.07 19.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.676 0.274 . . . . 0.0 110.462 179.359 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.453 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 3.2 mp -55.1 -33.52 62.9 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.165 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.507 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.18 -21.53 0.5 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.137 -0.483 . . . . 0.0 112.097 179.839 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.505 ' O ' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.5 -44.67 10.53 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.022 -179.579 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.466 HG13 ' N ' ' A' ' 13' ' ' LEU . 2.5 pt -54.76 -32.17 25.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 C-N-CA 120.552 -0.459 . . . . 0.0 111.163 -179.751 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.507 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -67.74 -29.25 68.43 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 178.201 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.583 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.96 -13.81 48.32 Favored Glycine 0 N--CA 1.445 -0.746 0 C-N-CA 120.478 -0.868 . . . . 0.0 111.458 178.137 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.505 ' N ' ' O ' ' A' ' 11' ' ' ARG . 0.4 OUTLIER -100.39 26.99 6.05 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 121.069 0.461 . . . . 0.0 110.775 -179.942 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.401 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 7.4 p -111.61 -49.36 6.2 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.032 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 179.491 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.401 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 39.9 mm -150.03 83.63 6.09 Favored Pre-proline 0 N--CA 1.424 -1.741 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 174.375 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.583 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.4 Cg_endo -91.19 -179.17 1.39 Allowed 'Trans proline' 0 N--CA 1.424 -2.575 0 C-N-CA 125.001 3.801 . . . . 0.0 109.695 178.756 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.21 -29.58 69.28 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 115.238 -0.892 . . . . 0.0 110.811 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.5 t . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.276 -0.869 . . . . 0.0 111.226 179.8 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 CA--C 1.519 -0.217 0 CA-C-O 121.45 0.643 . . . . 0.0 109.47 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.449 ' O ' ' N ' ' A' ' 8' ' ' ARG . 10.5 t -81.0 -27.91 11.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.604 179.459 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . 0.474 ' CD2' ' N ' ' A' ' 7' ' ' GLY . 0.1 OUTLIER -41.49 -25.44 0.05 OUTLIER 'General case' 0 C--O 1.231 0.128 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.738 -179.942 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.474 ' N ' ' CD2' ' A' ' 6' ' ' PHE . . . -69.05 -40.82 83.3 Favored Glycine 0 N--CA 1.45 -0.387 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.586 179.318 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.449 ' N ' ' O ' ' A' ' 5' ' ' VAL . 1.6 mpt_? -74.68 -47.18 33.13 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.878 0.371 . . . . 0.0 110.146 179.296 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.481 ' O ' HG13 ' A' ' 12' ' ' ILE . 1.0 OUTLIER -52.24 -60.25 3.44 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.993 179.709 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.547 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -44.64 -24.27 0.18 Allowed 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.963 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.435 ' O ' ' CD ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.56 -48.24 7.72 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.808 -179.897 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.481 HG13 ' O ' ' A' ' 9' ' ' LEU . 1.1 pp -58.81 -36.94 63.52 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.204 0 C-N-CA 120.416 -0.514 . . . . 0.0 111.447 -179.617 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.547 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -62.36 -34.63 77.06 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 178.482 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.596 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -71.7 -12.9 74.62 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.079 -1.057 . . . . 0.0 111.034 177.75 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.446 ' HD2' ' N ' ' A' ' 15' ' ' ARG . 0.9 OUTLIER -99.67 27.35 5.43 Favored 'General case' 0 N--CA 1.465 0.319 0 C-N-CA 123.016 0.527 . . . . 0.0 110.51 179.646 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.503 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 1.9 p -111.26 -49.01 6.37 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.934 0 N-CA-C 107.164 -1.421 . . . . 0.0 107.164 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.503 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 44.2 mm -150.41 83.2 6.03 Favored Pre-proline 0 N--CA 1.423 -1.789 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 174.316 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.596 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.0 Cg_endo -91.53 -179.1 1.28 Allowed 'Trans proline' 0 N--CA 1.423 -2.675 0 C-N-CA 125.071 3.847 . . . . 0.0 109.633 178.622 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.16 -29.0 68.58 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.901 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.277 -0.868 . . . . 0.0 111.211 179.799 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.52 -0.193 0 CA-C-O 121.428 0.632 . . . . 0.0 109.408 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.446 ' O ' ' N ' ' A' ' 8' ' ' ARG . 11.6 t -72.5 -22.87 20.68 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.493 0 CA-C-N 114.852 -1.067 . . . . 0.0 109.94 178.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -41.51 -25.28 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.573 179.652 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 5' ' ' VAL . . . -71.64 -41.37 57.2 Favored Glycine 0 N--CA 1.45 -0.373 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.674 179.268 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.446 ' N ' ' O ' ' A' ' 5' ' ' VAL . 2.9 mmm180 -68.21 -54.1 20.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.88 0.371 . . . . 0.0 110.055 179.249 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.413 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 5.3 mp -56.18 -31.63 63.59 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.854 179.77 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.478 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -47.3 -21.53 0.3 Allowed 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.036 -0.529 . . . . 0.0 112.082 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.499 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.7 ptm180 -88.7 -42.78 11.76 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 116.536 -0.302 . . . . 0.0 111.252 -179.46 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.457 HG13 ' N ' ' A' ' 13' ' ' LEU . 4.4 pt -54.64 -33.92 28.44 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.209 0 C-N-CA 120.465 -0.494 . . . . 0.0 110.858 -179.721 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.478 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.62 -28.68 68.69 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 178.056 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.612 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.52 -14.13 48.53 Favored Glycine 0 N--CA 1.445 -0.742 0 CA-C-N 115.253 -0.885 . . . . 0.0 111.678 178.315 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.499 ' N ' ' O ' ' A' ' 11' ' ' ARG . 9.2 mpt_? -100.2 26.87 6.07 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 120.999 0.428 . . . . 0.0 110.688 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.411 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 7.4 p -111.88 -49.48 6.08 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.047 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 179.744 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.411 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 40.7 mm -149.86 82.95 6.42 Favored Pre-proline 0 N--CA 1.422 -1.827 0 N-CA-C 106.574 -1.639 . . . . 0.0 106.574 174.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.612 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.7 Cg_endo -91.48 -179.01 1.28 Allowed 'Trans proline' 0 N--CA 1.423 -2.675 0 C-N-CA 125.091 3.861 . . . . 0.0 109.667 178.702 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.76 -27.23 67.43 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.948 179.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 C--O 1.25 1.1 0 CA-C-O 118.274 -0.869 . . . . 0.0 111.103 -179.855 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.52 -0.208 0 CA-C-O 121.465 0.65 . . . . 0.0 109.388 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.422 ' O ' ' N ' ' A' ' 7' ' ' GLY . 9.3 t -73.3 -21.27 18.8 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.561 0 CA-C-N 114.877 -1.056 . . . . 0.0 109.999 178.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -41.15 -25.21 0.03 OUTLIER 'General case' 0 CA--C 1.529 0.145 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.694 179.792 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.422 ' N ' ' O ' ' A' ' 5' ' ' VAL . . . -62.75 -40.22 98.93 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.686 -0.769 . . . . 0.0 111.407 179.131 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.406 ' O ' ' HG2' ' A' ' 11' ' ' ARG . 0.4 OUTLIER -74.61 -54.89 6.59 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 179.114 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.436 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 3.3 mp -52.02 -36.44 50.11 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.943 0.401 . . . . 0.0 110.745 179.597 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.501 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.86 -21.49 1.16 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.903 -0.59 . . . . 0.0 112.165 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.535 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.2 ptm180 -88.73 -42.42 11.96 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.453 -179.331 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.469 HG13 ' N ' ' A' ' 13' ' ' LEU . 2.8 pt -54.78 -33.79 28.85 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.221 0 C-N-CA 120.421 -0.512 . . . . 0.0 110.791 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.501 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.25 -29.27 69.48 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 177.971 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.645 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.25 -15.98 42.37 Favored Glycine 0 N--CA 1.444 -0.782 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.669 178.313 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.535 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.3 mpt_? -100.23 26.61 6.36 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 121.008 0.432 . . . . 0.0 110.677 179.694 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.412 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 7.4 p -112.02 -50.27 5.97 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 179.691 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.412 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 42.1 mm -150.27 83.75 5.93 Favored Pre-proline 0 N--CA 1.425 -1.7 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 174.855 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.645 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.3 Cg_endo -91.26 -179.28 1.39 Allowed 'Trans proline' 0 N--CA 1.423 -2.642 0 C-N-CA 124.893 3.728 . . . . 0.0 109.658 178.603 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.24 -28.69 69.9 Favored 'General case' 0 C--N 1.301 -1.541 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.964 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 18.5 t . . . . . 0 C--O 1.25 1.091 0 CA-C-O 118.235 -0.888 . . . . 0.0 111.185 179.879 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.52 -0.198 0 CA-C-O 121.431 0.634 . . . . 0.0 109.708 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.441 ' O ' ' N ' ' A' ' 8' ' ' ARG . 11.3 t -72.79 -28.07 26.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 114.933 -1.031 . . . . 0.0 110.209 179.269 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -41.78 -25.37 0.06 Allowed 'General case' 0 C--O 1.232 0.14 0 CA-C-N 115.406 -0.816 . . . . 0.0 110.695 179.683 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -67.98 -41.09 88.48 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.6 179.167 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.441 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -75.21 -59.47 2.73 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 110.393 -0.225 . . . . 0.0 110.393 179.25 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.414 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 1.0 OUTLIER -43.51 -30.88 0.62 Allowed 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 121.08 0.467 . . . . 0.0 111.04 179.506 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.513 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.89 -21.29 1.12 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.672 -0.695 . . . . 0.0 112.112 179.64 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.484 ' O ' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.4 -43.64 11.34 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 116.684 -0.234 . . . . 0.0 111.22 -179.146 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.474 ' N ' ' HG2' ' A' ' 11' ' ' ARG . 5.4 pt -54.79 -33.43 28.05 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 C-N-CA 120.429 -0.508 . . . . 0.0 111.101 -179.454 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.513 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -67.39 -28.86 68.28 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 178.08 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.608 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.98 -13.6 52.35 Favored Glycine 0 N--CA 1.444 -0.77 0 CA-C-N 115.2 -0.909 . . . . 0.0 111.783 178.473 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.484 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.4 mpt_? -100.18 26.76 6.18 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 120.963 0.411 . . . . 0.0 110.788 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.409 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 7.2 p -111.84 -49.29 6.12 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.037 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 179.624 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.409 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 42.1 mm -150.04 83.33 6.18 Favored Pre-proline 0 N--CA 1.424 -1.762 0 N-CA-C 106.402 -1.703 . . . . 0.0 106.402 174.539 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.608 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.9 Cg_endo -91.55 -179.38 1.32 Allowed 'Trans proline' 0 N--CA 1.422 -2.715 0 C-N-CA 125.026 3.817 . . . . 0.0 109.797 178.744 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.46 -28.46 69.23 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 115.153 -0.93 . . . . 0.0 111.074 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 19.6 t . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.218 -0.896 . . . . 0.0 111.093 179.896 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.5 m . . . . . 0 CA--C 1.518 -0.275 0 CA-C-O 121.525 0.678 . . . . 0.0 109.405 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.465 ' O ' ' N ' ' A' ' 8' ' ' ARG . 10.1 t -74.64 -33.49 32.04 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.462 0 CA-C-N 114.816 -1.084 . . . . 0.0 110.194 179.177 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -43.11 -25.65 0.12 Allowed 'General case' 0 C--O 1.231 0.123 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.404 179.666 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -67.28 -37.87 91.18 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.512 179.248 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.465 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -83.67 -43.54 15.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.79 0.329 . . . . 0.0 110.206 179.181 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.551 ' O ' HG13 ' A' ' 12' ' ' ILE . 0.8 OUTLIER -55.05 -58.44 7.63 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.818 179.655 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.538 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.73 -21.91 0.7 Allowed 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.405 -0.361 . . . . 0.0 111.701 179.709 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.88 -44.88 10.14 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.116 -179.488 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.551 HG13 ' O ' ' A' ' 9' ' ' LEU . 1.8 pp -55.2 -42.8 67.67 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.253 0 C-N-CA 120.405 -0.518 . . . . 0.0 110.927 -179.613 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.538 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -57.66 -34.71 69.66 Favored 'General case' 0 CA--C 1.515 -0.378 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 177.912 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.585 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -62.75 -20.97 62.52 Favored Glycine 0 N--CA 1.446 -0.697 0 C-N-CA 120.118 -1.039 . . . . 0.0 110.676 177.619 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.2 mpt_? -99.85 27.13 5.67 Favored 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 123.118 0.567 . . . . 0.0 110.082 178.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.503 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 0.3 OUTLIER -111.21 -49.47 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.918 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 -179.947 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.503 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 37.0 mm -150.24 82.67 6.3 Favored Pre-proline 0 N--CA 1.425 -1.684 0 N-CA-C 106.54 -1.652 . . . . 0.0 106.54 174.191 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.585 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.3 Cg_endo -91.82 -178.86 1.17 Allowed 'Trans proline' 0 N--CA 1.423 -2.631 0 C-N-CA 125.251 3.967 . . . . 0.0 109.899 178.611 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.08 -28.5 66.57 Favored 'General case' 0 C--N 1.301 -1.519 0 CA-C-N 115.148 -0.933 . . . . 0.0 111.012 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 18.8 t . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.274 -0.869 . . . . 0.0 111.294 179.899 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.519 -0.217 0 CA-C-O 121.568 0.699 . . . . 0.0 109.333 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.42 ' O ' ' N ' ' A' ' 7' ' ' GLY . 6.6 t -76.08 -21.3 15.5 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 CA-C-N 114.758 -1.11 . . . . 0.0 110.085 178.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -41.17 -25.3 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.121 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.705 179.829 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 5' ' ' VAL . . . -63.37 -40.67 99.17 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.791 -0.718 . . . . 0.0 111.425 179.255 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.412 ' O ' ' HG2' ' A' ' 11' ' ' ARG . 2.0 mpt_? -73.9 -54.9 6.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.803 0.335 . . . . 0.0 110.156 179.189 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.8 mp -52.25 -42.1 63.35 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.907 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.466 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.93 -21.6 0.69 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.016 -0.538 . . . . 0.0 112.288 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.534 ' O ' ' N ' ' A' ' 15' ' ' ARG . 1.4 ptm180 -88.93 -41.09 12.62 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-N 116.666 -0.243 . . . . 0.0 111.339 -179.514 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.479 HG13 ' N ' ' A' ' 13' ' ' LEU . 2.4 pt -54.91 -34.24 30.57 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.211 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.814 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.479 ' N ' HG13 ' A' ' 12' ' ' ILE . 0.0 OUTLIER -65.97 -28.49 68.94 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 178.032 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.634 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.43 -17.64 35.84 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.484 178.161 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.534 ' N ' ' O ' ' A' ' 11' ' ' ARG . 2.4 mpt_? -100.81 26.72 6.57 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 122.794 0.438 . . . . 0.0 110.623 179.673 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.418 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 7.4 p -111.89 -49.95 6.04 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.052 0 N-CA-C 107.741 -1.207 . . . . 0.0 107.741 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.418 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 41.6 mm -149.98 82.99 6.33 Favored Pre-proline 0 N--CA 1.426 -1.663 0 N-CA-C 106.486 -1.672 . . . . 0.0 106.486 174.634 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.634 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.1 Cg_endo -91.71 -179.0 1.22 Allowed 'Trans proline' 0 N--CA 1.424 -2.615 0 C-N-CA 125.212 3.941 . . . . 0.0 110.03 178.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.16 -28.39 69.72 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 115.021 -0.99 . . . . 0.0 111.148 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 16.6 t . . . . . 0 C--O 1.249 1.032 0 CA-C-O 118.274 -0.87 . . . . 0.0 111.154 -179.976 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.521 -0.17 0 CA-C-O 121.571 0.701 . . . . 0.0 109.262 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.426 ' O ' ' N ' ' A' ' 7' ' ' GLY . 8.3 t -73.9 -21.25 18.02 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.499 0 CA-C-N 114.739 -1.119 . . . . 0.0 109.968 178.827 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -41.01 -25.11 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.72 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 5' ' ' VAL . . . -60.74 -38.43 95.17 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.845 -0.693 . . . . 0.0 111.58 179.193 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.94 -54.34 6.13 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.03 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.413 ' HA ' HG12 ' A' ' 12' ' ' ILE . 4.8 mp -55.34 -22.77 20.63 Favored 'General case' 0 CA--C 1.528 0.132 0 CA-C-O 121.017 0.437 . . . . 0.0 110.424 179.028 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.48 ' HA ' ' CD2' ' A' ' 13' ' ' LEU . . . -63.07 -21.14 65.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.373 179.763 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.443 ' O ' ' N ' ' A' ' 14' ' ' GLY . 0.0 OUTLIER -89.41 -40.96 12.37 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.597 -179.472 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.485 HG13 ' N ' ' A' ' 13' ' ' LEU . 1.6 pt -53.79 -36.61 30.28 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.171 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.979 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.496 ' O ' HG12 ' A' ' 16' ' ' VAL . 1.5 pp -65.95 -24.34 66.79 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 177.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.652 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -92.23 -19.79 37.83 Favored Glycine 0 N--CA 1.444 -0.816 0 CA-C-N 115.102 -0.953 . . . . 0.0 111.603 178.31 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.439 ' CD ' ' O ' ' A' ' 11' ' ' ARG . 2.3 mpt_? -100.74 25.87 7.43 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 120.836 0.35 . . . . 0.0 110.947 179.614 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.496 HG12 ' O ' ' A' ' 13' ' ' LEU . 7.6 p -112.42 -50.35 5.82 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.11 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.758 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.409 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 31.9 mm -149.79 83.27 6.35 Favored Pre-proline 0 N--CA 1.423 -1.825 0 N-CA-C 106.578 -1.638 . . . . 0.0 106.578 175.446 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.652 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 3.6 Cg_endo -91.32 -178.94 1.31 Allowed 'Trans proline' 0 N--CA 1.424 -2.58 0 C-N-CA 125.049 3.833 . . . . 0.0 109.793 178.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -62.34 -23.07 66.57 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 115.227 -0.897 . . . . 0.0 111.164 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 2.6 t . . . . . 0 C--O 1.25 1.098 0 CA-C-O 118.152 -0.928 . . . . 0.0 110.848 -179.913 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.52 -0.188 0 CA-C-O 121.444 0.64 . . . . 0.0 109.578 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.432 ' O ' ' N ' ' A' ' 8' ' ' ARG . 14.1 t -74.65 -25.3 18.96 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.482 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.028 178.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -41.36 -25.47 0.04 OUTLIER 'General case' 0 C--N 1.333 -0.109 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.674 179.708 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.42 ' N ' ' C ' ' A' ' 5' ' ' VAL . . . -65.29 -40.54 96.64 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.556 179.34 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.432 ' N ' ' O ' ' A' ' 5' ' ' VAL . 1.8 mpt_? -78.23 -46.4 20.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.837 0.351 . . . . 0.0 110.459 179.368 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.447 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 1.6 mp -56.22 -60.58 3.3 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.903 179.803 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.529 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -44.44 -22.47 0.07 Allowed 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.195 -0.457 . . . . 0.0 112.056 179.74 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.431 ' HG2' ' HD3' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.57 -46.14 9.32 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.645 -179.861 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.464 HG13 ' N ' ' A' ' 13' ' ' LEU . 1.1 pp -57.48 -36.53 53.8 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.248 0 C-N-CA 120.52 -0.472 . . . . 0.0 111.149 -179.844 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.529 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -62.11 -35.35 78.45 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 178.198 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.593 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -70.6 -16.65 74.15 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.102 -1.047 . . . . 0.0 110.87 177.64 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.431 ' HD3' ' HG2' ' A' ' 11' ' ' ARG . 1.4 mpt_? -100.02 27.38 5.59 Favored 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 123.088 0.555 . . . . 0.0 110.491 179.566 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.5 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 1.0 OUTLIER -111.21 -48.82 6.38 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.972 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 179.822 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.5 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 44.1 mm -150.52 82.8 6.1 Favored Pre-proline 0 N--CA 1.424 -1.748 0 N-CA-C 106.568 -1.641 . . . . 0.0 106.568 174.257 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.593 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.7 Cg_endo -91.7 -178.9 1.2 Allowed 'Trans proline' 0 N--CA 1.423 -2.632 0 C-N-CA 125.135 3.89 . . . . 0.0 109.856 178.619 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.86 -28.9 67.94 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.197 -0.91 . . . . 0.0 110.912 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 16.6 t . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.217 -0.897 . . . . 0.0 111.266 179.819 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 13.3 m . . . . . 0 CA--C 1.519 -0.22 0 CA-C-O 121.579 0.704 . . . . 0.0 109.425 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.438 ' O ' ' N ' ' A' ' 8' ' ' ARG . 8.9 t -80.09 -24.68 11.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.472 179.387 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 7' ' ' GLY . 0.1 OUTLIER -41.36 -25.47 0.04 OUTLIER 'General case' 0 CA--C 1.527 0.073 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.657 179.84 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.446 ' N ' ' CD1' ' A' ' 6' ' ' PHE . . . -63.84 -41.37 98.83 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.666 -0.778 . . . . 0.0 111.426 179.169 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.438 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -76.66 -45.27 30.5 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.889 0.376 . . . . 0.0 110.165 179.201 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.447 ' O ' HG13 ' A' ' 12' ' ' ILE . 0.7 OUTLIER -55.35 -54.96 37.06 Favored 'General case' 0 CA--C 1.529 0.163 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.819 179.668 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.54 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -47.64 -21.88 0.43 Allowed 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 112.083 179.81 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.455 ' O ' ' HD3' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.61 -45.22 10.04 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.861 -179.655 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.471 HG13 ' N ' ' A' ' 13' ' ' LEU . 1.1 pt -53.97 -35.63 28.88 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.211 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.882 -179.711 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.54 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -63.42 -35.65 81.13 Favored 'General case' 0 CA--C 1.513 -0.473 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 177.793 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.599 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -69.56 -16.89 72.25 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 120.006 -1.092 . . . . 0.0 110.758 177.61 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.455 ' HD3' ' O ' ' A' ' 11' ' ' ARG . 9.8 mpt_? -99.7 27.06 5.64 Favored 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 123.054 0.542 . . . . 0.0 110.496 179.313 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.502 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 0.8 OUTLIER -111.42 -49.09 6.3 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.918 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 179.748 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.502 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 44.5 mm -150.51 83.16 5.98 Favored Pre-proline 0 N--CA 1.423 -1.796 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 174.292 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.599 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.3 Cg_endo -91.5 -179.27 1.32 Allowed 'Trans proline' 0 N--CA 1.423 -2.675 0 C-N-CA 125.029 3.82 . . . . 0.0 109.597 178.515 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.41 ' HG3' ' N ' ' A' ' 20' ' ' VAL . 0.0 OUTLIER -65.75 -29.7 70.25 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 115.307 -0.861 . . . . 0.0 110.818 179.856 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.41 ' N ' ' HG3' ' A' ' 19' ' ' LYS . 37.2 t . . . . . 0 C--O 1.25 1.098 0 CA-C-O 118.204 -0.903 . . . . 0.0 111.253 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.522 -0.131 0 CA-C-O 121.473 0.654 . . . . 0.0 109.325 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.423 ' C ' ' N ' ' A' ' 7' ' ' GLY . 9.1 t -73.23 -21.4 18.94 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.489 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.048 179.049 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -41.33 -24.98 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.244 -0.889 . . . . 0.0 110.747 179.885 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.423 ' N ' ' C ' ' A' ' 5' ' ' VAL . . . -65.39 -40.76 96.57 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.714 -0.755 . . . . 0.0 111.514 179.079 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.422 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -72.65 -54.31 9.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.815 0.341 . . . . 0.0 110.165 179.223 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.427 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 3.2 mp -56.71 -32.94 66.0 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.814 179.648 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.504 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.46 -21.58 0.58 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.923 -0.581 . . . . 0.0 112.008 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.519 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.9 ptm180 -88.76 -43.02 11.58 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.273 -179.43 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.449 HG13 ' N ' ' A' ' 13' ' ' LEU . 3.8 pt -54.58 -33.75 27.75 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.188 0 C-N-CA 120.47 -0.492 . . . . 0.0 110.949 -179.652 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.504 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.07 -28.42 68.82 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 177.967 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.645 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.96 -16.71 37.62 Favored Glycine 0 N--CA 1.446 -0.671 0 CA-C-N 115.256 -0.884 . . . . 0.0 111.507 178.287 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.519 ' N ' ' O ' ' A' ' 11' ' ' ARG . 9.5 mpt_? -100.38 26.72 6.33 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.967 0.413 . . . . 0.0 110.551 179.654 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.429 HG13 ' O ' ' A' ' 13' ' ' LEU . 7.6 p -111.83 -50.05 6.06 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.0 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 179.745 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.42 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 44.1 mm -150.28 83.75 5.92 Favored Pre-proline 0 N--CA 1.427 -1.625 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 174.44 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.645 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.8 Cg_endo -91.28 -179.07 1.34 Allowed 'Trans proline' 0 N--CA 1.423 -2.625 0 C-N-CA 124.909 3.74 . . . . 0.0 109.559 178.747 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.1 -27.53 68.82 Favored 'General case' 0 C--N 1.3 -1.565 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.994 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 19.2 t . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.235 -0.888 . . . . 0.0 111.156 179.821 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 2.7 m . . . . . 0 CA--C 1.519 -0.224 0 CA-C-O 121.572 0.701 . . . . 0.0 109.575 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.427 ' O ' ' N ' ' A' ' 8' ' ' ARG . 8.2 t -76.68 -30.9 19.19 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.438 0 CA-C-N 114.701 -1.136 . . . . 0.0 110.521 179.526 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . 0.454 ' CD2' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -41.78 -25.52 0.06 Allowed 'General case' 0 CA--C 1.528 0.128 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.72 -179.975 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.454 ' N ' ' CD2' ' A' ' 6' ' ' PHE . . . -65.34 -39.39 95.86 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.454 179.018 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.427 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.5 OUTLIER -80.01 -46.29 16.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.975 0.417 . . . . 0.0 110.058 179.209 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.45 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 0.5 OUTLIER -52.52 -59.58 4.27 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.255 179.945 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.535 ' HA ' HD22 ' A' ' 13' ' ' LEU . . . -43.58 -24.66 0.12 Allowed 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 116.293 -0.412 . . . . 0.0 112.089 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.471 ' O ' ' HD2' ' A' ' 15' ' ' ARG . 0.4 OUTLIER -88.57 -45.93 9.49 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.051 -179.807 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.451 HG13 ' N ' ' A' ' 13' ' ' LEU . 1.1 pp -56.25 -35.82 44.03 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.212 0 C-N-CA 120.446 -0.501 . . . . 0.0 111.113 -179.662 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.535 HD22 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -64.22 -33.56 76.08 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 178.128 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.593 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -73.22 -14.35 79.15 Favored Glycine 0 N--CA 1.444 -0.779 0 C-N-CA 120.117 -1.04 . . . . 0.0 110.827 177.537 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.471 ' HD2' ' O ' ' A' ' 11' ' ' ARG . 0.6 OUTLIER -99.88 27.04 5.74 Favored 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 123.03 0.532 . . . . 0.0 110.401 179.493 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.502 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 1.4 p -111.46 -48.89 6.28 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.926 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 179.824 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.502 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 43.3 mm -150.38 82.85 6.16 Favored Pre-proline 0 N--CA 1.423 -1.783 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 174.395 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.593 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.9 Cg_endo -91.69 -178.93 1.21 Allowed 'Trans proline' 0 N--CA 1.425 -2.544 0 C-N-CA 125.211 3.94 . . . . 0.0 109.942 178.771 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.47 -28.65 69.81 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.102 -0.954 . . . . 0.0 111.068 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.264 -0.875 . . . . 0.0 111.254 179.921 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.8 m . . . . . 0 CA--C 1.52 -0.206 0 CA-C-O 121.521 0.677 . . . . 0.0 109.659 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.476 ' O ' ' N ' ' A' ' 8' ' ' ARG . 6.3 t -80.39 -27.09 11.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.677 179.578 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . 0.459 ' CD1' ' N ' ' A' ' 7' ' ' GLY . 0.1 OUTLIER -42.9 -25.29 0.09 Allowed 'General case' 0 C--O 1.231 0.12 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.519 179.828 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.459 ' N ' ' CD1' ' A' ' 6' ' ' PHE . . . -72.48 -37.46 58.46 Favored Glycine 0 N--CA 1.45 -0.41 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.651 179.372 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.476 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -73.11 -59.76 2.56 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.649 0.262 . . . . 0.0 110.354 179.345 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.454 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 0.4 OUTLIER -48.08 -30.8 4.79 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 120.97 0.415 . . . . 0.0 110.875 179.638 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.529 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.96 -21.57 1.25 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.836 -0.62 . . . . 0.0 112.185 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.485 ' O ' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.98 -43.38 11.18 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 116.707 -0.224 . . . . 0.0 111.186 -179.417 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.476 ' N ' ' HG2' ' A' ' 11' ' ' ARG . 3.1 pt -54.27 -33.56 25.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 C-N-CA 120.475 -0.49 . . . . 0.0 111.085 -179.521 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.529 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.05 -28.55 68.93 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 177.908 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.637 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.78 -17.16 39.31 Favored Glycine 0 N--CA 1.444 -0.782 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.635 178.351 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.485 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.7 mpt_? -100.46 26.74 6.35 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 120.949 0.404 . . . . 0.0 110.809 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.421 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 7.1 p -111.6 -49.84 6.16 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.082 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 179.789 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.421 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 42.4 mm -150.2 83.23 6.13 Favored Pre-proline 0 N--CA 1.424 -1.754 0 N-CA-C 106.565 -1.642 . . . . 0.0 106.565 174.595 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.637 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.5 Cg_endo -91.32 -179.0 1.32 Allowed 'Trans proline' 0 N--CA 1.423 -2.659 0 C-N-CA 124.983 3.789 . . . . 0.0 109.777 178.768 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.58 -29.8 69.94 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 115.141 -0.936 . . . . 0.0 110.949 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 18.4 t . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.247 -0.882 . . . . 0.0 111.239 179.971 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 2.5 m . . . . . 0 CA--C 1.52 -0.19 0 CA-C-O 121.576 0.703 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.463 ' O ' ' N ' ' A' ' 8' ' ' ARG . 6.6 t -78.72 -31.49 15.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 114.689 -1.141 . . . . 0.0 110.644 179.53 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . 0.458 ' CD1' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -42.47 -25.61 0.09 Allowed 'General case' 0 CA--C 1.528 0.102 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.731 179.993 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . 0.458 ' N ' ' CD1' ' A' ' 6' ' ' PHE . . . -70.83 -38.58 65.72 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.768 -0.73 . . . . 0.0 111.587 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . 0.463 ' N ' ' O ' ' A' ' 5' ' ' VAL . 9.3 mmm180 -75.92 -52.52 10.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.857 0.36 . . . . 0.0 110.217 179.25 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.457 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 0.7 OUTLIER -50.1 -38.35 38.3 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.063 179.833 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.543 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -46.57 -21.53 0.19 Allowed 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.215 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . 0.468 ' HG2' ' N ' ' A' ' 12' ' ' ILE . 0.0 OUTLIER -88.44 -43.77 11.22 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.877 -179.398 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . 0.468 ' N ' ' HG2' ' A' ' 11' ' ' ARG . 2.7 pt -57.32 -32.3 40.59 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.178 0 C-N-CA 120.454 -0.498 . . . . 0.0 111.011 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . 0.543 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -68.41 -28.03 66.73 Favored 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 178.188 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.611 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -90.55 -15.01 57.63 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.435 -0.888 . . . . 0.0 111.07 177.985 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.449 ' HD3' ' CG ' ' A' ' 11' ' ' ARG . 0.7 OUTLIER -100.35 26.93 6.1 Favored 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 122.626 0.371 . . . . 0.0 110.938 179.841 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . 0.499 HG13 ' O ' ' A' ' 13' ' ' LEU . 8.6 p -111.63 -48.92 6.21 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.015 0 N-CA-C 107.391 -1.337 . . . . 0.0 107.391 179.679 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.419 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 39.7 mm -150.08 83.07 6.25 Favored Pre-proline 0 N--CA 1.425 -1.722 0 N-CA-C 106.522 -1.658 . . . . 0.0 106.522 174.579 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . 0.611 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 3.8 Cg_endo -91.56 -179.06 1.27 Allowed 'Trans proline' 0 N--CA 1.424 -2.612 0 C-N-CA 125.019 3.813 . . . . 0.0 109.961 178.838 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.2 -29.26 70.38 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.943 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 20.7 t . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.234 -0.889 . . . . 0.0 111.143 179.984 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.2 0 N-CA-C 112.51 -0.236 . . . . 0.0 112.51 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.413 ' CD2' ' N ' ' A' ' 2' ' ' LEU . 2.1 mm? 64.07 80.91 0.22 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.93 0.395 . . . . 0.0 110.47 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 106.34 -37.01 4.03 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.807 -0.711 . . . . 0.0 111.984 -179.448 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -82.87 -34.64 26.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.523 0.678 . . . . 0.0 109.519 178.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.413 ' CG1' ' CD1' ' A' ' 9' ' ' LEU . 9.2 t -79.31 -30.02 13.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 114.814 -1.084 . . . . 0.0 110.638 179.599 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.458 ' CD2' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -42.14 -25.38 0.07 Allowed 'General case' 0 CA--C 1.528 0.13 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.752 179.942 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.458 ' N ' ' CD2' ' A' ' 6' ' ' PHE . . . -66.02 -38.61 94.25 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.725 -0.75 . . . . 0.0 111.605 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.409 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -80.8 -51.99 8.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.67 0.272 . . . . 0.0 110.41 179.41 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.42 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 2.9 mp -51.96 -38.47 56.64 Favored 'General case' 0 CA--C 1.529 0.156 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.897 179.766 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.515 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -50.75 -21.45 1.64 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.183 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.47 ' O ' ' N ' ' A' ' 15' ' ' ARG . 1.7 ptm180 -88.77 -41.39 12.56 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.551 -179.183 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.467 HG13 ' N ' ' A' ' 13' ' ' LEU . 3.7 pt -54.62 -35.46 32.38 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.178 0 C-N-CA 120.369 -0.533 . . . . 0.0 110.817 -179.637 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.515 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.05 -26.98 67.75 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 177.879 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.641 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -93.96 -17.02 42.33 Favored Glycine 0 N--CA 1.444 -0.806 0 CA-C-N 115.187 -0.915 . . . . 0.0 111.532 178.273 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.47 ' N ' ' O ' ' A' ' 11' ' ' ARG . 2.5 mpt_? -100.35 26.58 6.46 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 120.956 0.408 . . . . 0.0 110.716 179.718 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.464 HG13 ' O ' ' A' ' 13' ' ' LEU . 7.3 p -112.19 -50.42 5.9 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.02 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 179.67 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.415 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 40.4 mm -150.15 83.82 5.97 Favored Pre-proline 0 N--CA 1.425 -1.703 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 174.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.641 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.8 Cg_endo -91.37 -179.18 1.34 Allowed 'Trans proline' 0 N--CA 1.422 -2.684 0 C-N-CA 124.904 3.736 . . . . 0.0 109.808 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.55 -29.46 70.72 Favored 'General case' 0 C--N 1.299 -1.604 0 CA-C-N 115.152 -0.931 . . . . 0.0 111.001 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.5 t . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.287 -0.863 . . . . 0.0 111.092 179.908 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.174 0 N-CA-C 112.463 -0.255 . . . . 0.0 112.463 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.2 mm? 62.61 85.8 0.12 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.96 0.409 . . . . 0.0 110.231 -179.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.408 ' O ' ' CD2' ' A' ' 6' ' ' PHE . . . 98.68 -33.96 5.68 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.764 -0.731 . . . . 0.0 111.678 -179.117 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -83.14 -37.58 23.55 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.577 0.703 . . . . 0.0 109.398 178.754 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.464 ' O ' ' N ' ' A' ' 8' ' ' ARG . 5.5 t -76.47 -30.0 19.09 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.448 0 CA-C-N 114.658 -1.155 . . . . 0.0 110.394 179.406 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.451 ' CD2' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -41.56 -25.61 0.05 Allowed 'General case' 0 C--O 1.232 0.138 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.738 179.936 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.451 ' N ' ' CD2' ' A' ' 6' ' ' PHE . . . -68.89 -42.01 80.18 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.359 179.045 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.464 ' N ' ' O ' ' A' ' 5' ' ' VAL . 2.0 mpt_? -71.03 -54.36 11.46 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 179.088 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.411 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 2.3 mp -50.58 -33.57 22.47 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 120.966 0.412 . . . . 0.0 110.71 179.646 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.474 ' HA ' HD23 ' A' ' 13' ' ' LEU . . . -49.61 -21.44 1.01 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.917 -0.583 . . . . 0.0 112.076 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.521 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.2 ptm180 -88.73 -42.43 11.95 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.326 -179.265 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.452 HG13 ' N ' ' A' ' 13' ' ' LEU . 3.8 pt -54.19 -34.38 27.07 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.181 0 C-N-CA 120.376 -0.529 . . . . 0.0 110.927 -179.685 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.474 HD23 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.39 -28.89 68.99 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 178.023 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.648 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.67 -15.95 44.33 Favored Glycine 0 N--CA 1.445 -0.76 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.59 178.271 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.521 ' N ' ' O ' ' A' ' 11' ' ' ARG . 9.1 mpt_? -100.71 26.69 6.55 Favored 'General case' 0 N--CA 1.465 0.316 0 C-N-CA 122.768 0.427 . . . . 0.0 110.642 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.437 HG13 ' O ' ' A' ' 13' ' ' LEU . 7.2 p -111.77 -50.41 6.05 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.994 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.427 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 42.4 mm -150.2 83.51 6.04 Favored Pre-proline 0 N--CA 1.425 -1.685 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 174.61 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.648 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.5 Cg_endo -91.35 -179.15 1.34 Allowed 'Trans proline' 0 N--CA 1.423 -2.653 0 C-N-CA 125.002 3.802 . . . . 0.0 109.95 178.782 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.01 -26.95 69.09 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 115.135 -0.939 . . . . 0.0 111.135 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 18.6 t . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.279 -0.867 . . . . 0.0 111.174 179.951 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.284 0 N-CA-C 112.477 -0.249 . . . . 0.0 112.477 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 2.6 mt 67.86 79.54 0.22 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.902 0.382 . . . . 0.0 110.439 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 106.64 -35.61 4.93 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.837 -0.697 . . . . 0.0 111.867 -179.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -82.8 -34.8 26.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.467 0.651 . . . . 0.0 109.483 178.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 9.3 t -78.04 -30.33 16.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 114.827 -1.079 . . . . 0.0 110.47 179.389 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.448 ' CD1' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -41.8 -25.28 0.05 Allowed 'General case' 0 CA--C 1.529 0.138 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.78 -179.978 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.448 ' N ' ' CD1' ' A' ' 6' ' ' PHE . . . -64.18 -40.25 97.85 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.721 -0.752 . . . . 0.0 111.476 179.124 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -79.72 -51.14 9.59 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.751 0.31 . . . . 0.0 110.364 179.277 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.414 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 1.4 mp -51.32 -38.28 52.16 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-O 121.09 0.471 . . . . 0.0 110.507 179.515 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.503 ' HA ' HD23 ' A' ' 13' ' ' LEU . . . -48.7 -21.12 0.55 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.949 179.567 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.481 ' O ' ' CD ' ' A' ' 15' ' ' ARG . 1.3 ptm180 -88.17 -42.31 12.41 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.235 -179.394 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.464 HG13 ' N ' ' A' ' 13' ' ' LEU . 5.1 pt -55.53 -34.68 35.66 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.17 0 C-N-CA 120.329 -0.549 . . . . 0.0 110.734 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.503 HD23 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.38 -27.25 67.72 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 178.053 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.636 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.06 -16.74 43.15 Favored Glycine 0 N--CA 1.443 -0.834 0 CA-C-N 115.276 -0.875 . . . . 0.0 111.303 178.197 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.481 ' CD ' ' O ' ' A' ' 11' ' ' ARG . 1.7 mpt_? -100.22 26.91 6.04 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.004 0.43 . . . . 0.0 110.528 179.602 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.489 HG13 ' O ' ' A' ' 13' ' ' LEU . 9.1 p -111.45 -49.82 6.22 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.038 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.437 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 40.5 mm -150.2 83.27 6.12 Favored Pre-proline 0 N--CA 1.424 -1.738 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 174.514 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.636 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.1 Cg_endo -91.39 -179.05 1.31 Allowed 'Trans proline' 0 N--CA 1.424 -2.616 0 C-N-CA 124.916 3.744 . . . . 0.0 109.801 178.696 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.39 -30.24 69.96 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.006 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 17.2 t . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.234 -0.889 . . . . 0.0 111.283 179.892 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.213 0 N-CA-C 112.543 -0.223 . . . . 0.0 112.543 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.449 ' CD2' ' N ' ' A' ' 2' ' ' LEU . 2.3 mm? 64.37 75.93 0.36 Allowed 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.989 0.423 . . . . 0.0 110.303 -179.81 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 108.72 -34.56 5.49 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.685 -179.244 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -82.96 -38.01 23.3 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-O 121.587 0.708 . . . . 0.0 109.354 178.676 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.461 ' O ' ' N ' ' A' ' 8' ' ' ARG . 5.5 t -74.64 -30.08 24.43 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.428 0 CA-C-N 114.621 -1.172 . . . . 0.0 110.279 179.237 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -42.78 -25.45 0.09 Allowed 'General case' 0 C--O 1.232 0.141 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.375 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -69.77 -40.67 75.57 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.816 -0.707 . . . . 0.0 111.388 178.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.461 ' N ' ' O ' ' A' ' 5' ' ' VAL . 1.0 OUTLIER -72.43 -54.14 10.19 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.772 0.32 . . . . 0.0 110.389 179.262 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.409 ' O ' ' CG1' ' A' ' 12' ' ' ILE . 1.7 mp -53.8 -35.03 60.95 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 121.057 0.456 . . . . 0.0 110.718 179.623 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.536 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -47.72 -21.6 0.41 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.759 -0.655 . . . . 0.0 112.209 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.458 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.2 ptm180 -89.1 -41.54 12.23 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-N 116.603 -0.272 . . . . 0.0 111.469 -179.574 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.445 HG13 ' N ' ' A' ' 13' ' ' LEU . 4.9 pt -54.87 -34.73 31.57 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.234 0 C-N-CA 120.497 -0.481 . . . . 0.0 110.82 -179.7 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.536 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -65.3 -27.16 68.43 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.811 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.612 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -93.65 -19.38 34.9 Favored Glycine 0 N--CA 1.444 -0.768 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.506 178.166 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.458 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.7 mpt_? -100.16 26.28 6.64 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 120.863 0.363 . . . . 0.0 110.638 179.571 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.473 HG13 ' O ' ' A' ' 13' ' ' LEU . 7.5 p -112.07 -49.63 6.0 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.064 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.406 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 38.7 mm -149.74 83.19 6.4 Favored Pre-proline 0 N--CA 1.424 -1.748 0 N-CA-C 106.51 -1.663 . . . . 0.0 106.51 174.823 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.612 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.0 Cg_endo -91.58 -178.94 1.24 Allowed 'Trans proline' 0 N--CA 1.423 -2.618 0 C-N-CA 125.048 3.832 . . . . 0.0 109.746 178.692 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.92 -30.56 68.0 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.845 179.786 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.189 -0.91 . . . . 0.0 111.182 179.984 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.401 ' O ' ' CD2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.24 0 N-CA-C 112.405 -0.278 . . . . 0.0 112.405 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.401 ' CD2' ' O ' ' A' ' 1' ' ' GLY . 0.1 OUTLIER 176.85 -70.11 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.916 0.389 . . . . 0.0 110.438 -179.967 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -99.38 -18.06 24.9 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.221 179.475 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -82.79 -25.8 32.39 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.398 0.618 . . . . 0.0 109.798 179.064 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.432 ' O ' ' N ' ' A' ' 8' ' ' ARG . 15.0 t -72.82 -23.81 20.83 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.425 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.282 179.323 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -41.54 -25.24 0.04 OUTLIER 'General case' 0 C--N 1.333 -0.132 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.633 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.417 ' N ' ' C ' ' A' ' 5' ' ' VAL . . . -67.22 -41.03 92.33 Favored Glycine 0 N--CA 1.45 -0.423 0 CA-C-N 115.577 -0.738 . . . . 0.0 111.68 179.217 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.432 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -73.62 -54.74 7.46 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 179.251 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.429 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 2.8 mp -52.44 -34.53 49.17 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 120.982 0.42 . . . . 0.0 110.741 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.515 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -50.28 -21.51 1.41 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.989 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.501 ' O ' ' N ' ' A' ' 15' ' ' ARG . 3.1 ptm180 -88.68 -42.78 11.77 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.392 -179.311 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.47 HG13 ' N ' ' A' ' 13' ' ' LEU . 4.8 pt -53.39 -35.89 25.71 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.194 0 C-N-CA 120.364 -0.534 . . . . 0.0 110.823 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.515 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -65.03 -28.73 69.69 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 178.133 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.638 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.6 -16.16 43.75 Favored Glycine 0 N--CA 1.445 -0.763 0 CA-C-N 115.269 -0.878 . . . . 0.0 111.672 178.412 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.501 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.8 mpt_? -100.46 26.69 6.4 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 122.721 0.408 . . . . 0.0 110.733 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.422 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 7.1 p -111.92 -50.22 6.01 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.015 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.422 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 42.6 mm -150.21 83.5 6.04 Favored Pre-proline 0 N--CA 1.424 -1.731 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 174.715 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.638 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.9 Cg_endo -91.36 -179.09 1.32 Allowed 'Trans proline' 0 N--CA 1.423 -2.629 0 C-N-CA 124.98 3.787 . . . . 0.0 109.754 178.774 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.61 -29.54 70.78 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.983 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 20.8 t . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.297 -0.859 . . . . 0.0 111.195 179.95 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.414 ' CA ' HG21 ' A' ' 5' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.227 0 N-CA-C 112.473 -0.251 . . . . 0.0 112.473 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.459 ' CD2' ' N ' ' A' ' 2' ' ' LEU . 2.0 mm? 65.54 87.43 0.12 Allowed 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.994 0.426 . . . . 0.0 110.232 -179.819 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 98.43 -35.6 4.5 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.802 -0.713 . . . . 0.0 111.69 -179.149 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -83.18 -36.61 24.56 Favored 'General case' 0 CA--C 1.519 -0.242 0 CA-C-O 121.53 0.681 . . . . 0.0 109.507 178.797 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.464 ' O ' ' N ' ' A' ' 8' ' ' ARG . 6.2 t -75.53 -29.2 20.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.402 179.384 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -41.53 -25.67 0.05 Allowed 'General case' 0 C--N 1.333 -0.121 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.661 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -65.18 -40.55 96.86 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.383 179.179 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.464 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -75.85 -52.55 10.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.789 0.328 . . . . 0.0 110.14 179.136 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.42 ' O ' ' CG1' ' A' ' 12' ' ' ILE . 5.1 mp -52.43 -38.53 59.39 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.006 0.431 . . . . 0.0 110.618 179.609 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.481 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.3 -21.18 0.78 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.981 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.519 ' O ' ' N ' ' A' ' 15' ' ' ARG . 2.2 ptm180 -88.13 -42.08 12.59 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.338 -179.311 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.445 HG13 ' N ' ' A' ' 13' ' ' LEU . 4.5 pt -55.36 -34.79 34.83 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.218 0 C-N-CA 120.35 -0.54 . . . . 0.0 110.838 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.481 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.45 -27.73 68.04 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 178.089 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.637 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.7 -17.22 39.35 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.303 178.014 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.519 ' N ' ' O ' ' A' ' 11' ' ' ARG . 9.2 mpt_? -100.87 26.41 6.94 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 122.693 0.397 . . . . 0.0 110.866 179.816 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.429 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 8.2 p -112.34 -50.32 5.85 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.059 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.429 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 44.4 mm -150.29 83.78 5.91 Favored Pre-proline 0 N--CA 1.424 -1.743 0 N-CA-C 106.517 -1.66 . . . . 0.0 106.517 174.816 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.637 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.0 Cg_endo -91.24 -179.28 1.39 Allowed 'Trans proline' 0 N--CA 1.422 -2.702 0 C-N-CA 124.836 3.691 . . . . 0.0 109.569 178.662 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.23 -28.73 69.56 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 115.116 -0.947 . . . . 0.0 111.051 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 20.1 t . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.245 -0.883 . . . . 0.0 111.232 179.881 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 112.461 -0.255 . . . . 0.0 112.461 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.429 ' CD2' ' N ' ' A' ' 2' ' ' LEU . 2.5 mm? 62.2 86.16 0.11 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.922 0.391 . . . . 0.0 110.3 -179.829 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 98.91 -34.07 5.64 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.972 -179.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -83.0 -39.33 21.45 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-O 121.65 0.738 . . . . 0.0 109.357 178.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.445 ' O ' ' N ' ' A' ' 8' ' ' ARG . 4.8 t -74.34 -32.19 30.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 114.652 -1.158 . . . . 0.0 110.315 179.352 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -42.14 -26.0 0.09 Allowed 'General case' 0 CA--C 1.528 0.112 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.583 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -71.72 -41.65 55.98 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.742 -0.742 . . . . 0.0 111.595 179.339 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.445 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -71.69 -52.07 19.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.676 0.274 . . . . 0.0 110.462 179.359 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.453 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 3.2 mp -55.1 -33.52 62.9 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.165 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.507 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.18 -21.53 0.5 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.137 -0.483 . . . . 0.0 112.097 179.839 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.505 ' O ' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.5 -44.67 10.53 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.022 -179.579 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.466 HG13 ' N ' ' A' ' 13' ' ' LEU . 2.5 pt -54.76 -32.17 25.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 C-N-CA 120.552 -0.459 . . . . 0.0 111.163 -179.751 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.507 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -67.74 -29.25 68.43 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 178.201 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.583 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.96 -13.81 48.32 Favored Glycine 0 N--CA 1.445 -0.746 0 C-N-CA 120.478 -0.868 . . . . 0.0 111.458 178.137 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.505 ' N ' ' O ' ' A' ' 11' ' ' ARG . 0.4 OUTLIER -100.39 26.99 6.05 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 121.069 0.461 . . . . 0.0 110.775 -179.942 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.401 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 7.4 p -111.61 -49.36 6.2 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.032 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 179.491 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.401 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 39.9 mm -150.03 83.63 6.09 Favored Pre-proline 0 N--CA 1.424 -1.741 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 174.375 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.583 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.4 Cg_endo -91.19 -179.17 1.39 Allowed 'Trans proline' 0 N--CA 1.424 -2.575 0 C-N-CA 125.001 3.801 . . . . 0.0 109.695 178.756 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.21 -29.58 69.28 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 115.238 -0.892 . . . . 0.0 110.811 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.5 t . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.276 -0.869 . . . . 0.0 111.226 179.8 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.438 ' CD2' ' N ' ' A' ' 2' ' ' LEU . 2.6 mm? 64.06 84.69 0.15 Allowed 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.018 0.437 . . . . 0.0 110.412 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.405 ' O ' ' CD2' ' A' ' 6' ' ' PHE . . . 100.5 -36.29 4.25 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.851 -0.69 . . . . 0.0 111.789 -179.363 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -82.73 -33.87 27.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.45 0.643 . . . . 0.0 109.47 178.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.449 ' O ' ' N ' ' A' ' 8' ' ' ARG . 10.5 t -81.0 -27.91 11.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.604 179.459 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.474 ' CD2' ' N ' ' A' ' 7' ' ' GLY . 0.1 OUTLIER -41.49 -25.44 0.05 OUTLIER 'General case' 0 C--O 1.231 0.128 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.738 -179.942 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.474 ' N ' ' CD2' ' A' ' 6' ' ' PHE . . . -69.05 -40.82 83.3 Favored Glycine 0 N--CA 1.45 -0.387 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.586 179.318 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.449 ' N ' ' O ' ' A' ' 5' ' ' VAL . 1.6 mpt_? -74.68 -47.18 33.13 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.878 0.371 . . . . 0.0 110.146 179.296 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.481 ' O ' HG13 ' A' ' 12' ' ' ILE . 1.0 OUTLIER -52.24 -60.25 3.44 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.993 179.709 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.547 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -44.64 -24.27 0.18 Allowed 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.963 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.435 ' O ' ' CD ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.56 -48.24 7.72 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.808 -179.897 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.481 HG13 ' O ' ' A' ' 9' ' ' LEU . 1.1 pp -58.81 -36.94 63.52 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.204 0 C-N-CA 120.416 -0.514 . . . . 0.0 111.447 -179.617 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.547 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -62.36 -34.63 77.06 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 178.482 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.596 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -71.7 -12.9 74.62 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.079 -1.057 . . . . 0.0 111.034 177.75 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.446 ' HD2' ' N ' ' A' ' 15' ' ' ARG . 0.9 OUTLIER -99.67 27.35 5.43 Favored 'General case' 0 N--CA 1.465 0.319 0 C-N-CA 123.016 0.527 . . . . 0.0 110.51 179.646 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.503 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 1.9 p -111.26 -49.01 6.37 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.934 0 N-CA-C 107.164 -1.421 . . . . 0.0 107.164 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.503 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 44.2 mm -150.41 83.2 6.03 Favored Pre-proline 0 N--CA 1.423 -1.789 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 174.316 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.596 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.0 Cg_endo -91.53 -179.1 1.28 Allowed 'Trans proline' 0 N--CA 1.423 -2.675 0 C-N-CA 125.071 3.847 . . . . 0.0 109.633 178.622 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.16 -29.0 68.58 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.901 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.277 -0.868 . . . . 0.0 111.211 179.799 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.417 ' O ' ' CD2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.489 2.197 0 N-CA-C 112.476 -0.25 . . . . 0.0 112.476 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.417 ' CD2' ' O ' ' A' ' 1' ' ' GLY . 0.2 OUTLIER 167.33 76.63 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.251 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.91 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 96.27 -29.09 10.69 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.652 -0.785 . . . . 0.0 111.619 -178.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -82.58 -30.42 29.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.428 0.632 . . . . 0.0 109.408 178.744 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.446 ' O ' ' N ' ' A' ' 8' ' ' ARG . 11.6 t -72.5 -22.87 20.68 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.493 0 CA-C-N 114.852 -1.067 . . . . 0.0 109.94 178.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -41.51 -25.28 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.573 179.652 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 5' ' ' VAL . . . -71.64 -41.37 57.2 Favored Glycine 0 N--CA 1.45 -0.373 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.674 179.268 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.446 ' N ' ' O ' ' A' ' 5' ' ' VAL . 2.9 mmm180 -68.21 -54.1 20.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.88 0.371 . . . . 0.0 110.055 179.249 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.413 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 5.3 mp -56.18 -31.63 63.59 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.854 179.77 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.478 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -47.3 -21.53 0.3 Allowed 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.036 -0.529 . . . . 0.0 112.082 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.499 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.7 ptm180 -88.7 -42.78 11.76 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 116.536 -0.302 . . . . 0.0 111.252 -179.46 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.457 HG13 ' N ' ' A' ' 13' ' ' LEU . 4.4 pt -54.64 -33.92 28.44 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.209 0 C-N-CA 120.465 -0.494 . . . . 0.0 110.858 -179.721 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.478 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.62 -28.68 68.69 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 178.056 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.612 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.52 -14.13 48.53 Favored Glycine 0 N--CA 1.445 -0.742 0 CA-C-N 115.253 -0.885 . . . . 0.0 111.678 178.315 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.499 ' N ' ' O ' ' A' ' 11' ' ' ARG . 9.2 mpt_? -100.2 26.87 6.07 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 120.999 0.428 . . . . 0.0 110.688 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.411 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 7.4 p -111.88 -49.48 6.08 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.047 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 179.744 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.411 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 40.7 mm -149.86 82.95 6.42 Favored Pre-proline 0 N--CA 1.422 -1.827 0 N-CA-C 106.574 -1.639 . . . . 0.0 106.574 174.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.612 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.7 Cg_endo -91.48 -179.01 1.28 Allowed 'Trans proline' 0 N--CA 1.423 -2.675 0 C-N-CA 125.091 3.861 . . . . 0.0 109.667 178.702 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.76 -27.23 67.43 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.948 179.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 C--O 1.25 1.1 0 CA-C-O 118.274 -0.869 . . . . 0.0 111.103 -179.855 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.423 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.241 0 N-CA-C 112.471 -0.252 . . . . 0.0 112.471 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.423 ' HB2' ' O ' ' A' ' 1' ' ' GLY . 0.2 OUTLIER 166.05 74.74 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -179.882 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 97.74 -28.86 12.45 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.592 -0.813 . . . . 0.0 111.444 -178.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -82.79 -29.09 29.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.465 0.65 . . . . 0.0 109.388 178.656 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.422 ' O ' ' N ' ' A' ' 7' ' ' GLY . 9.3 t -73.3 -21.27 18.8 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.561 0 CA-C-N 114.877 -1.056 . . . . 0.0 109.999 178.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -41.15 -25.21 0.03 OUTLIER 'General case' 0 CA--C 1.529 0.145 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.694 179.792 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.422 ' N ' ' O ' ' A' ' 5' ' ' VAL . . . -62.75 -40.22 98.93 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.686 -0.769 . . . . 0.0 111.407 179.131 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.406 ' O ' ' HG2' ' A' ' 11' ' ' ARG . 0.4 OUTLIER -74.61 -54.89 6.59 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 179.114 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.436 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 3.3 mp -52.02 -36.44 50.11 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.943 0.401 . . . . 0.0 110.745 179.597 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.501 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.86 -21.49 1.16 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.903 -0.59 . . . . 0.0 112.165 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.535 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.2 ptm180 -88.73 -42.42 11.96 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.453 -179.331 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.469 HG13 ' N ' ' A' ' 13' ' ' LEU . 2.8 pt -54.78 -33.79 28.85 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.221 0 C-N-CA 120.421 -0.512 . . . . 0.0 110.791 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.501 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.25 -29.27 69.48 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 177.971 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.645 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.25 -15.98 42.37 Favored Glycine 0 N--CA 1.444 -0.782 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.669 178.313 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.535 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.3 mpt_? -100.23 26.61 6.36 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 121.008 0.432 . . . . 0.0 110.677 179.694 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.412 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 7.4 p -112.02 -50.27 5.97 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 179.691 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.412 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 42.1 mm -150.27 83.75 5.93 Favored Pre-proline 0 N--CA 1.425 -1.7 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 174.855 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.645 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.3 Cg_endo -91.26 -179.28 1.39 Allowed 'Trans proline' 0 N--CA 1.423 -2.642 0 C-N-CA 124.893 3.728 . . . . 0.0 109.658 178.603 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.24 -28.69 69.9 Favored 'General case' 0 C--N 1.301 -1.541 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.964 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 18.5 t . . . . . 0 C--O 1.25 1.091 0 CA-C-O 118.235 -0.888 . . . . 0.0 111.185 179.879 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.168 0 N-CA-C 112.611 -0.195 . . . . 0.0 112.611 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.7 mt -161.73 -76.47 0.05 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.878 0.37 . . . . 0.0 110.259 179.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -87.56 -16.14 60.7 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.35 179.496 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -82.76 -33.23 27.46 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-O 121.431 0.634 . . . . 0.0 109.708 179.187 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.441 ' O ' ' N ' ' A' ' 8' ' ' ARG . 11.3 t -72.79 -28.07 26.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 114.933 -1.031 . . . . 0.0 110.209 179.269 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -41.78 -25.37 0.06 Allowed 'General case' 0 C--O 1.232 0.14 0 CA-C-N 115.406 -0.816 . . . . 0.0 110.695 179.683 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -67.98 -41.09 88.48 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.6 179.167 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.441 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -75.21 -59.47 2.73 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 110.393 -0.225 . . . . 0.0 110.393 179.25 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.414 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 1.0 OUTLIER -43.51 -30.88 0.62 Allowed 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 121.08 0.467 . . . . 0.0 111.04 179.506 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.513 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.89 -21.29 1.12 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.672 -0.695 . . . . 0.0 112.112 179.64 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.484 ' O ' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.4 -43.64 11.34 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 116.684 -0.234 . . . . 0.0 111.22 -179.146 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.474 ' N ' ' HG2' ' A' ' 11' ' ' ARG . 5.4 pt -54.79 -33.43 28.05 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 C-N-CA 120.429 -0.508 . . . . 0.0 111.101 -179.454 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.513 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -67.39 -28.86 68.28 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 178.08 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.608 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.98 -13.6 52.35 Favored Glycine 0 N--CA 1.444 -0.77 0 CA-C-N 115.2 -0.909 . . . . 0.0 111.783 178.473 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.484 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.4 mpt_? -100.18 26.76 6.18 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 120.963 0.411 . . . . 0.0 110.788 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.409 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 7.2 p -111.84 -49.29 6.12 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.037 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 179.624 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.409 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 42.1 mm -150.04 83.33 6.18 Favored Pre-proline 0 N--CA 1.424 -1.762 0 N-CA-C 106.402 -1.703 . . . . 0.0 106.402 174.539 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.608 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.9 Cg_endo -91.55 -179.38 1.32 Allowed 'Trans proline' 0 N--CA 1.422 -2.715 0 C-N-CA 125.026 3.817 . . . . 0.0 109.797 178.744 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.46 -28.46 69.23 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 115.153 -0.93 . . . . 0.0 111.074 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 19.6 t . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.218 -0.896 . . . . 0.0 111.093 179.896 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.205 0 N-CA-C 112.413 -0.275 . . . . 0.0 112.413 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.408 ' CD2' ' N ' ' A' ' 2' ' ' LEU . 2.8 mm? 61.99 85.83 0.12 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.904 0.383 . . . . 0.0 110.297 -179.716 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 99.16 -34.77 5.14 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.753 -0.737 . . . . 0.0 111.945 -179.269 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.5 m -82.78 -37.85 23.98 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-O 121.525 0.678 . . . . 0.0 109.405 178.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.465 ' O ' ' N ' ' A' ' 8' ' ' ARG . 10.1 t -74.64 -33.49 32.04 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.462 0 CA-C-N 114.816 -1.084 . . . . 0.0 110.194 179.177 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -43.11 -25.65 0.12 Allowed 'General case' 0 C--O 1.231 0.123 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.404 179.666 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -67.28 -37.87 91.18 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.512 179.248 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.465 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -83.67 -43.54 15.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.79 0.329 . . . . 0.0 110.206 179.181 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.551 ' O ' HG13 ' A' ' 12' ' ' ILE . 0.8 OUTLIER -55.05 -58.44 7.63 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.818 179.655 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.538 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.73 -21.91 0.7 Allowed 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.405 -0.361 . . . . 0.0 111.701 179.709 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.88 -44.88 10.14 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.116 -179.488 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.551 HG13 ' O ' ' A' ' 9' ' ' LEU . 1.8 pp -55.2 -42.8 67.67 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.253 0 C-N-CA 120.405 -0.518 . . . . 0.0 110.927 -179.613 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.538 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -57.66 -34.71 69.66 Favored 'General case' 0 CA--C 1.515 -0.378 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 177.912 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.585 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -62.75 -20.97 62.52 Favored Glycine 0 N--CA 1.446 -0.697 0 C-N-CA 120.118 -1.039 . . . . 0.0 110.676 177.619 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 2.2 mpt_? -99.85 27.13 5.67 Favored 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 123.118 0.567 . . . . 0.0 110.082 178.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.503 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 0.3 OUTLIER -111.21 -49.47 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.918 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 -179.947 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.503 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 37.0 mm -150.24 82.67 6.3 Favored Pre-proline 0 N--CA 1.425 -1.684 0 N-CA-C 106.54 -1.652 . . . . 0.0 106.54 174.191 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.585 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.3 Cg_endo -91.82 -178.86 1.17 Allowed 'Trans proline' 0 N--CA 1.423 -2.631 0 C-N-CA 125.251 3.967 . . . . 0.0 109.899 178.611 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.08 -28.5 66.57 Favored 'General case' 0 C--N 1.301 -1.519 0 CA-C-N 115.148 -0.933 . . . . 0.0 111.012 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 18.8 t . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.274 -0.869 . . . . 0.0 111.294 179.899 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.431 ' O ' ' HB2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.489 2.172 0 N-CA-C 112.553 -0.219 . . . . 0.0 112.553 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.431 ' HB2' ' O ' ' A' ' 1' ' ' GLY . 0.2 OUTLIER 164.98 80.22 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.924 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.402 ' O ' ' CD2' ' A' ' 6' ' ' PHE . . . 95.85 -28.4 12.72 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.64 -0.79 . . . . 0.0 111.785 -179.028 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -82.77 -30.79 28.68 Favored 'General case' 0 CA--C 1.519 -0.217 0 CA-C-O 121.568 0.699 . . . . 0.0 109.333 178.782 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.42 ' O ' ' N ' ' A' ' 7' ' ' GLY . 6.6 t -76.08 -21.3 15.5 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 CA-C-N 114.758 -1.11 . . . . 0.0 110.085 178.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.402 ' CD2' ' O ' ' A' ' 3' ' ' GLY . 0.5 OUTLIER -41.17 -25.3 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.121 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.705 179.829 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 5' ' ' VAL . . . -63.37 -40.67 99.17 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.791 -0.718 . . . . 0.0 111.425 179.255 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.412 ' O ' ' HG2' ' A' ' 11' ' ' ARG . 2.0 mpt_? -73.9 -54.9 6.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.803 0.335 . . . . 0.0 110.156 179.189 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.8 mp -52.25 -42.1 63.35 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.907 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.466 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.93 -21.6 0.69 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.016 -0.538 . . . . 0.0 112.288 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.534 ' O ' ' N ' ' A' ' 15' ' ' ARG . 1.4 ptm180 -88.93 -41.09 12.62 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-N 116.666 -0.243 . . . . 0.0 111.339 -179.514 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.479 HG13 ' N ' ' A' ' 13' ' ' LEU . 2.4 pt -54.91 -34.24 30.57 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.211 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.814 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.479 ' N ' HG13 ' A' ' 12' ' ' ILE . 0.0 OUTLIER -65.97 -28.49 68.94 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 178.032 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.634 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.43 -17.64 35.84 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.484 178.161 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.534 ' N ' ' O ' ' A' ' 11' ' ' ARG . 2.4 mpt_? -100.81 26.72 6.57 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 122.794 0.438 . . . . 0.0 110.623 179.673 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.418 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 7.4 p -111.89 -49.95 6.04 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.052 0 N-CA-C 107.741 -1.207 . . . . 0.0 107.741 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.418 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 41.6 mm -149.98 82.99 6.33 Favored Pre-proline 0 N--CA 1.426 -1.663 0 N-CA-C 106.486 -1.672 . . . . 0.0 106.486 174.634 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.634 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.1 Cg_endo -91.71 -179.0 1.22 Allowed 'Trans proline' 0 N--CA 1.424 -2.615 0 C-N-CA 125.212 3.941 . . . . 0.0 110.03 178.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.16 -28.39 69.72 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 115.021 -0.99 . . . . 0.0 111.148 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 16.6 t . . . . . 0 C--O 1.249 1.032 0 CA-C-O 118.274 -0.87 . . . . 0.0 111.154 -179.976 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.427 ' O ' ' CD2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.489 2.226 0 N-CA-C 112.398 -0.281 . . . . 0.0 112.398 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.427 ' CD2' ' O ' ' A' ' 1' ' ' GLY . 0.2 OUTLIER 166.5 76.22 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.947 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 98.03 -29.51 11.09 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.381 -178.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -82.66 -29.02 30.29 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.571 0.701 . . . . 0.0 109.262 178.472 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.426 ' O ' ' N ' ' A' ' 7' ' ' GLY . 8.3 t -73.9 -21.25 18.02 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.499 0 CA-C-N 114.739 -1.119 . . . . 0.0 109.968 178.827 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -41.01 -25.11 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.72 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 5' ' ' VAL . . . -60.74 -38.43 95.17 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.845 -0.693 . . . . 0.0 111.58 179.193 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.94 -54.34 6.13 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.03 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.413 ' HA ' HG12 ' A' ' 12' ' ' ILE . 4.8 mp -55.34 -22.77 20.63 Favored 'General case' 0 CA--C 1.528 0.132 0 CA-C-O 121.017 0.437 . . . . 0.0 110.424 179.028 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.48 ' HA ' ' CD2' ' A' ' 13' ' ' LEU . . . -63.07 -21.14 65.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.373 179.763 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.443 ' O ' ' N ' ' A' ' 14' ' ' GLY . 0.0 OUTLIER -89.41 -40.96 12.37 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.597 -179.472 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.485 HG13 ' N ' ' A' ' 13' ' ' LEU . 1.6 pt -53.79 -36.61 30.28 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.171 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.979 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.496 ' O ' HG12 ' A' ' 16' ' ' VAL . 1.5 pp -65.95 -24.34 66.79 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 177.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.652 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -92.23 -19.79 37.83 Favored Glycine 0 N--CA 1.444 -0.816 0 CA-C-N 115.102 -0.953 . . . . 0.0 111.603 178.31 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.439 ' CD ' ' O ' ' A' ' 11' ' ' ARG . 2.3 mpt_? -100.74 25.87 7.43 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 120.836 0.35 . . . . 0.0 110.947 179.614 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.496 HG12 ' O ' ' A' ' 13' ' ' LEU . 7.6 p -112.42 -50.35 5.82 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.11 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.758 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.409 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 31.9 mm -149.79 83.27 6.35 Favored Pre-proline 0 N--CA 1.423 -1.825 0 N-CA-C 106.578 -1.638 . . . . 0.0 106.578 175.446 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.652 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 3.6 Cg_endo -91.32 -178.94 1.31 Allowed 'Trans proline' 0 N--CA 1.424 -2.58 0 C-N-CA 125.049 3.833 . . . . 0.0 109.793 178.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -62.34 -23.07 66.57 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 115.227 -0.897 . . . . 0.0 111.164 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 2.6 t . . . . . 0 C--O 1.25 1.098 0 CA-C-O 118.152 -0.928 . . . . 0.0 110.848 -179.913 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.42 ' O ' ' HG ' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.489 2.208 0 N-CA-C 112.444 -0.262 . . . . 0.0 112.444 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.42 ' HG ' ' O ' ' A' ' 1' ' ' GLY . 16.9 mt -163.41 -75.14 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.938 0.399 . . . . 0.0 110.152 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -89.29 -17.84 54.51 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.188 179.203 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -82.48 -28.8 30.96 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.444 0.64 . . . . 0.0 109.578 179.005 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.432 ' O ' ' N ' ' A' ' 8' ' ' ARG . 14.1 t -74.65 -25.3 18.96 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.482 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.028 178.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -41.36 -25.47 0.04 OUTLIER 'General case' 0 C--N 1.333 -0.109 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.674 179.708 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.42 ' N ' ' C ' ' A' ' 5' ' ' VAL . . . -65.29 -40.54 96.64 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.556 179.34 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.432 ' N ' ' O ' ' A' ' 5' ' ' VAL . 1.8 mpt_? -78.23 -46.4 20.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.837 0.351 . . . . 0.0 110.459 179.368 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.447 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 1.6 mp -56.22 -60.58 3.3 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.903 179.803 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.529 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -44.44 -22.47 0.07 Allowed 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.195 -0.457 . . . . 0.0 112.056 179.74 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.431 ' HG2' ' HD3' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.57 -46.14 9.32 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.645 -179.861 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.464 HG13 ' N ' ' A' ' 13' ' ' LEU . 1.1 pp -57.48 -36.53 53.8 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.248 0 C-N-CA 120.52 -0.472 . . . . 0.0 111.149 -179.844 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.529 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -62.11 -35.35 78.45 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 178.198 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.593 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -70.6 -16.65 74.15 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.102 -1.047 . . . . 0.0 110.87 177.64 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.431 ' HD3' ' HG2' ' A' ' 11' ' ' ARG . 1.4 mpt_? -100.02 27.38 5.59 Favored 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 123.088 0.555 . . . . 0.0 110.491 179.566 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.5 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 1.0 OUTLIER -111.21 -48.82 6.38 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.972 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 179.822 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.5 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 44.1 mm -150.52 82.8 6.1 Favored Pre-proline 0 N--CA 1.424 -1.748 0 N-CA-C 106.568 -1.641 . . . . 0.0 106.568 174.257 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.593 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.7 Cg_endo -91.7 -178.9 1.2 Allowed 'Trans proline' 0 N--CA 1.423 -2.632 0 C-N-CA 125.135 3.89 . . . . 0.0 109.856 178.619 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.86 -28.9 67.94 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.197 -0.91 . . . . 0.0 110.912 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 16.6 t . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.217 -0.897 . . . . 0.0 111.266 179.819 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.184 0 N-CA-C 112.573 -0.211 . . . . 0.0 112.573 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 72.16 84.84 0.12 Allowed 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.965 0.412 . . . . 0.0 110.19 -179.652 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.418 ' O ' ' CD1' ' A' ' 6' ' ' PHE . . . 100.67 -34.58 5.47 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.797 -0.716 . . . . 0.0 111.743 -179.224 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 13.3 m -82.82 -34.69 26.84 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.579 0.704 . . . . 0.0 109.425 178.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.438 ' O ' ' N ' ' A' ' 8' ' ' ARG . 8.9 t -80.09 -24.68 11.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.472 179.387 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 7' ' ' GLY . 0.1 OUTLIER -41.36 -25.47 0.04 OUTLIER 'General case' 0 CA--C 1.527 0.073 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.657 179.84 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.446 ' N ' ' CD1' ' A' ' 6' ' ' PHE . . . -63.84 -41.37 98.83 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.666 -0.778 . . . . 0.0 111.426 179.169 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.438 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -76.66 -45.27 30.5 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.889 0.376 . . . . 0.0 110.165 179.201 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.447 ' O ' HG13 ' A' ' 12' ' ' ILE . 0.7 OUTLIER -55.35 -54.96 37.06 Favored 'General case' 0 CA--C 1.529 0.163 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.819 179.668 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.54 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -47.64 -21.88 0.43 Allowed 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 112.083 179.81 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.455 ' O ' ' HD3' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.61 -45.22 10.04 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.861 -179.655 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.471 HG13 ' N ' ' A' ' 13' ' ' LEU . 1.1 pt -53.97 -35.63 28.88 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.211 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.882 -179.711 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.54 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -63.42 -35.65 81.13 Favored 'General case' 0 CA--C 1.513 -0.473 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 177.793 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.599 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -69.56 -16.89 72.25 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 120.006 -1.092 . . . . 0.0 110.758 177.61 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.455 ' HD3' ' O ' ' A' ' 11' ' ' ARG . 9.8 mpt_? -99.7 27.06 5.64 Favored 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 123.054 0.542 . . . . 0.0 110.496 179.313 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.502 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 0.8 OUTLIER -111.42 -49.09 6.3 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.918 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 179.748 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.502 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 44.5 mm -150.51 83.16 5.98 Favored Pre-proline 0 N--CA 1.423 -1.796 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 174.292 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.599 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.3 Cg_endo -91.5 -179.27 1.32 Allowed 'Trans proline' 0 N--CA 1.423 -2.675 0 C-N-CA 125.029 3.82 . . . . 0.0 109.597 178.515 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.41 ' HG3' ' N ' ' A' ' 20' ' ' VAL . 0.0 OUTLIER -65.75 -29.7 70.25 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 115.307 -0.861 . . . . 0.0 110.818 179.856 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.41 ' N ' ' HG3' ' A' ' 19' ' ' LYS . 37.2 t . . . . . 0 C--O 1.25 1.098 0 CA-C-O 118.204 -0.903 . . . . 0.0 111.253 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.462 ' CA ' ' CG2' ' A' ' 5' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.207 0 N-CA-C 112.507 -0.237 . . . . 0.0 112.507 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.446 ' HB2' ' O ' ' A' ' 1' ' ' GLY . 0.2 OUTLIER 164.2 72.39 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -179.881 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 97.62 -28.24 15.17 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.176 -178.535 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -82.91 -27.03 30.93 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.473 0.654 . . . . 0.0 109.325 178.448 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.462 ' CG2' ' CA ' ' A' ' 1' ' ' GLY . 9.1 t -73.23 -21.4 18.94 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.489 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.048 179.049 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -41.33 -24.98 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.244 -0.889 . . . . 0.0 110.747 179.885 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.423 ' N ' ' C ' ' A' ' 5' ' ' VAL . . . -65.39 -40.76 96.57 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.714 -0.755 . . . . 0.0 111.514 179.079 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.422 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -72.65 -54.31 9.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.815 0.341 . . . . 0.0 110.165 179.223 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.427 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 3.2 mp -56.71 -32.94 66.0 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.814 179.648 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.504 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.46 -21.58 0.58 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.923 -0.581 . . . . 0.0 112.008 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.519 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.9 ptm180 -88.76 -43.02 11.58 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.273 -179.43 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.449 HG13 ' N ' ' A' ' 13' ' ' LEU . 3.8 pt -54.58 -33.75 27.75 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.188 0 C-N-CA 120.47 -0.492 . . . . 0.0 110.949 -179.652 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.504 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.07 -28.42 68.82 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 177.967 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.645 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.96 -16.71 37.62 Favored Glycine 0 N--CA 1.446 -0.671 0 CA-C-N 115.256 -0.884 . . . . 0.0 111.507 178.287 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.519 ' N ' ' O ' ' A' ' 11' ' ' ARG . 9.5 mpt_? -100.38 26.72 6.33 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.967 0.413 . . . . 0.0 110.551 179.654 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.429 HG13 ' O ' ' A' ' 13' ' ' LEU . 7.6 p -111.83 -50.05 6.06 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.0 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 179.745 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.42 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 44.1 mm -150.28 83.75 5.92 Favored Pre-proline 0 N--CA 1.427 -1.625 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 174.44 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.645 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.8 Cg_endo -91.28 -179.07 1.34 Allowed 'Trans proline' 0 N--CA 1.423 -2.625 0 C-N-CA 124.909 3.74 . . . . 0.0 109.559 178.747 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.1 -27.53 68.82 Favored 'General case' 0 C--N 1.3 -1.565 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.994 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 19.2 t . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.235 -0.888 . . . . 0.0 111.156 179.821 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.189 0 N-CA-C 112.503 -0.239 . . . . 0.0 112.503 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.421 ' CD2' ' N ' ' A' ' 2' ' ' LEU . 2.4 mm? 65.36 83.39 0.17 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.967 0.413 . . . . 0.0 110.178 -179.749 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 100.03 -33.67 6.11 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.752 -179.218 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 2.7 m -82.98 -36.55 24.98 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.572 0.701 . . . . 0.0 109.575 178.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.427 ' O ' ' N ' ' A' ' 8' ' ' ARG . 8.2 t -76.68 -30.9 19.19 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.438 0 CA-C-N 114.701 -1.136 . . . . 0.0 110.521 179.526 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.454 ' CD2' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -41.78 -25.52 0.06 Allowed 'General case' 0 CA--C 1.528 0.128 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.72 -179.975 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.454 ' N ' ' CD2' ' A' ' 6' ' ' PHE . . . -65.34 -39.39 95.86 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.454 179.018 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.427 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.5 OUTLIER -80.01 -46.29 16.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.975 0.417 . . . . 0.0 110.058 179.209 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.45 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 0.5 OUTLIER -52.52 -59.58 4.27 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.255 179.945 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.535 ' HA ' HD22 ' A' ' 13' ' ' LEU . . . -43.58 -24.66 0.12 Allowed 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 116.293 -0.412 . . . . 0.0 112.089 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.471 ' O ' ' HD2' ' A' ' 15' ' ' ARG . 0.4 OUTLIER -88.57 -45.93 9.49 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.051 -179.807 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.451 HG13 ' N ' ' A' ' 13' ' ' LEU . 1.1 pp -56.25 -35.82 44.03 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.212 0 C-N-CA 120.446 -0.501 . . . . 0.0 111.113 -179.662 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.535 HD22 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -64.22 -33.56 76.08 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 178.128 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.593 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -73.22 -14.35 79.15 Favored Glycine 0 N--CA 1.444 -0.779 0 C-N-CA 120.117 -1.04 . . . . 0.0 110.827 177.537 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.471 ' HD2' ' O ' ' A' ' 11' ' ' ARG . 0.6 OUTLIER -99.88 27.04 5.74 Favored 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 123.03 0.532 . . . . 0.0 110.401 179.493 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.502 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 1.4 p -111.46 -48.89 6.28 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.926 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 179.824 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.502 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 43.3 mm -150.38 82.85 6.16 Favored Pre-proline 0 N--CA 1.423 -1.783 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 174.395 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.593 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.9 Cg_endo -91.69 -178.93 1.21 Allowed 'Trans proline' 0 N--CA 1.425 -2.544 0 C-N-CA 125.211 3.94 . . . . 0.0 109.942 178.771 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.47 -28.65 69.81 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.102 -0.954 . . . . 0.0 111.068 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.264 -0.875 . . . . 0.0 111.254 179.921 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.181 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.6 mt 69.69 -66.37 0.27 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.83 0.348 . . . . 0.0 110.642 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.419 ' O ' ' CD1' ' A' ' 6' ' ' PHE . . . -91.49 -24.26 26.6 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.292 179.578 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.8 m -83.01 -33.17 26.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.521 0.677 . . . . 0.0 109.659 179.019 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.476 ' O ' ' N ' ' A' ' 8' ' ' ARG . 6.3 t -80.39 -27.09 11.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.677 179.578 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.459 ' CD1' ' N ' ' A' ' 7' ' ' GLY . 0.1 OUTLIER -42.9 -25.29 0.09 Allowed 'General case' 0 C--O 1.231 0.12 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.519 179.828 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.459 ' N ' ' CD1' ' A' ' 6' ' ' PHE . . . -72.48 -37.46 58.46 Favored Glycine 0 N--CA 1.45 -0.41 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.651 179.372 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.476 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -73.11 -59.76 2.56 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.649 0.262 . . . . 0.0 110.354 179.345 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.454 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 0.4 OUTLIER -48.08 -30.8 4.79 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 120.97 0.415 . . . . 0.0 110.875 179.638 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.529 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.96 -21.57 1.25 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.836 -0.62 . . . . 0.0 112.185 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.485 ' O ' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.98 -43.38 11.18 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 116.707 -0.224 . . . . 0.0 111.186 -179.417 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.476 ' N ' ' HG2' ' A' ' 11' ' ' ARG . 3.1 pt -54.27 -33.56 25.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 C-N-CA 120.475 -0.49 . . . . 0.0 111.085 -179.521 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.529 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.05 -28.55 68.93 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 177.908 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.637 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.78 -17.16 39.31 Favored Glycine 0 N--CA 1.444 -0.782 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.635 178.351 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.485 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.7 mpt_? -100.46 26.74 6.35 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 120.949 0.404 . . . . 0.0 110.809 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.421 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 7.1 p -111.6 -49.84 6.16 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.082 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 179.789 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.421 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 42.4 mm -150.2 83.23 6.13 Favored Pre-proline 0 N--CA 1.424 -1.754 0 N-CA-C 106.565 -1.642 . . . . 0.0 106.565 174.595 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.637 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.5 Cg_endo -91.32 -179.0 1.32 Allowed 'Trans proline' 0 N--CA 1.423 -2.659 0 C-N-CA 124.983 3.789 . . . . 0.0 109.777 178.768 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.58 -29.8 69.94 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 115.141 -0.936 . . . . 0.0 110.949 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 18.4 t . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.247 -0.882 . . . . 0.0 111.239 179.971 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.205 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.2 mm? 62.49 86.15 0.12 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.856 0.36 . . . . 0.0 110.554 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 98.31 -33.76 5.76 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.776 -0.726 . . . . 0.0 111.925 -179.426 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 2.5 m -83.02 -36.88 24.63 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.576 0.703 . . . . 0.0 109.417 178.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.463 ' O ' ' N ' ' A' ' 8' ' ' ARG . 6.6 t -78.72 -31.49 15.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 114.689 -1.141 . . . . 0.0 110.644 179.53 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.458 ' CD1' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -42.47 -25.61 0.09 Allowed 'General case' 0 CA--C 1.528 0.102 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.731 179.993 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . 0.458 ' N ' ' CD1' ' A' ' 6' ' ' PHE . . . -70.83 -38.58 65.72 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.768 -0.73 . . . . 0.0 111.587 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . 0.463 ' N ' ' O ' ' A' ' 5' ' ' VAL . 9.3 mmm180 -75.92 -52.52 10.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.857 0.36 . . . . 0.0 110.217 179.25 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.457 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 0.7 OUTLIER -50.1 -38.35 38.3 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.063 179.833 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.543 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -46.57 -21.53 0.19 Allowed 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.215 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.468 ' HG2' ' N ' ' A' ' 12' ' ' ILE . 0.0 OUTLIER -88.44 -43.77 11.22 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.877 -179.398 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . 0.468 ' N ' ' HG2' ' A' ' 11' ' ' ARG . 2.7 pt -57.32 -32.3 40.59 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.178 0 C-N-CA 120.454 -0.498 . . . . 0.0 111.011 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . 0.543 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -68.41 -28.03 66.73 Favored 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 178.188 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.611 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -90.55 -15.01 57.63 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.435 -0.888 . . . . 0.0 111.07 177.985 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.449 ' HD3' ' CG ' ' A' ' 11' ' ' ARG . 0.7 OUTLIER -100.35 26.93 6.1 Favored 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 122.626 0.371 . . . . 0.0 110.938 179.841 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.499 HG13 ' O ' ' A' ' 13' ' ' LEU . 8.6 p -111.63 -48.92 6.21 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.015 0 N-CA-C 107.391 -1.337 . . . . 0.0 107.391 179.679 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.419 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 39.7 mm -150.08 83.07 6.25 Favored Pre-proline 0 N--CA 1.425 -1.722 0 N-CA-C 106.522 -1.658 . . . . 0.0 106.522 174.579 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.611 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 3.8 Cg_endo -91.56 -179.06 1.27 Allowed 'Trans proline' 0 N--CA 1.424 -2.612 0 C-N-CA 125.019 3.813 . . . . 0.0 109.961 178.838 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.2 -29.26 70.38 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.943 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 20.7 t . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.234 -0.889 . . . . 0.0 111.143 179.984 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.52 -0.203 0 CA-C-O 121.523 0.678 . . . . 0.0 109.519 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.701 HG12 HD12 ' A' ' 9' ' ' LEU . 9.2 t -79.31 -30.02 13.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 114.814 -1.084 . . . . 0.0 110.638 179.599 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.458 ' CD2' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -42.14 -25.38 0.07 Allowed 'General case' 0 CA--C 1.528 0.13 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.752 179.942 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.458 ' N ' ' CD2' ' A' ' 6' ' ' PHE . . . -66.02 -38.61 94.25 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.725 -0.75 . . . . 0.0 111.605 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.409 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -80.8 -51.99 8.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.67 0.272 . . . . 0.0 110.41 179.41 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.701 HD12 HG12 ' A' ' 5' ' ' VAL . 2.9 mp -51.96 -38.47 56.64 Favored 'General case' 0 CA--C 1.529 0.156 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.897 179.766 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.579 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -50.75 -21.45 1.64 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.183 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.47 ' O ' ' N ' ' A' ' 15' ' ' ARG . 1.7 ptm180 -88.77 -41.39 12.56 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.551 -179.183 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.477 HG13 ' N ' ' A' ' 13' ' ' LEU . 3.7 pt -54.62 -35.46 32.38 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.178 0 C-N-CA 120.369 -0.533 . . . . 0.0 110.817 -179.637 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.579 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.05 -26.98 67.75 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 177.879 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.633 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -93.96 -17.02 42.33 Favored Glycine 0 N--CA 1.444 -0.806 0 CA-C-N 115.187 -0.915 . . . . 0.0 111.532 178.273 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.47 ' N ' ' O ' ' A' ' 11' ' ' ARG . 2.5 mpt_? -100.35 26.58 6.46 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 120.956 0.408 . . . . 0.0 110.716 179.718 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.622 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.3 p -112.19 -50.42 5.9 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.02 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 179.67 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.622 HD13 ' O ' ' A' ' 16' ' ' VAL . 40.4 mm -150.15 83.82 5.97 Favored Pre-proline 0 N--CA 1.425 -1.703 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 174.94 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.633 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.8 Cg_endo -91.37 -179.18 1.34 Allowed 'Trans proline' 0 N--CA 1.422 -2.684 0 C-N-CA 124.904 3.736 . . . . 0.0 109.808 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.55 -29.46 70.72 Favored 'General case' 0 C--N 1.299 -1.604 0 CA-C-N 115.152 -0.931 . . . . 0.0 111.001 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 18' ' ' PRO . 21.5 t . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.287 -0.863 . . . . 0.0 111.092 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.518 -0.253 0 CA-C-O 121.577 0.703 . . . . 0.0 109.398 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.638 HG12 HD12 ' A' ' 9' ' ' LEU . 5.5 t -76.47 -30.0 19.09 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.448 0 CA-C-N 114.658 -1.155 . . . . 0.0 110.394 179.406 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.451 ' CD2' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -41.56 -25.61 0.05 Allowed 'General case' 0 C--O 1.232 0.138 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.738 179.936 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.451 ' N ' ' CD2' ' A' ' 6' ' ' PHE . . . -68.89 -42.01 80.18 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.359 179.045 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.464 ' N ' ' O ' ' A' ' 5' ' ' VAL . 2.0 mpt_? -71.03 -54.36 11.46 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 179.088 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.638 HD12 HG12 ' A' ' 5' ' ' VAL . 2.3 mp -50.58 -33.57 22.47 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 120.966 0.412 . . . . 0.0 110.71 179.646 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.549 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.61 -21.44 1.01 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.917 -0.583 . . . . 0.0 112.076 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.521 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.2 ptm180 -88.73 -42.43 11.95 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.326 -179.265 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.464 HG13 ' N ' ' A' ' 13' ' ' LEU . 3.8 pt -54.19 -34.38 27.07 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.181 0 C-N-CA 120.376 -0.529 . . . . 0.0 110.927 -179.685 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.564 ' O ' HG12 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -66.39 -28.89 68.99 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 178.023 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.638 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.67 -15.95 44.33 Favored Glycine 0 N--CA 1.445 -0.76 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.59 178.271 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.521 ' N ' ' O ' ' A' ' 11' ' ' ARG . 9.1 mpt_? -100.71 26.69 6.55 Favored 'General case' 0 N--CA 1.465 0.316 0 C-N-CA 122.768 0.427 . . . . 0.0 110.642 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.627 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.2 p -111.77 -50.41 6.05 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.994 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.627 HD13 ' O ' ' A' ' 16' ' ' VAL . 42.4 mm -150.2 83.51 6.04 Favored Pre-proline 0 N--CA 1.425 -1.685 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 174.61 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.638 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.5 Cg_endo -91.35 -179.15 1.34 Allowed 'Trans proline' 0 N--CA 1.423 -2.653 0 C-N-CA 125.002 3.802 . . . . 0.0 109.95 178.782 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.01 -26.95 69.09 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 115.135 -0.939 . . . . 0.0 111.135 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.495 HG23 ' O ' ' A' ' 18' ' ' PRO . 18.6 t . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.279 -0.867 . . . . 0.0 111.174 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.52 -0.193 0 CA-C-O 121.467 0.651 . . . . 0.0 109.483 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.726 HG12 HD12 ' A' ' 9' ' ' LEU . 9.3 t -78.04 -30.33 16.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 114.827 -1.079 . . . . 0.0 110.47 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.448 ' CD1' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -41.8 -25.28 0.05 Allowed 'General case' 0 CA--C 1.529 0.138 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.78 -179.978 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.448 ' N ' ' CD1' ' A' ' 6' ' ' PHE . . . -64.18 -40.25 97.85 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.721 -0.752 . . . . 0.0 111.476 179.124 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -79.72 -51.14 9.59 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.751 0.31 . . . . 0.0 110.364 179.277 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.726 HD12 HG12 ' A' ' 5' ' ' VAL . 1.4 mp -51.32 -38.28 52.16 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-O 121.09 0.471 . . . . 0.0 110.507 179.515 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.546 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.7 -21.12 0.55 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.949 179.567 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.481 ' O ' ' CD ' ' A' ' 15' ' ' ARG . 1.3 ptm180 -88.17 -42.31 12.41 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.235 -179.394 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.478 HG13 ' N ' ' A' ' 13' ' ' LEU . 5.1 pt -55.53 -34.68 35.66 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.17 0 C-N-CA 120.329 -0.549 . . . . 0.0 110.734 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.591 ' O ' HG12 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -66.38 -27.25 67.72 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 178.053 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.626 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.06 -16.74 43.15 Favored Glycine 0 N--CA 1.443 -0.834 0 CA-C-N 115.276 -0.875 . . . . 0.0 111.303 178.197 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.481 ' CD ' ' O ' ' A' ' 11' ' ' ARG . 1.7 mpt_? -100.22 26.91 6.04 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.004 0.43 . . . . 0.0 110.528 179.602 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.631 ' O ' HD13 ' A' ' 17' ' ' ILE . 9.1 p -111.45 -49.82 6.22 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.038 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.631 HD13 ' O ' ' A' ' 16' ' ' VAL . 40.5 mm -150.2 83.27 6.12 Favored Pre-proline 0 N--CA 1.424 -1.738 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 174.514 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.626 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.1 Cg_endo -91.39 -179.05 1.31 Allowed 'Trans proline' 0 N--CA 1.424 -2.616 0 C-N-CA 124.916 3.744 . . . . 0.0 109.801 178.696 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.39 -30.24 69.96 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.006 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 17.2 t . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.234 -0.889 . . . . 0.0 111.283 179.892 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.518 -0.281 0 CA-C-O 121.587 0.708 . . . . 0.0 109.354 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.821 HG12 HD12 ' A' ' 9' ' ' LEU . 5.5 t -74.64 -30.08 24.43 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.428 0 CA-C-N 114.621 -1.172 . . . . 0.0 110.279 179.237 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -42.78 -25.45 0.09 Allowed 'General case' 0 C--O 1.232 0.141 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.375 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -69.77 -40.67 75.57 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.816 -0.707 . . . . 0.0 111.388 178.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.461 ' N ' ' O ' ' A' ' 5' ' ' VAL . 1.0 OUTLIER -72.43 -54.14 10.19 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.772 0.32 . . . . 0.0 110.389 179.262 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.821 HD12 HG12 ' A' ' 5' ' ' VAL . 1.7 mp -53.8 -35.03 60.95 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 121.057 0.456 . . . . 0.0 110.718 179.623 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.623 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -47.72 -21.6 0.41 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.759 -0.655 . . . . 0.0 112.209 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.458 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.2 ptm180 -89.1 -41.54 12.23 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-N 116.603 -0.272 . . . . 0.0 111.469 -179.574 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.459 HG13 ' N ' ' A' ' 13' ' ' LEU . 4.9 pt -54.87 -34.73 31.57 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.234 0 C-N-CA 120.497 -0.481 . . . . 0.0 110.82 -179.7 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.623 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -65.3 -27.16 68.43 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.811 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.606 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -93.65 -19.38 34.9 Favored Glycine 0 N--CA 1.444 -0.768 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.506 178.166 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.458 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.7 mpt_? -100.16 26.28 6.64 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 120.863 0.363 . . . . 0.0 110.638 179.571 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.61 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.5 p -112.07 -49.63 6.0 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.064 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.61 HD13 ' O ' ' A' ' 16' ' ' VAL . 38.7 mm -149.74 83.19 6.4 Favored Pre-proline 0 N--CA 1.424 -1.748 0 N-CA-C 106.51 -1.663 . . . . 0.0 106.51 174.823 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.606 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.0 Cg_endo -91.58 -178.94 1.24 Allowed 'Trans proline' 0 N--CA 1.423 -2.618 0 C-N-CA 125.048 3.832 . . . . 0.0 109.746 178.692 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.92 -30.56 68.0 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.845 179.786 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.189 -0.91 . . . . 0.0 111.182 179.984 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.521 -0.153 0 CA-C-O 121.398 0.618 . . . . 0.0 109.798 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.608 HG12 HD12 ' A' ' 9' ' ' LEU . 15.0 t -72.82 -23.81 20.83 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.425 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.282 179.323 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -41.54 -25.24 0.04 OUTLIER 'General case' 0 C--N 1.333 -0.132 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.633 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.417 ' N ' ' C ' ' A' ' 5' ' ' VAL . . . -67.22 -41.03 92.33 Favored Glycine 0 N--CA 1.45 -0.423 0 CA-C-N 115.577 -0.738 . . . . 0.0 111.68 179.217 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.432 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -73.62 -54.74 7.46 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 179.251 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.608 HD12 HG12 ' A' ' 5' ' ' VAL . 2.8 mp -52.44 -34.53 49.17 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 120.982 0.42 . . . . 0.0 110.741 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.567 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -50.28 -21.51 1.41 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.989 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.501 ' O ' ' N ' ' A' ' 15' ' ' ARG . 3.1 ptm180 -88.68 -42.78 11.77 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.392 -179.311 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.485 HG13 ' N ' ' A' ' 13' ' ' LEU . 4.8 pt -53.39 -35.89 25.71 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.194 0 C-N-CA 120.364 -0.534 . . . . 0.0 110.823 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.567 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -65.03 -28.73 69.69 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 178.133 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.632 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.6 -16.16 43.75 Favored Glycine 0 N--CA 1.445 -0.763 0 CA-C-N 115.269 -0.878 . . . . 0.0 111.672 178.412 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.501 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.8 mpt_? -100.46 26.69 6.4 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 122.721 0.408 . . . . 0.0 110.733 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.618 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.1 p -111.92 -50.22 6.01 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.015 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.618 HD13 ' O ' ' A' ' 16' ' ' VAL . 42.6 mm -150.21 83.5 6.04 Favored Pre-proline 0 N--CA 1.424 -1.731 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 174.715 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.632 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.9 Cg_endo -91.36 -179.09 1.32 Allowed 'Trans proline' 0 N--CA 1.423 -2.629 0 C-N-CA 124.98 3.787 . . . . 0.0 109.754 178.774 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.61 -29.54 70.78 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.983 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 18' ' ' PRO . 20.8 t . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.297 -0.859 . . . . 0.0 111.195 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.519 -0.242 0 CA-C-O 121.53 0.681 . . . . 0.0 109.507 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.739 HG12 HD12 ' A' ' 9' ' ' LEU . 6.2 t -75.53 -29.2 20.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.402 179.384 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -41.53 -25.67 0.05 Allowed 'General case' 0 C--N 1.333 -0.121 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.661 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -65.18 -40.55 96.86 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.383 179.179 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.464 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -75.85 -52.55 10.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.789 0.328 . . . . 0.0 110.14 179.136 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.739 HD12 HG12 ' A' ' 5' ' ' VAL . 5.1 mp -52.43 -38.53 59.39 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.006 0.431 . . . . 0.0 110.618 179.609 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.561 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.3 -21.18 0.78 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.981 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.519 ' O ' ' N ' ' A' ' 15' ' ' ARG . 2.2 ptm180 -88.13 -42.08 12.59 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.338 -179.311 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.459 HG13 ' N ' ' A' ' 13' ' ' LEU . 4.5 pt -55.36 -34.79 34.83 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.218 0 C-N-CA 120.35 -0.54 . . . . 0.0 110.838 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.561 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.45 -27.73 68.04 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 178.089 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.632 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.7 -17.22 39.35 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.303 178.014 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.519 ' N ' ' O ' ' A' ' 11' ' ' ARG . 9.2 mpt_? -100.87 26.41 6.94 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 122.693 0.397 . . . . 0.0 110.866 179.816 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.608 ' O ' HD13 ' A' ' 17' ' ' ILE . 8.2 p -112.34 -50.32 5.85 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.059 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.608 HD13 ' O ' ' A' ' 16' ' ' VAL . 44.4 mm -150.29 83.78 5.91 Favored Pre-proline 0 N--CA 1.424 -1.743 0 N-CA-C 106.517 -1.66 . . . . 0.0 106.517 174.816 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.632 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.0 Cg_endo -91.24 -179.28 1.39 Allowed 'Trans proline' 0 N--CA 1.422 -2.702 0 C-N-CA 124.836 3.691 . . . . 0.0 109.569 178.662 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.23 -28.73 69.56 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 115.116 -0.947 . . . . 0.0 111.051 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.416 HG23 ' O ' ' A' ' 18' ' ' PRO . 20.1 t . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.245 -0.883 . . . . 0.0 111.232 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.517 -0.304 0 CA-C-O 121.65 0.738 . . . . 0.0 109.357 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.721 HG12 HD12 ' A' ' 9' ' ' LEU . 4.8 t -74.34 -32.19 30.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 114.652 -1.158 . . . . 0.0 110.315 179.352 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -42.14 -26.0 0.09 Allowed 'General case' 0 CA--C 1.528 0.112 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.583 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -71.72 -41.65 55.98 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.742 -0.742 . . . . 0.0 111.595 179.339 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.445 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -71.69 -52.07 19.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.676 0.274 . . . . 0.0 110.462 179.359 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.721 HD12 HG12 ' A' ' 5' ' ' VAL . 3.2 mp -55.1 -33.52 62.9 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.165 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.539 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.18 -21.53 0.5 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.137 -0.483 . . . . 0.0 112.097 179.839 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.505 ' O ' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.5 -44.67 10.53 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.022 -179.579 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.479 ' HA ' ' HB2' ' A' ' 15' ' ' ARG . 2.5 pt -54.76 -32.17 25.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 C-N-CA 120.552 -0.459 . . . . 0.0 111.163 -179.751 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.539 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -67.74 -29.25 68.43 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 178.201 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.577 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.96 -13.81 48.32 Favored Glycine 0 N--CA 1.445 -0.746 0 C-N-CA 120.478 -0.868 . . . . 0.0 111.458 178.137 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.505 ' N ' ' O ' ' A' ' 11' ' ' ARG . 0.4 OUTLIER -100.39 26.99 6.05 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 121.069 0.461 . . . . 0.0 110.775 -179.942 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.615 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.4 p -111.61 -49.36 6.2 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.032 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 179.491 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.615 HD13 ' O ' ' A' ' 16' ' ' VAL . 39.9 mm -150.03 83.63 6.09 Favored Pre-proline 0 N--CA 1.424 -1.741 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 174.375 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.577 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.4 Cg_endo -91.19 -179.17 1.39 Allowed 'Trans proline' 0 N--CA 1.424 -2.575 0 C-N-CA 125.001 3.801 . . . . 0.0 109.695 178.756 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.21 -29.58 69.28 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 115.238 -0.892 . . . . 0.0 110.811 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.5 t . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.276 -0.869 . . . . 0.0 111.226 179.8 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 CA--C 1.519 -0.217 0 CA-C-O 121.45 0.643 . . . . 0.0 109.47 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.449 ' O ' ' N ' ' A' ' 8' ' ' ARG . 10.5 t -81.0 -27.91 11.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.604 179.459 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.474 ' CD2' ' N ' ' A' ' 7' ' ' GLY . 0.1 OUTLIER -41.49 -25.44 0.05 OUTLIER 'General case' 0 C--O 1.231 0.128 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.738 -179.942 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.474 ' N ' ' CD2' ' A' ' 6' ' ' PHE . . . -69.05 -40.82 83.3 Favored Glycine 0 N--CA 1.45 -0.387 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.586 179.318 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.449 ' N ' ' O ' ' A' ' 5' ' ' VAL . 1.6 mpt_? -74.68 -47.18 33.13 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.878 0.371 . . . . 0.0 110.146 179.296 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.507 ' O ' HG13 ' A' ' 12' ' ' ILE . 1.0 OUTLIER -52.24 -60.25 3.44 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.993 179.709 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.604 ' HA ' HD11 ' A' ' 13' ' ' LEU . . . -44.64 -24.27 0.18 Allowed 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.963 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.475 ' NH2' HG22 ' A' ' 12' ' ' ILE . 0.0 OUTLIER -88.56 -48.24 7.72 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.808 -179.897 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.507 HG13 ' O ' ' A' ' 9' ' ' LEU . 1.1 pp -58.81 -36.94 63.52 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.204 0 C-N-CA 120.416 -0.514 . . . . 0.0 111.447 -179.617 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.604 HD11 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -62.36 -34.63 77.06 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 178.482 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.584 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -71.7 -12.9 74.62 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.079 -1.057 . . . . 0.0 111.034 177.75 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.45 ' HD2' ' N ' ' A' ' 15' ' ' ARG . 0.9 OUTLIER -99.67 27.35 5.43 Favored 'General case' 0 N--CA 1.465 0.319 0 C-N-CA 123.016 0.527 . . . . 0.0 110.51 179.646 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.592 ' O ' HD13 ' A' ' 17' ' ' ILE . 1.9 p -111.26 -49.01 6.37 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.934 0 N-CA-C 107.164 -1.421 . . . . 0.0 107.164 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.592 HD13 ' O ' ' A' ' 16' ' ' VAL . 44.2 mm -150.41 83.2 6.03 Favored Pre-proline 0 N--CA 1.423 -1.789 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 174.316 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.584 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.0 Cg_endo -91.53 -179.1 1.28 Allowed 'Trans proline' 0 N--CA 1.423 -2.675 0 C-N-CA 125.071 3.847 . . . . 0.0 109.633 178.622 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.16 -29.0 68.58 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.901 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.277 -0.868 . . . . 0.0 111.211 179.799 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.52 -0.193 0 CA-C-O 121.428 0.632 . . . . 0.0 109.408 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.676 HG12 HD12 ' A' ' 9' ' ' LEU . 11.6 t -72.5 -22.87 20.68 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.493 0 CA-C-N 114.852 -1.067 . . . . 0.0 109.94 178.86 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -41.51 -25.28 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.573 179.652 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 5' ' ' VAL . . . -71.64 -41.37 57.2 Favored Glycine 0 N--CA 1.45 -0.373 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.674 179.268 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.446 ' N ' ' O ' ' A' ' 5' ' ' VAL . 2.9 mmm180 -68.21 -54.1 20.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.88 0.371 . . . . 0.0 110.055 179.249 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.676 HD12 HG12 ' A' ' 5' ' ' VAL . 5.3 mp -56.18 -31.63 63.59 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.854 179.77 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.554 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -47.3 -21.53 0.3 Allowed 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.036 -0.529 . . . . 0.0 112.082 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.499 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.7 ptm180 -88.7 -42.78 11.76 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 116.536 -0.302 . . . . 0.0 111.252 -179.46 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.469 HG13 ' N ' ' A' ' 13' ' ' LEU . 4.4 pt -54.64 -33.92 28.44 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.209 0 C-N-CA 120.465 -0.494 . . . . 0.0 110.858 -179.721 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.554 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.62 -28.68 68.69 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 178.056 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.604 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.52 -14.13 48.53 Favored Glycine 0 N--CA 1.445 -0.742 0 CA-C-N 115.253 -0.885 . . . . 0.0 111.678 178.315 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.499 ' N ' ' O ' ' A' ' 11' ' ' ARG . 9.2 mpt_? -100.2 26.87 6.07 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 120.999 0.428 . . . . 0.0 110.688 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.62 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.4 p -111.88 -49.48 6.08 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.047 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 179.744 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.62 HD13 ' O ' ' A' ' 16' ' ' VAL . 40.7 mm -149.86 82.95 6.42 Favored Pre-proline 0 N--CA 1.422 -1.827 0 N-CA-C 106.574 -1.639 . . . . 0.0 106.574 174.747 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.604 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.7 Cg_endo -91.48 -179.01 1.28 Allowed 'Trans proline' 0 N--CA 1.423 -2.675 0 C-N-CA 125.091 3.861 . . . . 0.0 109.667 178.702 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.451 ' HZ2' ' C ' ' A' ' 20' ' ' VAL . 0.0 OUTLIER -66.76 -27.23 67.43 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.948 179.908 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.451 ' C ' ' HZ2' ' A' ' 19' ' ' LYS . 16.2 t . . . . . 0 C--O 1.25 1.1 0 CA-C-O 118.274 -0.869 . . . . 0.0 111.103 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.52 -0.208 0 CA-C-O 121.465 0.65 . . . . 0.0 109.388 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.442 ' O ' ' N ' ' A' ' 8' ' ' ARG . 9.3 t -73.3 -21.27 18.8 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.561 0 CA-C-N 114.877 -1.056 . . . . 0.0 109.999 178.897 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -41.15 -25.21 0.03 OUTLIER 'General case' 0 CA--C 1.529 0.145 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.694 179.792 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.422 ' N ' ' O ' ' A' ' 5' ' ' VAL . . . -62.75 -40.22 98.93 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.686 -0.769 . . . . 0.0 111.407 179.131 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.442 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.4 OUTLIER -74.61 -54.89 6.59 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 179.114 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.436 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 3.3 mp -52.02 -36.44 50.11 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.943 0.401 . . . . 0.0 110.745 179.597 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.556 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.86 -21.49 1.16 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.903 -0.59 . . . . 0.0 112.165 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.535 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.2 ptm180 -88.73 -42.42 11.96 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.453 -179.331 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.481 HG13 ' N ' ' A' ' 13' ' ' LEU . 2.8 pt -54.78 -33.79 28.85 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.221 0 C-N-CA 120.421 -0.512 . . . . 0.0 110.791 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.556 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.25 -29.27 69.48 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 177.971 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.636 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.25 -15.98 42.37 Favored Glycine 0 N--CA 1.444 -0.782 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.669 178.313 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.535 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.3 mpt_? -100.23 26.61 6.36 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 121.008 0.432 . . . . 0.0 110.677 179.694 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.623 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.4 p -112.02 -50.27 5.97 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 179.691 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.623 HD13 ' O ' ' A' ' 16' ' ' VAL . 42.1 mm -150.27 83.75 5.93 Favored Pre-proline 0 N--CA 1.425 -1.7 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 174.855 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.636 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.3 Cg_endo -91.26 -179.28 1.39 Allowed 'Trans proline' 0 N--CA 1.423 -2.642 0 C-N-CA 124.893 3.728 . . . . 0.0 109.658 178.603 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.24 -28.69 69.9 Favored 'General case' 0 C--N 1.301 -1.541 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.964 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.45 HG23 ' O ' ' A' ' 18' ' ' PRO . 18.5 t . . . . . 0 C--O 1.25 1.091 0 CA-C-O 118.235 -0.888 . . . . 0.0 111.185 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.52 -0.198 0 CA-C-O 121.431 0.634 . . . . 0.0 109.708 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.59 HG12 HD12 ' A' ' 9' ' ' LEU . 11.3 t -72.79 -28.07 26.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 114.933 -1.031 . . . . 0.0 110.209 179.269 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -41.78 -25.37 0.06 Allowed 'General case' 0 C--O 1.232 0.14 0 CA-C-N 115.406 -0.816 . . . . 0.0 110.695 179.683 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -67.98 -41.09 88.48 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.6 179.167 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.441 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -75.21 -59.47 2.73 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 110.393 -0.225 . . . . 0.0 110.393 179.25 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.59 HD12 HG12 ' A' ' 5' ' ' VAL . 1.0 OUTLIER -43.51 -30.88 0.62 Allowed 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 121.08 0.467 . . . . 0.0 111.04 179.506 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.562 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.89 -21.29 1.12 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.672 -0.695 . . . . 0.0 112.112 179.64 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.484 ' O ' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.4 -43.64 11.34 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 116.684 -0.234 . . . . 0.0 111.22 -179.146 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.472 ' N ' ' HG2' ' A' ' 11' ' ' ARG . 5.4 pt -54.79 -33.43 28.05 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 C-N-CA 120.429 -0.508 . . . . 0.0 111.101 -179.454 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.562 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -67.39 -28.86 68.28 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 178.08 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.6 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.98 -13.6 52.35 Favored Glycine 0 N--CA 1.444 -0.77 0 CA-C-N 115.2 -0.909 . . . . 0.0 111.783 178.473 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.484 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.4 mpt_? -100.18 26.76 6.18 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 120.963 0.411 . . . . 0.0 110.788 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.615 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.2 p -111.84 -49.29 6.12 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.037 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 179.624 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.615 HD13 ' O ' ' A' ' 16' ' ' VAL . 42.1 mm -150.04 83.33 6.18 Favored Pre-proline 0 N--CA 1.424 -1.762 0 N-CA-C 106.402 -1.703 . . . . 0.0 106.402 174.539 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.6 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.9 Cg_endo -91.55 -179.38 1.32 Allowed 'Trans proline' 0 N--CA 1.422 -2.715 0 C-N-CA 125.026 3.817 . . . . 0.0 109.797 178.744 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.46 -28.46 69.23 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 115.153 -0.93 . . . . 0.0 111.074 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.401 HG23 ' O ' ' A' ' 18' ' ' PRO . 19.6 t . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.218 -0.896 . . . . 0.0 111.093 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.5 m . . . . . 0 CA--C 1.518 -0.275 0 CA-C-O 121.525 0.678 . . . . 0.0 109.405 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.78 HG12 HD12 ' A' ' 9' ' ' LEU . 10.1 t -74.64 -33.49 32.04 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.462 0 CA-C-N 114.816 -1.084 . . . . 0.0 110.194 179.177 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -43.11 -25.65 0.12 Allowed 'General case' 0 C--O 1.231 0.123 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.404 179.666 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -67.28 -37.87 91.18 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.512 179.248 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.465 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -83.67 -43.54 15.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.79 0.329 . . . . 0.0 110.206 179.181 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.78 HD12 HG12 ' A' ' 5' ' ' VAL . 0.8 OUTLIER -55.05 -58.44 7.63 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.818 179.655 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.627 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.73 -21.91 0.7 Allowed 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.405 -0.361 . . . . 0.0 111.701 179.709 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.699 HH21 HG22 ' A' ' 12' ' ' ILE . 0.0 OUTLIER -88.88 -44.88 10.14 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.116 -179.488 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.699 HG22 HH21 ' A' ' 11' ' ' ARG . 1.8 pp -55.2 -42.8 67.67 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.253 0 C-N-CA 120.405 -0.518 . . . . 0.0 110.927 -179.613 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.627 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -57.66 -34.71 69.66 Favored 'General case' 0 CA--C 1.515 -0.378 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 177.912 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.581 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -62.75 -20.97 62.52 Favored Glycine 0 N--CA 1.446 -0.697 0 C-N-CA 120.118 -1.039 . . . . 0.0 110.676 177.619 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.406 ' NE ' ' HG2' ' A' ' 11' ' ' ARG . 2.2 mpt_? -99.85 27.13 5.67 Favored 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 123.118 0.567 . . . . 0.0 110.082 178.951 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.503 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 0.3 OUTLIER -111.21 -49.47 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.918 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 -179.947 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.503 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 37.0 mm -150.24 82.67 6.3 Favored Pre-proline 0 N--CA 1.425 -1.684 0 N-CA-C 106.54 -1.652 . . . . 0.0 106.54 174.191 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.581 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.3 Cg_endo -91.82 -178.86 1.17 Allowed 'Trans proline' 0 N--CA 1.423 -2.631 0 C-N-CA 125.251 3.967 . . . . 0.0 109.899 178.611 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.08 -28.5 66.57 Favored 'General case' 0 C--N 1.301 -1.519 0 CA-C-N 115.148 -0.933 . . . . 0.0 111.012 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 18.8 t . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.274 -0.869 . . . . 0.0 111.294 179.899 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.519 -0.217 0 CA-C-O 121.568 0.699 . . . . 0.0 109.333 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.442 ' O ' ' N ' ' A' ' 8' ' ' ARG . 6.6 t -76.08 -21.3 15.5 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 CA-C-N 114.758 -1.11 . . . . 0.0 110.085 178.953 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -41.17 -25.3 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.121 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.705 179.829 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 5' ' ' VAL . . . -63.37 -40.67 99.17 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.791 -0.718 . . . . 0.0 111.425 179.255 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.442 ' N ' ' O ' ' A' ' 5' ' ' VAL . 2.0 mpt_? -73.9 -54.9 6.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.803 0.335 . . . . 0.0 110.156 179.189 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.8 mp -52.25 -42.1 63.35 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.907 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.548 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.93 -21.6 0.69 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.016 -0.538 . . . . 0.0 112.288 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.534 ' O ' ' N ' ' A' ' 15' ' ' ARG . 1.4 ptm180 -88.93 -41.09 12.62 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-N 116.666 -0.243 . . . . 0.0 111.339 -179.514 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.491 HG13 ' N ' ' A' ' 13' ' ' LEU . 2.4 pt -54.91 -34.24 30.57 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.211 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.814 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.548 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -65.97 -28.49 68.94 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 178.032 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.626 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.43 -17.64 35.84 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.484 178.161 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.534 ' N ' ' O ' ' A' ' 11' ' ' ARG . 2.4 mpt_? -100.81 26.72 6.57 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 122.794 0.438 . . . . 0.0 110.623 179.673 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.602 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.4 p -111.89 -49.95 6.04 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.052 0 N-CA-C 107.741 -1.207 . . . . 0.0 107.741 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.602 HD13 ' O ' ' A' ' 16' ' ' VAL . 41.6 mm -149.98 82.99 6.33 Favored Pre-proline 0 N--CA 1.426 -1.663 0 N-CA-C 106.486 -1.672 . . . . 0.0 106.486 174.634 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.626 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.1 Cg_endo -91.71 -179.0 1.22 Allowed 'Trans proline' 0 N--CA 1.424 -2.615 0 C-N-CA 125.212 3.941 . . . . 0.0 110.03 178.944 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.16 -28.39 69.72 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 115.021 -0.99 . . . . 0.0 111.148 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.444 HG23 ' O ' ' A' ' 18' ' ' PRO . 16.6 t . . . . . 0 C--O 1.249 1.032 0 CA-C-O 118.274 -0.87 . . . . 0.0 111.154 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.521 -0.17 0 CA-C-O 121.571 0.701 . . . . 0.0 109.262 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.426 ' O ' ' N ' ' A' ' 7' ' ' GLY . 8.3 t -73.9 -21.25 18.02 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.499 0 CA-C-N 114.739 -1.119 . . . . 0.0 109.968 178.827 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.439 ' O ' ' HB2' ' A' ' 10' ' ' ALA . 0.5 OUTLIER -41.01 -25.11 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.72 179.954 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 5' ' ' VAL . . . -60.74 -38.43 95.17 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.845 -0.693 . . . . 0.0 111.58 179.193 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.94 -54.34 6.13 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.03 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.44 ' HA ' HG12 ' A' ' 12' ' ' ILE . 4.8 mp -55.34 -22.77 20.63 Favored 'General case' 0 CA--C 1.528 0.132 0 CA-C-O 121.017 0.437 . . . . 0.0 110.424 179.028 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.717 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -63.07 -21.14 65.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.373 179.763 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.443 ' O ' ' N ' ' A' ' 14' ' ' GLY . 0.0 OUTLIER -89.41 -40.96 12.37 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.597 -179.472 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.49 HG13 ' N ' ' A' ' 13' ' ' LEU . 1.6 pt -53.79 -36.61 30.28 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.171 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.979 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.717 HD21 ' HA ' ' A' ' 10' ' ' ALA . 1.5 pp -65.95 -24.34 66.79 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 177.893 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.643 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -92.23 -19.79 37.83 Favored Glycine 0 N--CA 1.444 -0.816 0 CA-C-N 115.102 -0.953 . . . . 0.0 111.603 178.31 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.439 ' CD ' ' O ' ' A' ' 11' ' ' ARG . 2.3 mpt_? -100.74 25.87 7.43 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 120.836 0.35 . . . . 0.0 110.947 179.614 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.622 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.6 p -112.42 -50.35 5.82 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.11 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.758 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.622 HD13 ' O ' ' A' ' 16' ' ' VAL . 31.9 mm -149.79 83.27 6.35 Favored Pre-proline 0 N--CA 1.423 -1.825 0 N-CA-C 106.578 -1.638 . . . . 0.0 106.578 175.446 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.643 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 3.6 Cg_endo -91.32 -178.94 1.31 Allowed 'Trans proline' 0 N--CA 1.424 -2.58 0 C-N-CA 125.049 3.833 . . . . 0.0 109.793 178.937 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -62.34 -23.07 66.57 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 115.227 -0.897 . . . . 0.0 111.164 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 2.6 t . . . . . 0 C--O 1.25 1.098 0 CA-C-O 118.152 -0.928 . . . . 0.0 110.848 -179.913 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.52 -0.188 0 CA-C-O 121.444 0.64 . . . . 0.0 109.578 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.674 HG12 HD12 ' A' ' 9' ' ' LEU . 14.1 t -74.65 -25.3 18.96 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.482 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.028 178.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -41.36 -25.47 0.04 OUTLIER 'General case' 0 C--N 1.333 -0.109 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.674 179.708 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.42 ' N ' ' C ' ' A' ' 5' ' ' VAL . . . -65.29 -40.54 96.64 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.556 179.34 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.432 ' N ' ' O ' ' A' ' 5' ' ' VAL . 1.8 mpt_? -78.23 -46.4 20.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.837 0.351 . . . . 0.0 110.459 179.368 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.674 HD12 HG12 ' A' ' 5' ' ' VAL . 1.6 mp -56.22 -60.58 3.3 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.903 179.803 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.646 ' HA ' HD11 ' A' ' 13' ' ' LEU . . . -44.44 -22.47 0.07 Allowed 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.195 -0.457 . . . . 0.0 112.056 179.74 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.723 ' NH2' HG22 ' A' ' 12' ' ' ILE . 0.0 OUTLIER -88.57 -46.14 9.32 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.645 -179.861 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.723 HG22 ' NH2' ' A' ' 11' ' ' ARG . 1.1 pp -57.48 -36.53 53.8 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.248 0 C-N-CA 120.52 -0.472 . . . . 0.0 111.149 -179.844 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.646 HD11 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -62.11 -35.35 78.45 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 178.198 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.588 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -70.6 -16.65 74.15 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.102 -1.047 . . . . 0.0 110.87 177.64 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.443 ' HD3' ' HG2' ' A' ' 11' ' ' ARG . 1.4 mpt_? -100.02 27.38 5.59 Favored 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 123.088 0.555 . . . . 0.0 110.491 179.566 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.567 ' O ' HD13 ' A' ' 17' ' ' ILE . 1.0 OUTLIER -111.21 -48.82 6.38 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.972 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 179.822 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.567 HD13 ' O ' ' A' ' 16' ' ' VAL . 44.1 mm -150.52 82.8 6.1 Favored Pre-proline 0 N--CA 1.424 -1.748 0 N-CA-C 106.568 -1.641 . . . . 0.0 106.568 174.257 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.588 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.7 Cg_endo -91.7 -178.9 1.2 Allowed 'Trans proline' 0 N--CA 1.423 -2.632 0 C-N-CA 125.135 3.89 . . . . 0.0 109.856 178.619 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.86 -28.9 67.94 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.197 -0.91 . . . . 0.0 110.912 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 16.6 t . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.217 -0.897 . . . . 0.0 111.266 179.819 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 13.3 m . . . . . 0 CA--C 1.519 -0.22 0 CA-C-O 121.579 0.704 . . . . 0.0 109.425 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.438 ' O ' ' N ' ' A' ' 8' ' ' ARG . 8.9 t -80.09 -24.68 11.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.472 179.387 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 7' ' ' GLY . 0.1 OUTLIER -41.36 -25.47 0.04 OUTLIER 'General case' 0 CA--C 1.527 0.073 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.657 179.84 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.446 ' N ' ' CD1' ' A' ' 6' ' ' PHE . . . -63.84 -41.37 98.83 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.666 -0.778 . . . . 0.0 111.426 179.169 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.438 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -76.66 -45.27 30.5 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.889 0.376 . . . . 0.0 110.165 179.201 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.474 ' O ' HG13 ' A' ' 12' ' ' ILE . 0.7 OUTLIER -55.35 -54.96 37.06 Favored 'General case' 0 CA--C 1.529 0.163 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.819 179.668 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.627 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -47.64 -21.88 0.43 Allowed 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 112.083 179.81 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.481 ' O ' ' HD3' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.61 -45.22 10.04 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.861 -179.655 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.474 HG13 ' O ' ' A' ' 9' ' ' LEU . 1.1 pt -53.97 -35.63 28.88 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.211 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.882 -179.711 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.627 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -63.42 -35.65 81.13 Favored 'General case' 0 CA--C 1.513 -0.473 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 177.793 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.591 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -69.56 -16.89 72.25 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 120.006 -1.092 . . . . 0.0 110.758 177.61 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.481 ' HD3' ' O ' ' A' ' 11' ' ' ARG . 9.8 mpt_? -99.7 27.06 5.64 Favored 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 123.054 0.542 . . . . 0.0 110.496 179.313 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.554 ' O ' HD13 ' A' ' 17' ' ' ILE . 0.8 OUTLIER -111.42 -49.09 6.3 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.918 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 179.748 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.554 HD13 ' O ' ' A' ' 16' ' ' VAL . 44.5 mm -150.51 83.16 5.98 Favored Pre-proline 0 N--CA 1.423 -1.796 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 174.292 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.591 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.3 Cg_endo -91.5 -179.27 1.32 Allowed 'Trans proline' 0 N--CA 1.423 -2.675 0 C-N-CA 125.029 3.82 . . . . 0.0 109.597 178.515 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.425 ' HZ2' ' C ' ' A' ' 20' ' ' VAL . 0.0 OUTLIER -65.75 -29.7 70.25 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 115.307 -0.861 . . . . 0.0 110.818 179.856 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.425 ' C ' ' HZ2' ' A' ' 19' ' ' LYS . 37.2 t . . . . . 0 C--O 1.25 1.098 0 CA-C-O 118.204 -0.903 . . . . 0.0 111.253 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.522 -0.131 0 CA-C-O 121.473 0.654 . . . . 0.0 109.325 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.423 ' C ' ' N ' ' A' ' 7' ' ' GLY . 9.1 t -73.23 -21.4 18.94 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.489 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.048 179.049 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.435 ' O ' ' HB2' ' A' ' 10' ' ' ALA . 0.5 OUTLIER -41.33 -24.98 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.244 -0.889 . . . . 0.0 110.747 179.885 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.423 ' N ' ' C ' ' A' ' 5' ' ' VAL . . . -65.39 -40.76 96.57 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.714 -0.755 . . . . 0.0 111.514 179.079 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.422 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -72.65 -54.31 9.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.815 0.341 . . . . 0.0 110.165 179.223 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.427 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 3.2 mp -56.71 -32.94 66.0 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.814 179.648 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.561 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.46 -21.58 0.58 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.923 -0.581 . . . . 0.0 112.008 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.519 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.9 ptm180 -88.76 -43.02 11.58 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.273 -179.43 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.463 HG13 ' N ' ' A' ' 13' ' ' LEU . 3.8 pt -54.58 -33.75 27.75 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.188 0 C-N-CA 120.47 -0.492 . . . . 0.0 110.949 -179.652 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.561 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.07 -28.42 68.82 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 177.967 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.638 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.96 -16.71 37.62 Favored Glycine 0 N--CA 1.446 -0.671 0 CA-C-N 115.256 -0.884 . . . . 0.0 111.507 178.287 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.519 ' N ' ' O ' ' A' ' 11' ' ' ARG . 9.5 mpt_? -100.38 26.72 6.33 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.967 0.413 . . . . 0.0 110.551 179.654 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.623 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.6 p -111.83 -50.05 6.06 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.0 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 179.745 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.623 HD13 ' O ' ' A' ' 16' ' ' VAL . 44.1 mm -150.28 83.75 5.92 Favored Pre-proline 0 N--CA 1.427 -1.625 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 174.44 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.638 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.8 Cg_endo -91.28 -179.07 1.34 Allowed 'Trans proline' 0 N--CA 1.423 -2.625 0 C-N-CA 124.909 3.74 . . . . 0.0 109.559 178.747 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.1 -27.53 68.82 Favored 'General case' 0 C--N 1.3 -1.565 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.994 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 18' ' ' PRO . 19.2 t . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.235 -0.888 . . . . 0.0 111.156 179.821 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 2.7 m . . . . . 0 CA--C 1.519 -0.224 0 CA-C-O 121.572 0.701 . . . . 0.0 109.575 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.467 ' O ' ' N ' ' A' ' 8' ' ' ARG . 8.2 t -76.68 -30.9 19.19 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.438 0 CA-C-N 114.701 -1.136 . . . . 0.0 110.521 179.526 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.454 ' CD2' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -41.78 -25.52 0.06 Allowed 'General case' 0 CA--C 1.528 0.128 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.72 -179.975 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.454 ' N ' ' CD2' ' A' ' 6' ' ' PHE . . . -65.34 -39.39 95.86 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.454 179.018 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.467 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.5 OUTLIER -80.01 -46.29 16.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.975 0.417 . . . . 0.0 110.058 179.209 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.47 ' O ' HG13 ' A' ' 12' ' ' ILE . 0.5 OUTLIER -52.52 -59.58 4.27 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.255 179.945 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.576 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -43.58 -24.66 0.12 Allowed 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 116.293 -0.412 . . . . 0.0 112.089 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.499 ' O ' ' HD2' ' A' ' 15' ' ' ARG . 0.4 OUTLIER -88.57 -45.93 9.49 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.051 -179.807 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.47 HG13 ' O ' ' A' ' 9' ' ' LEU . 1.1 pp -56.25 -35.82 44.03 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.212 0 C-N-CA 120.446 -0.501 . . . . 0.0 111.113 -179.662 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.576 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -64.22 -33.56 76.08 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 178.128 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.585 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -73.22 -14.35 79.15 Favored Glycine 0 N--CA 1.444 -0.779 0 C-N-CA 120.117 -1.04 . . . . 0.0 110.827 177.537 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.499 ' HD2' ' O ' ' A' ' 11' ' ' ARG . 0.6 OUTLIER -99.88 27.04 5.74 Favored 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 123.03 0.532 . . . . 0.0 110.401 179.493 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.547 ' O ' HD13 ' A' ' 17' ' ' ILE . 1.4 p -111.46 -48.89 6.28 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.926 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 179.824 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.547 HD13 ' O ' ' A' ' 16' ' ' VAL . 43.3 mm -150.38 82.85 6.16 Favored Pre-proline 0 N--CA 1.423 -1.783 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 174.395 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.585 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.9 Cg_endo -91.69 -178.93 1.21 Allowed 'Trans proline' 0 N--CA 1.425 -2.544 0 C-N-CA 125.211 3.94 . . . . 0.0 109.942 178.771 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.47 -28.65 69.81 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.102 -0.954 . . . . 0.0 111.068 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 18' ' ' PRO . 19.3 t . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.264 -0.875 . . . . 0.0 111.254 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.8 m . . . . . 0 CA--C 1.52 -0.206 0 CA-C-O 121.521 0.677 . . . . 0.0 109.659 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.528 HG12 HD12 ' A' ' 9' ' ' LEU . 6.3 t -80.39 -27.09 11.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.677 179.578 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.459 ' CD1' ' N ' ' A' ' 7' ' ' GLY . 0.1 OUTLIER -42.9 -25.29 0.09 Allowed 'General case' 0 C--O 1.231 0.12 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.519 179.828 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.459 ' N ' ' CD1' ' A' ' 6' ' ' PHE . . . -72.48 -37.46 58.46 Favored Glycine 0 N--CA 1.45 -0.41 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.651 179.372 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.476 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -73.11 -59.76 2.56 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.649 0.262 . . . . 0.0 110.354 179.345 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.528 HD12 HG12 ' A' ' 5' ' ' VAL . 0.4 OUTLIER -48.08 -30.8 4.79 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 120.97 0.415 . . . . 0.0 110.875 179.638 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.586 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.96 -21.57 1.25 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.836 -0.62 . . . . 0.0 112.185 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.485 ' O ' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.98 -43.38 11.18 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 116.707 -0.224 . . . . 0.0 111.186 -179.417 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.477 ' N ' ' HG2' ' A' ' 11' ' ' ARG . 3.1 pt -54.27 -33.56 25.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 C-N-CA 120.475 -0.49 . . . . 0.0 111.085 -179.521 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.586 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.05 -28.55 68.93 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 177.908 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.63 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.78 -17.16 39.31 Favored Glycine 0 N--CA 1.444 -0.782 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.635 178.351 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.485 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.7 mpt_? -100.46 26.74 6.35 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 120.949 0.404 . . . . 0.0 110.809 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.615 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.1 p -111.6 -49.84 6.16 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.082 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 179.789 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.615 HD13 ' O ' ' A' ' 16' ' ' VAL . 42.4 mm -150.2 83.23 6.13 Favored Pre-proline 0 N--CA 1.424 -1.754 0 N-CA-C 106.565 -1.642 . . . . 0.0 106.565 174.595 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.63 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.5 Cg_endo -91.32 -179.0 1.32 Allowed 'Trans proline' 0 N--CA 1.423 -2.659 0 C-N-CA 124.983 3.789 . . . . 0.0 109.777 178.768 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.58 -29.8 69.94 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 115.141 -0.936 . . . . 0.0 110.949 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 18.4 t . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.247 -0.882 . . . . 0.0 111.239 179.971 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 2.5 m . . . . . 0 CA--C 1.52 -0.19 0 CA-C-O 121.576 0.703 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.908 HG12 HD12 ' A' ' 9' ' ' LEU . 6.6 t -78.72 -31.49 15.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 114.689 -1.141 . . . . 0.0 110.644 179.53 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.458 ' CD1' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -42.47 -25.61 0.09 Allowed 'General case' 0 CA--C 1.528 0.102 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.731 179.993 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 7' ' ' GLY . . . . . 0.458 ' N ' ' CD1' ' A' ' 6' ' ' PHE . . . -70.83 -38.58 65.72 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.768 -0.73 . . . . 0.0 111.587 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ARG . . . . . 0.463 ' N ' ' O ' ' A' ' 5' ' ' VAL . 9.3 mmm180 -75.92 -52.52 10.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.857 0.36 . . . . 0.0 110.217 179.25 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.908 HD12 HG12 ' A' ' 5' ' ' VAL . 0.7 OUTLIER -50.1 -38.35 38.3 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.063 179.833 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.58 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -46.57 -21.53 0.19 Allowed 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.215 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ARG . . . . . 0.477 ' HG2' ' N ' ' A' ' 12' ' ' ILE . 0.0 OUTLIER -88.44 -43.77 11.22 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.877 -179.398 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ILE . . . . . 0.477 ' N ' ' HG2' ' A' ' 11' ' ' ARG . 2.7 pt -57.32 -32.3 40.59 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.178 0 C-N-CA 120.454 -0.498 . . . . 0.0 111.011 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.658 ' O ' HG12 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -68.41 -28.03 66.73 Favored 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 178.188 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.605 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -90.55 -15.01 57.63 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.435 -0.888 . . . . 0.0 111.07 177.985 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.455 ' HD3' ' CG ' ' A' ' 11' ' ' ARG . 0.7 OUTLIER -100.35 26.93 6.1 Favored 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 122.626 0.371 . . . . 0.0 110.938 179.841 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.658 HG12 ' O ' ' A' ' 13' ' ' LEU . 8.6 p -111.63 -48.92 6.21 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.015 0 N-CA-C 107.391 -1.337 . . . . 0.0 107.391 179.679 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.628 HD13 ' O ' ' A' ' 16' ' ' VAL . 39.7 mm -150.08 83.07 6.25 Favored Pre-proline 0 N--CA 1.425 -1.722 0 N-CA-C 106.522 -1.658 . . . . 0.0 106.522 174.579 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.605 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 3.8 Cg_endo -91.56 -179.06 1.27 Allowed 'Trans proline' 0 N--CA 1.424 -2.612 0 C-N-CA 125.019 3.813 . . . . 0.0 109.961 178.838 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.435 ' HZ2' ' C ' ' A' ' 20' ' ' VAL . 0.0 OUTLIER -64.2 -29.26 70.38 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.943 179.912 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.442 HG23 ' O ' ' A' ' 18' ' ' PRO . 20.7 t . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.234 -0.889 . . . . 0.0 111.143 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.647 ' HA2' HG23 ' A' ' 5' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.2 0 N-CA-C 112.51 -0.236 . . . . 0.0 112.51 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.639 ' N ' HD22 ' A' ' 2' ' ' LEU . 2.1 mm? 64.07 80.91 0.22 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.93 0.395 . . . . 0.0 110.47 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 106.34 -37.01 4.03 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.807 -0.711 . . . . 0.0 111.984 -179.448 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -82.87 -34.64 26.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.523 0.678 . . . . 0.0 109.519 178.912 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.701 HG12 HD12 ' A' ' 9' ' ' LEU . 9.2 t -79.31 -30.02 13.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 114.814 -1.084 . . . . 0.0 110.638 179.599 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.458 ' CD2' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -42.14 -25.38 0.07 Allowed 'General case' 0 CA--C 1.528 0.13 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.752 179.942 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.458 ' N ' ' CD2' ' A' ' 6' ' ' PHE . . . -66.02 -38.61 94.25 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.725 -0.75 . . . . 0.0 111.605 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.409 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -80.8 -51.99 8.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.67 0.272 . . . . 0.0 110.41 179.41 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.701 HD12 HG12 ' A' ' 5' ' ' VAL . 2.9 mp -51.96 -38.47 56.64 Favored 'General case' 0 CA--C 1.529 0.156 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.897 179.766 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.579 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -50.75 -21.45 1.64 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.183 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.47 ' O ' ' N ' ' A' ' 15' ' ' ARG . 1.7 ptm180 -88.77 -41.39 12.56 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.551 -179.183 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.477 HG13 ' N ' ' A' ' 13' ' ' LEU . 3.7 pt -54.62 -35.46 32.38 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.178 0 C-N-CA 120.369 -0.533 . . . . 0.0 110.817 -179.637 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.579 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.05 -26.98 67.75 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 177.879 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.633 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -93.96 -17.02 42.33 Favored Glycine 0 N--CA 1.444 -0.806 0 CA-C-N 115.187 -0.915 . . . . 0.0 111.532 178.273 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.47 ' N ' ' O ' ' A' ' 11' ' ' ARG . 2.5 mpt_? -100.35 26.58 6.46 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 120.956 0.408 . . . . 0.0 110.716 179.718 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.622 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.3 p -112.19 -50.42 5.9 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.02 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 179.67 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.622 HD13 ' O ' ' A' ' 16' ' ' VAL . 40.4 mm -150.15 83.82 5.97 Favored Pre-proline 0 N--CA 1.425 -1.703 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 174.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.633 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.8 Cg_endo -91.37 -179.18 1.34 Allowed 'Trans proline' 0 N--CA 1.422 -2.684 0 C-N-CA 124.904 3.736 . . . . 0.0 109.808 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.55 -29.46 70.72 Favored 'General case' 0 C--N 1.299 -1.604 0 CA-C-N 115.152 -0.931 . . . . 0.0 111.001 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 18' ' ' PRO . 21.5 t . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.287 -0.863 . . . . 0.0 111.092 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.564 ' HA2' HG23 ' A' ' 5' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.174 0 N-CA-C 112.463 -0.255 . . . . 0.0 112.463 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.2 mm? 62.61 85.8 0.12 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.96 0.409 . . . . 0.0 110.231 -179.687 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.408 ' O ' ' CD2' ' A' ' 6' ' ' PHE . . . 98.68 -33.96 5.68 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.764 -0.731 . . . . 0.0 111.678 -179.117 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -83.14 -37.58 23.55 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.577 0.703 . . . . 0.0 109.398 178.754 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.638 HG12 HD12 ' A' ' 9' ' ' LEU . 5.5 t -76.47 -30.0 19.09 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.448 0 CA-C-N 114.658 -1.155 . . . . 0.0 110.394 179.406 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.451 ' CD2' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -41.56 -25.61 0.05 Allowed 'General case' 0 C--O 1.232 0.138 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.738 179.936 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.451 ' N ' ' CD2' ' A' ' 6' ' ' PHE . . . -68.89 -42.01 80.18 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.359 179.045 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.464 ' N ' ' O ' ' A' ' 5' ' ' VAL . 2.0 mpt_? -71.03 -54.36 11.46 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 179.088 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.638 HD12 HG12 ' A' ' 5' ' ' VAL . 2.3 mp -50.58 -33.57 22.47 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 120.966 0.412 . . . . 0.0 110.71 179.646 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.549 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.61 -21.44 1.01 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.917 -0.583 . . . . 0.0 112.076 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.521 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.2 ptm180 -88.73 -42.43 11.95 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.326 -179.265 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.464 HG13 ' N ' ' A' ' 13' ' ' LEU . 3.8 pt -54.19 -34.38 27.07 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.181 0 C-N-CA 120.376 -0.529 . . . . 0.0 110.927 -179.685 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.564 ' O ' HG12 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -66.39 -28.89 68.99 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 178.023 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.638 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.67 -15.95 44.33 Favored Glycine 0 N--CA 1.445 -0.76 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.59 178.271 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.521 ' N ' ' O ' ' A' ' 11' ' ' ARG . 9.1 mpt_? -100.71 26.69 6.55 Favored 'General case' 0 N--CA 1.465 0.316 0 C-N-CA 122.768 0.427 . . . . 0.0 110.642 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.627 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.2 p -111.77 -50.41 6.05 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.994 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.627 HD13 ' O ' ' A' ' 16' ' ' VAL . 42.4 mm -150.2 83.51 6.04 Favored Pre-proline 0 N--CA 1.425 -1.685 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 174.61 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.638 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.5 Cg_endo -91.35 -179.15 1.34 Allowed 'Trans proline' 0 N--CA 1.423 -2.653 0 C-N-CA 125.002 3.802 . . . . 0.0 109.95 178.782 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.01 -26.95 69.09 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 115.135 -0.939 . . . . 0.0 111.135 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.495 HG23 ' O ' ' A' ' 18' ' ' PRO . 18.6 t . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.279 -0.867 . . . . 0.0 111.174 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.634 ' HA2' HG23 ' A' ' 5' ' ' VAL . . . . . . . . 0 N--CA 1.49 2.284 0 N-CA-C 112.477 -0.249 . . . . 0.0 112.477 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 2.6 mt 67.86 79.54 0.22 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.902 0.382 . . . . 0.0 110.439 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 106.64 -35.61 4.93 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.837 -0.697 . . . . 0.0 111.867 -179.476 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -82.8 -34.8 26.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.467 0.651 . . . . 0.0 109.483 178.9 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.726 HG12 HD12 ' A' ' 9' ' ' LEU . 9.3 t -78.04 -30.33 16.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 114.827 -1.079 . . . . 0.0 110.47 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.448 ' CD1' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -41.8 -25.28 0.05 Allowed 'General case' 0 CA--C 1.529 0.138 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.78 -179.978 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.448 ' N ' ' CD1' ' A' ' 6' ' ' PHE . . . -64.18 -40.25 97.85 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.721 -0.752 . . . . 0.0 111.476 179.124 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -79.72 -51.14 9.59 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.751 0.31 . . . . 0.0 110.364 179.277 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.726 HD12 HG12 ' A' ' 5' ' ' VAL . 1.4 mp -51.32 -38.28 52.16 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-O 121.09 0.471 . . . . 0.0 110.507 179.515 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.546 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.7 -21.12 0.55 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.949 179.567 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.481 ' O ' ' CD ' ' A' ' 15' ' ' ARG . 1.3 ptm180 -88.17 -42.31 12.41 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.235 -179.394 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.478 HG13 ' N ' ' A' ' 13' ' ' LEU . 5.1 pt -55.53 -34.68 35.66 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.17 0 C-N-CA 120.329 -0.549 . . . . 0.0 110.734 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.591 ' O ' HG12 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -66.38 -27.25 67.72 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 178.053 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.626 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.06 -16.74 43.15 Favored Glycine 0 N--CA 1.443 -0.834 0 CA-C-N 115.276 -0.875 . . . . 0.0 111.303 178.197 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.481 ' CD ' ' O ' ' A' ' 11' ' ' ARG . 1.7 mpt_? -100.22 26.91 6.04 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.004 0.43 . . . . 0.0 110.528 179.602 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.631 ' O ' HD13 ' A' ' 17' ' ' ILE . 9.1 p -111.45 -49.82 6.22 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.038 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.631 HD13 ' O ' ' A' ' 16' ' ' VAL . 40.5 mm -150.2 83.27 6.12 Favored Pre-proline 0 N--CA 1.424 -1.738 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 174.514 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.626 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.1 Cg_endo -91.39 -179.05 1.31 Allowed 'Trans proline' 0 N--CA 1.424 -2.616 0 C-N-CA 124.916 3.744 . . . . 0.0 109.801 178.696 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.39 -30.24 69.96 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.006 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 17.2 t . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.234 -0.889 . . . . 0.0 111.283 179.892 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.656 ' HA2' HG23 ' A' ' 5' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.213 0 N-CA-C 112.543 -0.223 . . . . 0.0 112.543 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.566 HD22 ' N ' ' A' ' 2' ' ' LEU . 2.3 mm? 64.37 75.93 0.36 Allowed 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.989 0.423 . . . . 0.0 110.303 -179.81 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 108.72 -34.56 5.49 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.685 -179.244 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -82.96 -38.01 23.3 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-O 121.587 0.708 . . . . 0.0 109.354 178.676 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.821 HG12 HD12 ' A' ' 9' ' ' LEU . 5.5 t -74.64 -30.08 24.43 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.428 0 CA-C-N 114.621 -1.172 . . . . 0.0 110.279 179.237 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -42.78 -25.45 0.09 Allowed 'General case' 0 C--O 1.232 0.141 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.375 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -69.77 -40.67 75.57 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.816 -0.707 . . . . 0.0 111.388 178.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.461 ' N ' ' O ' ' A' ' 5' ' ' VAL . 1.0 OUTLIER -72.43 -54.14 10.19 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.772 0.32 . . . . 0.0 110.389 179.262 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.821 HD12 HG12 ' A' ' 5' ' ' VAL . 1.7 mp -53.8 -35.03 60.95 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 121.057 0.456 . . . . 0.0 110.718 179.623 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.623 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -47.72 -21.6 0.41 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.759 -0.655 . . . . 0.0 112.209 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.458 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.2 ptm180 -89.1 -41.54 12.23 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-N 116.603 -0.272 . . . . 0.0 111.469 -179.574 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.459 HG13 ' N ' ' A' ' 13' ' ' LEU . 4.9 pt -54.87 -34.73 31.57 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.234 0 C-N-CA 120.497 -0.481 . . . . 0.0 110.82 -179.7 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.623 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -65.3 -27.16 68.43 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.811 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.606 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -93.65 -19.38 34.9 Favored Glycine 0 N--CA 1.444 -0.768 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.506 178.166 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.458 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.7 mpt_? -100.16 26.28 6.64 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 120.863 0.363 . . . . 0.0 110.638 179.571 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.61 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.5 p -112.07 -49.63 6.0 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.064 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.61 HD13 ' O ' ' A' ' 16' ' ' VAL . 38.7 mm -149.74 83.19 6.4 Favored Pre-proline 0 N--CA 1.424 -1.748 0 N-CA-C 106.51 -1.663 . . . . 0.0 106.51 174.823 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.606 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.0 Cg_endo -91.58 -178.94 1.24 Allowed 'Trans proline' 0 N--CA 1.423 -2.618 0 C-N-CA 125.048 3.832 . . . . 0.0 109.746 178.692 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.92 -30.56 68.0 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.845 179.786 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.189 -0.91 . . . . 0.0 111.182 179.984 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.401 ' O ' ' CD2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.24 0 N-CA-C 112.405 -0.278 . . . . 0.0 112.405 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.522 ' H ' HG23 ' A' ' 5' ' ' VAL . 0.1 OUTLIER 176.85 -70.11 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.916 0.389 . . . . 0.0 110.438 -179.967 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -99.38 -18.06 24.9 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.221 179.475 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -82.79 -25.8 32.39 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.398 0.618 . . . . 0.0 109.798 179.064 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.608 HG12 HD12 ' A' ' 9' ' ' LEU . 15.0 t -72.82 -23.81 20.83 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.425 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.282 179.323 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -41.54 -25.24 0.04 OUTLIER 'General case' 0 C--N 1.333 -0.132 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.633 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.417 ' N ' ' C ' ' A' ' 5' ' ' VAL . . . -67.22 -41.03 92.33 Favored Glycine 0 N--CA 1.45 -0.423 0 CA-C-N 115.577 -0.738 . . . . 0.0 111.68 179.217 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.432 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -73.62 -54.74 7.46 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 179.251 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.608 HD12 HG12 ' A' ' 5' ' ' VAL . 2.8 mp -52.44 -34.53 49.17 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 120.982 0.42 . . . . 0.0 110.741 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.567 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -50.28 -21.51 1.41 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.989 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.501 ' O ' ' N ' ' A' ' 15' ' ' ARG . 3.1 ptm180 -88.68 -42.78 11.77 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.392 -179.311 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.485 HG13 ' N ' ' A' ' 13' ' ' LEU . 4.8 pt -53.39 -35.89 25.71 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.194 0 C-N-CA 120.364 -0.534 . . . . 0.0 110.823 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.567 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -65.03 -28.73 69.69 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 178.133 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.632 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.6 -16.16 43.75 Favored Glycine 0 N--CA 1.445 -0.763 0 CA-C-N 115.269 -0.878 . . . . 0.0 111.672 178.412 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.501 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.8 mpt_? -100.46 26.69 6.4 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 122.721 0.408 . . . . 0.0 110.733 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.618 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.1 p -111.92 -50.22 6.01 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.015 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.618 HD13 ' O ' ' A' ' 16' ' ' VAL . 42.6 mm -150.21 83.5 6.04 Favored Pre-proline 0 N--CA 1.424 -1.731 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 174.715 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.632 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.9 Cg_endo -91.36 -179.09 1.32 Allowed 'Trans proline' 0 N--CA 1.423 -2.629 0 C-N-CA 124.98 3.787 . . . . 0.0 109.754 178.774 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.61 -29.54 70.78 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.983 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 18' ' ' PRO . 20.8 t . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.297 -0.859 . . . . 0.0 111.195 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.48 ' HA2' HG23 ' A' ' 5' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.227 0 N-CA-C 112.473 -0.251 . . . . 0.0 112.473 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.55 ' N ' HD22 ' A' ' 2' ' ' LEU . 2.0 mm? 65.54 87.43 0.12 Allowed 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.994 0.426 . . . . 0.0 110.232 -179.819 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 98.43 -35.6 4.5 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.802 -0.713 . . . . 0.0 111.69 -179.149 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -83.18 -36.61 24.56 Favored 'General case' 0 CA--C 1.519 -0.242 0 CA-C-O 121.53 0.681 . . . . 0.0 109.507 178.797 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.739 HG12 HD12 ' A' ' 9' ' ' LEU . 6.2 t -75.53 -29.2 20.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.402 179.384 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -41.53 -25.67 0.05 Allowed 'General case' 0 C--N 1.333 -0.121 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.661 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -65.18 -40.55 96.86 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.383 179.179 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.464 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -75.85 -52.55 10.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.789 0.328 . . . . 0.0 110.14 179.136 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.739 HD12 HG12 ' A' ' 5' ' ' VAL . 5.1 mp -52.43 -38.53 59.39 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.006 0.431 . . . . 0.0 110.618 179.609 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.561 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.3 -21.18 0.78 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.981 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.519 ' O ' ' N ' ' A' ' 15' ' ' ARG . 2.2 ptm180 -88.13 -42.08 12.59 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.338 -179.311 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.459 HG13 ' N ' ' A' ' 13' ' ' LEU . 4.5 pt -55.36 -34.79 34.83 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.218 0 C-N-CA 120.35 -0.54 . . . . 0.0 110.838 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.561 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.45 -27.73 68.04 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 178.089 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.632 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.7 -17.22 39.35 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.303 178.014 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.519 ' N ' ' O ' ' A' ' 11' ' ' ARG . 9.2 mpt_? -100.87 26.41 6.94 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 122.693 0.397 . . . . 0.0 110.866 179.816 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.608 ' O ' HD13 ' A' ' 17' ' ' ILE . 8.2 p -112.34 -50.32 5.85 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.059 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.608 HD13 ' O ' ' A' ' 16' ' ' VAL . 44.4 mm -150.29 83.78 5.91 Favored Pre-proline 0 N--CA 1.424 -1.743 0 N-CA-C 106.517 -1.66 . . . . 0.0 106.517 174.816 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.632 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.0 Cg_endo -91.24 -179.28 1.39 Allowed 'Trans proline' 0 N--CA 1.422 -2.702 0 C-N-CA 124.836 3.691 . . . . 0.0 109.569 178.662 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.23 -28.73 69.56 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 115.116 -0.947 . . . . 0.0 111.051 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.416 HG23 ' O ' ' A' ' 18' ' ' PRO . 20.1 t . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.245 -0.883 . . . . 0.0 111.232 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.561 ' HA2' HG23 ' A' ' 5' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 112.461 -0.255 . . . . 0.0 112.461 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.615 ' N ' HD22 ' A' ' 2' ' ' LEU . 2.5 mm? 62.2 86.16 0.11 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.922 0.391 . . . . 0.0 110.3 -179.829 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 98.91 -34.07 5.64 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.972 -179.45 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -83.0 -39.33 21.45 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-O 121.65 0.738 . . . . 0.0 109.357 178.907 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.721 HG12 HD12 ' A' ' 9' ' ' LEU . 4.8 t -74.34 -32.19 30.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 114.652 -1.158 . . . . 0.0 110.315 179.352 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -42.14 -26.0 0.09 Allowed 'General case' 0 CA--C 1.528 0.112 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.583 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -71.72 -41.65 55.98 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.742 -0.742 . . . . 0.0 111.595 179.339 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.445 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -71.69 -52.07 19.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.676 0.274 . . . . 0.0 110.462 179.359 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.721 HD12 HG12 ' A' ' 5' ' ' VAL . 3.2 mp -55.1 -33.52 62.9 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.165 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.539 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.18 -21.53 0.5 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.137 -0.483 . . . . 0.0 112.097 179.839 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.505 ' O ' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.5 -44.67 10.53 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.022 -179.579 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.479 ' HA ' ' HB2' ' A' ' 15' ' ' ARG . 2.5 pt -54.76 -32.17 25.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 C-N-CA 120.552 -0.459 . . . . 0.0 111.163 -179.751 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.539 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -67.74 -29.25 68.43 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 178.201 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.577 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.96 -13.81 48.32 Favored Glycine 0 N--CA 1.445 -0.746 0 C-N-CA 120.478 -0.868 . . . . 0.0 111.458 178.137 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.505 ' N ' ' O ' ' A' ' 11' ' ' ARG . 0.4 OUTLIER -100.39 26.99 6.05 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 121.069 0.461 . . . . 0.0 110.775 -179.942 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.615 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.4 p -111.61 -49.36 6.2 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.032 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 179.491 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.615 HD13 ' O ' ' A' ' 16' ' ' VAL . 39.9 mm -150.03 83.63 6.09 Favored Pre-proline 0 N--CA 1.424 -1.741 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 174.375 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.577 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.4 Cg_endo -91.19 -179.17 1.39 Allowed 'Trans proline' 0 N--CA 1.424 -2.575 0 C-N-CA 125.001 3.801 . . . . 0.0 109.695 178.756 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.21 -29.58 69.28 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 115.238 -0.892 . . . . 0.0 110.811 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.5 t . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.276 -0.869 . . . . 0.0 111.226 179.8 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.61 ' HA2' HG23 ' A' ' 5' ' ' VAL . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.543 ' N ' HD22 ' A' ' 2' ' ' LEU . 2.6 mm? 64.06 84.69 0.15 Allowed 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.018 0.437 . . . . 0.0 110.412 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.405 ' O ' ' CD2' ' A' ' 6' ' ' PHE . . . 100.5 -36.29 4.25 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.851 -0.69 . . . . 0.0 111.789 -179.363 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -82.73 -33.87 27.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.45 0.643 . . . . 0.0 109.47 178.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.61 HG23 ' HA2' ' A' ' 1' ' ' GLY . 10.5 t -81.0 -27.91 11.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.604 179.459 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.474 ' CD2' ' N ' ' A' ' 7' ' ' GLY . 0.1 OUTLIER -41.49 -25.44 0.05 OUTLIER 'General case' 0 C--O 1.231 0.128 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.738 -179.942 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.474 ' N ' ' CD2' ' A' ' 6' ' ' PHE . . . -69.05 -40.82 83.3 Favored Glycine 0 N--CA 1.45 -0.387 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.586 179.318 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.449 ' N ' ' O ' ' A' ' 5' ' ' VAL . 1.6 mpt_? -74.68 -47.18 33.13 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.878 0.371 . . . . 0.0 110.146 179.296 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.507 ' O ' HG13 ' A' ' 12' ' ' ILE . 1.0 OUTLIER -52.24 -60.25 3.44 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.993 179.709 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.604 ' HA ' HD11 ' A' ' 13' ' ' LEU . . . -44.64 -24.27 0.18 Allowed 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.963 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.475 ' NH2' HG22 ' A' ' 12' ' ' ILE . 0.0 OUTLIER -88.56 -48.24 7.72 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.808 -179.897 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.507 HG13 ' O ' ' A' ' 9' ' ' LEU . 1.1 pp -58.81 -36.94 63.52 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.204 0 C-N-CA 120.416 -0.514 . . . . 0.0 111.447 -179.617 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.604 HD11 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -62.36 -34.63 77.06 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 178.482 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.584 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -71.7 -12.9 74.62 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.079 -1.057 . . . . 0.0 111.034 177.75 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.45 ' N ' ' HD2' ' A' ' 15' ' ' ARG . 0.9 OUTLIER -99.67 27.35 5.43 Favored 'General case' 0 N--CA 1.465 0.319 0 C-N-CA 123.016 0.527 . . . . 0.0 110.51 179.646 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.592 ' O ' HD13 ' A' ' 17' ' ' ILE . 1.9 p -111.26 -49.01 6.37 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.934 0 N-CA-C 107.164 -1.421 . . . . 0.0 107.164 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.592 HD13 ' O ' ' A' ' 16' ' ' VAL . 44.2 mm -150.41 83.2 6.03 Favored Pre-proline 0 N--CA 1.423 -1.789 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 174.316 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.584 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.0 Cg_endo -91.53 -179.1 1.28 Allowed 'Trans proline' 0 N--CA 1.423 -2.675 0 C-N-CA 125.071 3.847 . . . . 0.0 109.633 178.622 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.16 -29.0 68.58 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.901 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.277 -0.868 . . . . 0.0 111.211 179.799 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.539 ' O ' HD23 ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.489 2.197 0 N-CA-C 112.476 -0.25 . . . . 0.0 112.476 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.539 HD23 ' O ' ' A' ' 1' ' ' GLY . 0.2 OUTLIER 167.33 76.63 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.251 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.91 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 96.27 -29.09 10.69 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.652 -0.785 . . . . 0.0 111.619 -178.849 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -82.58 -30.42 29.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.428 0.632 . . . . 0.0 109.408 178.744 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.676 HG12 HD12 ' A' ' 9' ' ' LEU . 11.6 t -72.5 -22.87 20.68 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.493 0 CA-C-N 114.852 -1.067 . . . . 0.0 109.94 178.86 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -41.51 -25.28 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.573 179.652 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 5' ' ' VAL . . . -71.64 -41.37 57.2 Favored Glycine 0 N--CA 1.45 -0.373 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.674 179.268 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.446 ' N ' ' O ' ' A' ' 5' ' ' VAL . 2.9 mmm180 -68.21 -54.1 20.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.88 0.371 . . . . 0.0 110.055 179.249 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.676 HD12 HG12 ' A' ' 5' ' ' VAL . 5.3 mp -56.18 -31.63 63.59 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.854 179.77 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.554 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -47.3 -21.53 0.3 Allowed 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.036 -0.529 . . . . 0.0 112.082 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.499 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.7 ptm180 -88.7 -42.78 11.76 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 116.536 -0.302 . . . . 0.0 111.252 -179.46 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.469 HG13 ' N ' ' A' ' 13' ' ' LEU . 4.4 pt -54.64 -33.92 28.44 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.209 0 C-N-CA 120.465 -0.494 . . . . 0.0 110.858 -179.721 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.554 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.62 -28.68 68.69 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 178.056 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.604 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.52 -14.13 48.53 Favored Glycine 0 N--CA 1.445 -0.742 0 CA-C-N 115.253 -0.885 . . . . 0.0 111.678 178.315 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.499 ' N ' ' O ' ' A' ' 11' ' ' ARG . 9.2 mpt_? -100.2 26.87 6.07 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 120.999 0.428 . . . . 0.0 110.688 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.62 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.4 p -111.88 -49.48 6.08 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.047 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 179.744 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.62 HD13 ' O ' ' A' ' 16' ' ' VAL . 40.7 mm -149.86 82.95 6.42 Favored Pre-proline 0 N--CA 1.422 -1.827 0 N-CA-C 106.574 -1.639 . . . . 0.0 106.574 174.747 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.604 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.7 Cg_endo -91.48 -179.01 1.28 Allowed 'Trans proline' 0 N--CA 1.423 -2.675 0 C-N-CA 125.091 3.861 . . . . 0.0 109.667 178.702 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.451 ' HZ2' ' C ' ' A' ' 20' ' ' VAL . 0.0 OUTLIER -66.76 -27.23 67.43 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.948 179.908 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.451 ' C ' ' HZ2' ' A' ' 19' ' ' LYS . 16.2 t . . . . . 0 C--O 1.25 1.1 0 CA-C-O 118.274 -0.869 . . . . 0.0 111.103 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.542 ' O ' HD23 ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.241 0 N-CA-C 112.471 -0.252 . . . . 0.0 112.471 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.542 HD23 ' O ' ' A' ' 1' ' ' GLY . 0.2 OUTLIER 166.05 74.74 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -179.882 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 97.74 -28.86 12.45 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.592 -0.813 . . . . 0.0 111.444 -178.78 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -82.79 -29.09 29.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.465 0.65 . . . . 0.0 109.388 178.656 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.442 ' O ' ' N ' ' A' ' 8' ' ' ARG . 9.3 t -73.3 -21.27 18.8 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.561 0 CA-C-N 114.877 -1.056 . . . . 0.0 109.999 178.897 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -41.15 -25.21 0.03 OUTLIER 'General case' 0 CA--C 1.529 0.145 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.694 179.792 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.422 ' N ' ' O ' ' A' ' 5' ' ' VAL . . . -62.75 -40.22 98.93 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.686 -0.769 . . . . 0.0 111.407 179.131 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.442 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.4 OUTLIER -74.61 -54.89 6.59 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 179.114 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.436 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 3.3 mp -52.02 -36.44 50.11 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.943 0.401 . . . . 0.0 110.745 179.597 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.556 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.86 -21.49 1.16 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.903 -0.59 . . . . 0.0 112.165 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.535 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.2 ptm180 -88.73 -42.42 11.96 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.453 -179.331 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.481 HG13 ' N ' ' A' ' 13' ' ' LEU . 2.8 pt -54.78 -33.79 28.85 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.221 0 C-N-CA 120.421 -0.512 . . . . 0.0 110.791 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.556 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.25 -29.27 69.48 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 177.971 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.636 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.25 -15.98 42.37 Favored Glycine 0 N--CA 1.444 -0.782 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.669 178.313 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.535 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.3 mpt_? -100.23 26.61 6.36 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 121.008 0.432 . . . . 0.0 110.677 179.694 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.623 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.4 p -112.02 -50.27 5.97 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 179.691 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.623 HD13 ' O ' ' A' ' 16' ' ' VAL . 42.1 mm -150.27 83.75 5.93 Favored Pre-proline 0 N--CA 1.425 -1.7 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 174.855 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.636 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.3 Cg_endo -91.26 -179.28 1.39 Allowed 'Trans proline' 0 N--CA 1.423 -2.642 0 C-N-CA 124.893 3.728 . . . . 0.0 109.658 178.603 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.24 -28.69 69.9 Favored 'General case' 0 C--N 1.301 -1.541 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.964 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.45 HG23 ' O ' ' A' ' 18' ' ' PRO . 18.5 t . . . . . 0 C--O 1.25 1.091 0 CA-C-O 118.235 -0.888 . . . . 0.0 111.185 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.168 0 N-CA-C 112.611 -0.195 . . . . 0.0 112.611 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.7 mt -161.73 -76.47 0.05 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.878 0.37 . . . . 0.0 110.259 179.851 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -87.56 -16.14 60.7 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.35 179.496 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -82.76 -33.23 27.46 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-O 121.431 0.634 . . . . 0.0 109.708 179.187 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.59 HG12 HD12 ' A' ' 9' ' ' LEU . 11.3 t -72.79 -28.07 26.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 114.933 -1.031 . . . . 0.0 110.209 179.269 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -41.78 -25.37 0.06 Allowed 'General case' 0 C--O 1.232 0.14 0 CA-C-N 115.406 -0.816 . . . . 0.0 110.695 179.683 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -67.98 -41.09 88.48 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.6 179.167 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.441 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -75.21 -59.47 2.73 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 110.393 -0.225 . . . . 0.0 110.393 179.25 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.59 HD12 HG12 ' A' ' 5' ' ' VAL . 1.0 OUTLIER -43.51 -30.88 0.62 Allowed 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 121.08 0.467 . . . . 0.0 111.04 179.506 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.562 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.89 -21.29 1.12 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.672 -0.695 . . . . 0.0 112.112 179.64 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.484 ' O ' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.4 -43.64 11.34 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 116.684 -0.234 . . . . 0.0 111.22 -179.146 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.472 ' N ' ' HG2' ' A' ' 11' ' ' ARG . 5.4 pt -54.79 -33.43 28.05 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 C-N-CA 120.429 -0.508 . . . . 0.0 111.101 -179.454 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.562 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -67.39 -28.86 68.28 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 178.08 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.6 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.98 -13.6 52.35 Favored Glycine 0 N--CA 1.444 -0.77 0 CA-C-N 115.2 -0.909 . . . . 0.0 111.783 178.473 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.484 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.4 mpt_? -100.18 26.76 6.18 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 120.963 0.411 . . . . 0.0 110.788 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.615 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.2 p -111.84 -49.29 6.12 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.037 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 179.624 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.615 HD13 ' O ' ' A' ' 16' ' ' VAL . 42.1 mm -150.04 83.33 6.18 Favored Pre-proline 0 N--CA 1.424 -1.762 0 N-CA-C 106.402 -1.703 . . . . 0.0 106.402 174.539 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.6 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.9 Cg_endo -91.55 -179.38 1.32 Allowed 'Trans proline' 0 N--CA 1.422 -2.715 0 C-N-CA 125.026 3.817 . . . . 0.0 109.797 178.744 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.46 -28.46 69.23 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 115.153 -0.93 . . . . 0.0 111.074 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.401 HG23 ' O ' ' A' ' 18' ' ' PRO . 19.6 t . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.218 -0.896 . . . . 0.0 111.093 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.605 ' HA2' HG23 ' A' ' 5' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.205 0 N-CA-C 112.413 -0.275 . . . . 0.0 112.413 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.472 HD22 ' N ' ' A' ' 2' ' ' LEU . 2.8 mm? 61.99 85.83 0.12 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.904 0.383 . . . . 0.0 110.297 -179.716 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 99.16 -34.77 5.14 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.753 -0.737 . . . . 0.0 111.945 -179.269 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.5 m -82.78 -37.85 23.98 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-O 121.525 0.678 . . . . 0.0 109.405 178.894 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.78 HG12 HD12 ' A' ' 9' ' ' LEU . 10.1 t -74.64 -33.49 32.04 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.462 0 CA-C-N 114.816 -1.084 . . . . 0.0 110.194 179.177 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -43.11 -25.65 0.12 Allowed 'General case' 0 C--O 1.231 0.123 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.404 179.666 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -67.28 -37.87 91.18 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.512 179.248 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.465 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -83.67 -43.54 15.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.79 0.329 . . . . 0.0 110.206 179.181 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.78 HD12 HG12 ' A' ' 5' ' ' VAL . 0.8 OUTLIER -55.05 -58.44 7.63 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.818 179.655 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.627 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.73 -21.91 0.7 Allowed 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.405 -0.361 . . . . 0.0 111.701 179.709 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.699 HH21 HG22 ' A' ' 12' ' ' ILE . 0.0 OUTLIER -88.88 -44.88 10.14 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.116 -179.488 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.699 HG22 HH21 ' A' ' 11' ' ' ARG . 1.8 pp -55.2 -42.8 67.67 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.253 0 C-N-CA 120.405 -0.518 . . . . 0.0 110.927 -179.613 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.627 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -57.66 -34.71 69.66 Favored 'General case' 0 CA--C 1.515 -0.378 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 177.912 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.581 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -62.75 -20.97 62.52 Favored Glycine 0 N--CA 1.446 -0.697 0 C-N-CA 120.118 -1.039 . . . . 0.0 110.676 177.619 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.406 ' NE ' ' HG2' ' A' ' 11' ' ' ARG . 2.2 mpt_? -99.85 27.13 5.67 Favored 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 123.118 0.567 . . . . 0.0 110.082 178.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.503 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 0.3 OUTLIER -111.21 -49.47 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.918 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 -179.947 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.503 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 37.0 mm -150.24 82.67 6.3 Favored Pre-proline 0 N--CA 1.425 -1.684 0 N-CA-C 106.54 -1.652 . . . . 0.0 106.54 174.191 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.581 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.3 Cg_endo -91.82 -178.86 1.17 Allowed 'Trans proline' 0 N--CA 1.423 -2.631 0 C-N-CA 125.251 3.967 . . . . 0.0 109.899 178.611 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.08 -28.5 66.57 Favored 'General case' 0 C--N 1.301 -1.519 0 CA-C-N 115.148 -0.933 . . . . 0.0 111.012 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 18.8 t . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.274 -0.869 . . . . 0.0 111.294 179.899 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.581 ' O ' HD23 ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.489 2.172 0 N-CA-C 112.553 -0.219 . . . . 0.0 112.553 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.581 HD23 ' O ' ' A' ' 1' ' ' GLY . 0.2 OUTLIER 164.98 80.22 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.924 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.402 ' O ' ' CD2' ' A' ' 6' ' ' PHE . . . 95.85 -28.4 12.72 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.64 -0.79 . . . . 0.0 111.785 -179.028 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -82.77 -30.79 28.68 Favored 'General case' 0 CA--C 1.519 -0.217 0 CA-C-O 121.568 0.699 . . . . 0.0 109.333 178.782 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.442 ' O ' ' N ' ' A' ' 8' ' ' ARG . 6.6 t -76.08 -21.3 15.5 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 CA-C-N 114.758 -1.11 . . . . 0.0 110.085 178.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.402 ' CD2' ' O ' ' A' ' 3' ' ' GLY . 0.5 OUTLIER -41.17 -25.3 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.121 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.705 179.829 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 5' ' ' VAL . . . -63.37 -40.67 99.17 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.791 -0.718 . . . . 0.0 111.425 179.255 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.442 ' N ' ' O ' ' A' ' 5' ' ' VAL . 2.0 mpt_? -73.9 -54.9 6.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.803 0.335 . . . . 0.0 110.156 179.189 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.8 mp -52.25 -42.1 63.35 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.907 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.548 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.93 -21.6 0.69 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.016 -0.538 . . . . 0.0 112.288 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.534 ' O ' ' N ' ' A' ' 15' ' ' ARG . 1.4 ptm180 -88.93 -41.09 12.62 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-N 116.666 -0.243 . . . . 0.0 111.339 -179.514 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.491 HG13 ' N ' ' A' ' 13' ' ' LEU . 2.4 pt -54.91 -34.24 30.57 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.211 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.814 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.548 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -65.97 -28.49 68.94 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 178.032 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.626 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.43 -17.64 35.84 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.484 178.161 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.534 ' N ' ' O ' ' A' ' 11' ' ' ARG . 2.4 mpt_? -100.81 26.72 6.57 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 122.794 0.438 . . . . 0.0 110.623 179.673 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.602 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.4 p -111.89 -49.95 6.04 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.052 0 N-CA-C 107.741 -1.207 . . . . 0.0 107.741 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.602 HD13 ' O ' ' A' ' 16' ' ' VAL . 41.6 mm -149.98 82.99 6.33 Favored Pre-proline 0 N--CA 1.426 -1.663 0 N-CA-C 106.486 -1.672 . . . . 0.0 106.486 174.634 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.626 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.1 Cg_endo -91.71 -179.0 1.22 Allowed 'Trans proline' 0 N--CA 1.424 -2.615 0 C-N-CA 125.212 3.941 . . . . 0.0 110.03 178.944 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.16 -28.39 69.72 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 115.021 -0.99 . . . . 0.0 111.148 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.444 HG23 ' O ' ' A' ' 18' ' ' PRO . 16.6 t . . . . . 0 C--O 1.249 1.032 0 CA-C-O 118.274 -0.87 . . . . 0.0 111.154 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.542 ' O ' HD23 ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.489 2.226 0 N-CA-C 112.398 -0.281 . . . . 0.0 112.398 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.542 HD23 ' O ' ' A' ' 1' ' ' GLY . 0.2 OUTLIER 166.5 76.22 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.947 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 98.03 -29.51 11.09 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.381 -178.802 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -82.66 -29.02 30.29 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.571 0.701 . . . . 0.0 109.262 178.472 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.426 ' O ' ' N ' ' A' ' 7' ' ' GLY . 8.3 t -73.9 -21.25 18.02 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.499 0 CA-C-N 114.739 -1.119 . . . . 0.0 109.968 178.827 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.439 ' O ' ' HB2' ' A' ' 10' ' ' ALA . 0.5 OUTLIER -41.01 -25.11 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.72 179.954 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 5' ' ' VAL . . . -60.74 -38.43 95.17 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.845 -0.693 . . . . 0.0 111.58 179.193 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.94 -54.34 6.13 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.03 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.44 ' HA ' HG12 ' A' ' 12' ' ' ILE . 4.8 mp -55.34 -22.77 20.63 Favored 'General case' 0 CA--C 1.528 0.132 0 CA-C-O 121.017 0.437 . . . . 0.0 110.424 179.028 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.717 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -63.07 -21.14 65.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.373 179.763 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.443 ' O ' ' N ' ' A' ' 14' ' ' GLY . 0.0 OUTLIER -89.41 -40.96 12.37 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.597 -179.472 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.49 HG13 ' N ' ' A' ' 13' ' ' LEU . 1.6 pt -53.79 -36.61 30.28 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.171 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.979 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.717 HD21 ' HA ' ' A' ' 10' ' ' ALA . 1.5 pp -65.95 -24.34 66.79 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 177.893 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.643 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -92.23 -19.79 37.83 Favored Glycine 0 N--CA 1.444 -0.816 0 CA-C-N 115.102 -0.953 . . . . 0.0 111.603 178.31 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.439 ' CD ' ' O ' ' A' ' 11' ' ' ARG . 2.3 mpt_? -100.74 25.87 7.43 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 120.836 0.35 . . . . 0.0 110.947 179.614 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.622 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.6 p -112.42 -50.35 5.82 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.11 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.758 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.622 HD13 ' O ' ' A' ' 16' ' ' VAL . 31.9 mm -149.79 83.27 6.35 Favored Pre-proline 0 N--CA 1.423 -1.825 0 N-CA-C 106.578 -1.638 . . . . 0.0 106.578 175.446 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.643 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 3.6 Cg_endo -91.32 -178.94 1.31 Allowed 'Trans proline' 0 N--CA 1.424 -2.58 0 C-N-CA 125.049 3.833 . . . . 0.0 109.793 178.937 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -62.34 -23.07 66.57 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 115.227 -0.897 . . . . 0.0 111.164 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 2.6 t . . . . . 0 C--O 1.25 1.098 0 CA-C-O 118.152 -0.928 . . . . 0.0 110.848 -179.913 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.434 ' O ' ' HG ' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.489 2.208 0 N-CA-C 112.444 -0.262 . . . . 0.0 112.444 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.434 ' HG ' ' O ' ' A' ' 1' ' ' GLY . 16.9 mt -163.41 -75.14 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.938 0.399 . . . . 0.0 110.152 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -89.29 -17.84 54.51 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.188 179.203 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -82.48 -28.8 30.96 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.444 0.64 . . . . 0.0 109.578 179.005 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.674 HG12 HD12 ' A' ' 9' ' ' LEU . 14.1 t -74.65 -25.3 18.96 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.482 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.028 178.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -41.36 -25.47 0.04 OUTLIER 'General case' 0 C--N 1.333 -0.109 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.674 179.708 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.42 ' N ' ' C ' ' A' ' 5' ' ' VAL . . . -65.29 -40.54 96.64 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.556 179.34 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.432 ' N ' ' O ' ' A' ' 5' ' ' VAL . 1.8 mpt_? -78.23 -46.4 20.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.837 0.351 . . . . 0.0 110.459 179.368 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.674 HD12 HG12 ' A' ' 5' ' ' VAL . 1.6 mp -56.22 -60.58 3.3 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.903 179.803 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.646 ' HA ' HD11 ' A' ' 13' ' ' LEU . . . -44.44 -22.47 0.07 Allowed 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.195 -0.457 . . . . 0.0 112.056 179.74 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.723 ' NH2' HG22 ' A' ' 12' ' ' ILE . 0.0 OUTLIER -88.57 -46.14 9.32 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.645 -179.861 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.723 HG22 ' NH2' ' A' ' 11' ' ' ARG . 1.1 pp -57.48 -36.53 53.8 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.248 0 C-N-CA 120.52 -0.472 . . . . 0.0 111.149 -179.844 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.646 HD11 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -62.11 -35.35 78.45 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 178.198 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.588 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -70.6 -16.65 74.15 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.102 -1.047 . . . . 0.0 110.87 177.64 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.443 ' HD3' ' HG2' ' A' ' 11' ' ' ARG . 1.4 mpt_? -100.02 27.38 5.59 Favored 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 123.088 0.555 . . . . 0.0 110.491 179.566 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.567 ' O ' HD13 ' A' ' 17' ' ' ILE . 1.0 OUTLIER -111.21 -48.82 6.38 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.972 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 179.822 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.567 HD13 ' O ' ' A' ' 16' ' ' VAL . 44.1 mm -150.52 82.8 6.1 Favored Pre-proline 0 N--CA 1.424 -1.748 0 N-CA-C 106.568 -1.641 . . . . 0.0 106.568 174.257 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.588 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.7 Cg_endo -91.7 -178.9 1.2 Allowed 'Trans proline' 0 N--CA 1.423 -2.632 0 C-N-CA 125.135 3.89 . . . . 0.0 109.856 178.619 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.86 -28.9 67.94 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.197 -0.91 . . . . 0.0 110.912 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 16.6 t . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.217 -0.897 . . . . 0.0 111.266 179.819 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.618 ' HA3' HG23 ' A' ' 5' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.184 0 N-CA-C 112.573 -0.211 . . . . 0.0 112.573 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 72.16 84.84 0.12 Allowed 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.965 0.412 . . . . 0.0 110.19 -179.652 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.418 ' O ' ' CD1' ' A' ' 6' ' ' PHE . . . 100.67 -34.58 5.47 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.797 -0.716 . . . . 0.0 111.743 -179.224 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 13.3 m -82.82 -34.69 26.84 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.579 0.704 . . . . 0.0 109.425 178.85 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.618 HG23 ' HA3' ' A' ' 1' ' ' GLY . 8.9 t -80.09 -24.68 11.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.472 179.387 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 7' ' ' GLY . 0.1 OUTLIER -41.36 -25.47 0.04 OUTLIER 'General case' 0 CA--C 1.527 0.073 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.657 179.84 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.446 ' N ' ' CD1' ' A' ' 6' ' ' PHE . . . -63.84 -41.37 98.83 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.666 -0.778 . . . . 0.0 111.426 179.169 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.438 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -76.66 -45.27 30.5 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.889 0.376 . . . . 0.0 110.165 179.201 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.474 ' O ' HG13 ' A' ' 12' ' ' ILE . 0.7 OUTLIER -55.35 -54.96 37.06 Favored 'General case' 0 CA--C 1.529 0.163 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.819 179.668 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.627 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -47.64 -21.88 0.43 Allowed 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 112.083 179.81 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.481 ' O ' ' HD3' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.61 -45.22 10.04 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.861 -179.655 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.474 HG13 ' O ' ' A' ' 9' ' ' LEU . 1.1 pt -53.97 -35.63 28.88 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.211 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.882 -179.711 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.627 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -63.42 -35.65 81.13 Favored 'General case' 0 CA--C 1.513 -0.473 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 177.793 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.591 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -69.56 -16.89 72.25 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 120.006 -1.092 . . . . 0.0 110.758 177.61 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.481 ' HD3' ' O ' ' A' ' 11' ' ' ARG . 9.8 mpt_? -99.7 27.06 5.64 Favored 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 123.054 0.542 . . . . 0.0 110.496 179.313 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.554 ' O ' HD13 ' A' ' 17' ' ' ILE . 0.8 OUTLIER -111.42 -49.09 6.3 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.918 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 179.748 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.554 HD13 ' O ' ' A' ' 16' ' ' VAL . 44.5 mm -150.51 83.16 5.98 Favored Pre-proline 0 N--CA 1.423 -1.796 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 174.292 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.591 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.3 Cg_endo -91.5 -179.27 1.32 Allowed 'Trans proline' 0 N--CA 1.423 -2.675 0 C-N-CA 125.029 3.82 . . . . 0.0 109.597 178.515 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.425 ' HZ2' ' C ' ' A' ' 20' ' ' VAL . 0.0 OUTLIER -65.75 -29.7 70.25 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 115.307 -0.861 . . . . 0.0 110.818 179.856 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.425 ' C ' ' HZ2' ' A' ' 19' ' ' LYS . 37.2 t . . . . . 0 C--O 1.25 1.098 0 CA-C-O 118.204 -0.903 . . . . 0.0 111.253 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.577 ' O ' HD23 ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.489 2.207 0 N-CA-C 112.507 -0.237 . . . . 0.0 112.507 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.577 HD23 ' O ' ' A' ' 1' ' ' GLY . 0.2 OUTLIER 164.2 72.39 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -179.881 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 97.62 -28.24 15.17 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.176 -178.535 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -82.91 -27.03 30.93 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.473 0.654 . . . . 0.0 109.325 178.448 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.462 ' CG2' ' CA ' ' A' ' 1' ' ' GLY . 9.1 t -73.23 -21.4 18.94 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.489 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.048 179.049 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.435 ' O ' ' HB2' ' A' ' 10' ' ' ALA . 0.5 OUTLIER -41.33 -24.98 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.244 -0.889 . . . . 0.0 110.747 179.885 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.423 ' N ' ' C ' ' A' ' 5' ' ' VAL . . . -65.39 -40.76 96.57 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.714 -0.755 . . . . 0.0 111.514 179.079 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.422 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -72.65 -54.31 9.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.815 0.341 . . . . 0.0 110.165 179.223 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.427 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 3.2 mp -56.71 -32.94 66.0 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.814 179.648 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.561 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.46 -21.58 0.58 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.923 -0.581 . . . . 0.0 112.008 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.519 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.9 ptm180 -88.76 -43.02 11.58 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.273 -179.43 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.463 HG13 ' N ' ' A' ' 13' ' ' LEU . 3.8 pt -54.58 -33.75 27.75 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.188 0 C-N-CA 120.47 -0.492 . . . . 0.0 110.949 -179.652 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.561 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.07 -28.42 68.82 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 177.967 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.638 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.96 -16.71 37.62 Favored Glycine 0 N--CA 1.446 -0.671 0 CA-C-N 115.256 -0.884 . . . . 0.0 111.507 178.287 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.519 ' N ' ' O ' ' A' ' 11' ' ' ARG . 9.5 mpt_? -100.38 26.72 6.33 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.967 0.413 . . . . 0.0 110.551 179.654 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.623 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.6 p -111.83 -50.05 6.06 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.0 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 179.745 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.623 HD13 ' O ' ' A' ' 16' ' ' VAL . 44.1 mm -150.28 83.75 5.92 Favored Pre-proline 0 N--CA 1.427 -1.625 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 174.44 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.638 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.8 Cg_endo -91.28 -179.07 1.34 Allowed 'Trans proline' 0 N--CA 1.423 -2.625 0 C-N-CA 124.909 3.74 . . . . 0.0 109.559 178.747 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.1 -27.53 68.82 Favored 'General case' 0 C--N 1.3 -1.565 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.994 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 18' ' ' PRO . 19.2 t . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.235 -0.888 . . . . 0.0 111.156 179.821 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.611 ' HA2' HG23 ' A' ' 5' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.189 0 N-CA-C 112.503 -0.239 . . . . 0.0 112.503 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.617 ' N ' HD22 ' A' ' 2' ' ' LEU . 2.4 mm? 65.36 83.39 0.17 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.967 0.413 . . . . 0.0 110.178 -179.749 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 100.03 -33.67 6.11 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.752 -179.218 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 2.7 m -82.98 -36.55 24.98 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.572 0.701 . . . . 0.0 109.575 178.858 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.611 HG23 ' HA2' ' A' ' 1' ' ' GLY . 8.2 t -76.68 -30.9 19.19 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.438 0 CA-C-N 114.701 -1.136 . . . . 0.0 110.521 179.526 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.454 ' CD2' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -41.78 -25.52 0.06 Allowed 'General case' 0 CA--C 1.528 0.128 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.72 -179.975 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.454 ' N ' ' CD2' ' A' ' 6' ' ' PHE . . . -65.34 -39.39 95.86 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.454 179.018 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.467 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.5 OUTLIER -80.01 -46.29 16.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.975 0.417 . . . . 0.0 110.058 179.209 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.47 ' O ' HG13 ' A' ' 12' ' ' ILE . 0.5 OUTLIER -52.52 -59.58 4.27 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.255 179.945 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.576 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -43.58 -24.66 0.12 Allowed 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 116.293 -0.412 . . . . 0.0 112.089 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.499 ' O ' ' HD2' ' A' ' 15' ' ' ARG . 0.4 OUTLIER -88.57 -45.93 9.49 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.051 -179.807 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.47 HG13 ' O ' ' A' ' 9' ' ' LEU . 1.1 pp -56.25 -35.82 44.03 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.212 0 C-N-CA 120.446 -0.501 . . . . 0.0 111.113 -179.662 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.576 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -64.22 -33.56 76.08 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 178.128 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.585 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -73.22 -14.35 79.15 Favored Glycine 0 N--CA 1.444 -0.779 0 C-N-CA 120.117 -1.04 . . . . 0.0 110.827 177.537 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.499 ' HD2' ' O ' ' A' ' 11' ' ' ARG . 0.6 OUTLIER -99.88 27.04 5.74 Favored 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 123.03 0.532 . . . . 0.0 110.401 179.493 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.547 ' O ' HD13 ' A' ' 17' ' ' ILE . 1.4 p -111.46 -48.89 6.28 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.926 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 179.824 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.547 HD13 ' O ' ' A' ' 16' ' ' VAL . 43.3 mm -150.38 82.85 6.16 Favored Pre-proline 0 N--CA 1.423 -1.783 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 174.395 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.585 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.9 Cg_endo -91.69 -178.93 1.21 Allowed 'Trans proline' 0 N--CA 1.425 -2.544 0 C-N-CA 125.211 3.94 . . . . 0.0 109.942 178.771 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.47 -28.65 69.81 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.102 -0.954 . . . . 0.0 111.068 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 18' ' ' PRO . 19.3 t . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.264 -0.875 . . . . 0.0 111.254 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.181 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.6 mt 69.69 -66.37 0.27 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.83 0.348 . . . . 0.0 110.642 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.419 ' O ' ' CD1' ' A' ' 6' ' ' PHE . . . -91.49 -24.26 26.6 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.292 179.578 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.8 m -83.01 -33.17 26.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.521 0.677 . . . . 0.0 109.659 179.019 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.528 HG12 HD12 ' A' ' 9' ' ' LEU . 6.3 t -80.39 -27.09 11.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.677 179.578 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.459 ' CD1' ' N ' ' A' ' 7' ' ' GLY . 0.1 OUTLIER -42.9 -25.29 0.09 Allowed 'General case' 0 C--O 1.231 0.12 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.519 179.828 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.459 ' N ' ' CD1' ' A' ' 6' ' ' PHE . . . -72.48 -37.46 58.46 Favored Glycine 0 N--CA 1.45 -0.41 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.651 179.372 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.476 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -73.11 -59.76 2.56 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.649 0.262 . . . . 0.0 110.354 179.345 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.528 HD12 HG12 ' A' ' 5' ' ' VAL . 0.4 OUTLIER -48.08 -30.8 4.79 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 120.97 0.415 . . . . 0.0 110.875 179.638 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.586 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.96 -21.57 1.25 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.836 -0.62 . . . . 0.0 112.185 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.485 ' O ' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.98 -43.38 11.18 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 116.707 -0.224 . . . . 0.0 111.186 -179.417 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.477 ' N ' ' HG2' ' A' ' 11' ' ' ARG . 3.1 pt -54.27 -33.56 25.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 C-N-CA 120.475 -0.49 . . . . 0.0 111.085 -179.521 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.586 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.05 -28.55 68.93 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 177.908 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.63 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.78 -17.16 39.31 Favored Glycine 0 N--CA 1.444 -0.782 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.635 178.351 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.485 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.7 mpt_? -100.46 26.74 6.35 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 120.949 0.404 . . . . 0.0 110.809 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.615 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.1 p -111.6 -49.84 6.16 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.082 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 179.789 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.615 HD13 ' O ' ' A' ' 16' ' ' VAL . 42.4 mm -150.2 83.23 6.13 Favored Pre-proline 0 N--CA 1.424 -1.754 0 N-CA-C 106.565 -1.642 . . . . 0.0 106.565 174.595 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.63 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.5 Cg_endo -91.32 -179.0 1.32 Allowed 'Trans proline' 0 N--CA 1.423 -2.659 0 C-N-CA 124.983 3.789 . . . . 0.0 109.777 178.768 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.58 -29.8 69.94 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 115.141 -0.936 . . . . 0.0 110.949 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 18.4 t . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.247 -0.882 . . . . 0.0 111.239 179.971 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.61 ' HA2' HG23 ' A' ' 5' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.205 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.2 mm? 62.49 86.15 0.12 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.856 0.36 . . . . 0.0 110.554 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 98.31 -33.76 5.76 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.776 -0.726 . . . . 0.0 111.925 -179.426 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 2.5 m -83.02 -36.88 24.63 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.576 0.703 . . . . 0.0 109.417 178.904 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.908 HG12 HD12 ' A' ' 9' ' ' LEU . 6.6 t -78.72 -31.49 15.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 114.689 -1.141 . . . . 0.0 110.644 179.53 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.458 ' CD1' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -42.47 -25.61 0.09 Allowed 'General case' 0 CA--C 1.528 0.102 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.731 179.993 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . 0.458 ' N ' ' CD1' ' A' ' 6' ' ' PHE . . . -70.83 -38.58 65.72 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.768 -0.73 . . . . 0.0 111.587 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ARG . . . . . 0.463 ' N ' ' O ' ' A' ' 5' ' ' VAL . 9.3 mmm180 -75.92 -52.52 10.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.857 0.36 . . . . 0.0 110.217 179.25 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.908 HD12 HG12 ' A' ' 5' ' ' VAL . 0.7 OUTLIER -50.1 -38.35 38.3 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.063 179.833 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.58 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -46.57 -21.53 0.19 Allowed 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.215 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.477 ' HG2' ' N ' ' A' ' 12' ' ' ILE . 0.0 OUTLIER -88.44 -43.77 11.22 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.877 -179.398 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.477 ' N ' ' HG2' ' A' ' 11' ' ' ARG . 2.7 pt -57.32 -32.3 40.59 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.178 0 C-N-CA 120.454 -0.498 . . . . 0.0 111.011 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.658 ' O ' HG12 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -68.41 -28.03 66.73 Favored 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 178.188 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.605 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -90.55 -15.01 57.63 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.435 -0.888 . . . . 0.0 111.07 177.985 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.455 ' HD3' ' CG ' ' A' ' 11' ' ' ARG . 0.7 OUTLIER -100.35 26.93 6.1 Favored 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 122.626 0.371 . . . . 0.0 110.938 179.841 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.658 HG12 ' O ' ' A' ' 13' ' ' LEU . 8.6 p -111.63 -48.92 6.21 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.015 0 N-CA-C 107.391 -1.337 . . . . 0.0 107.391 179.679 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.628 HD13 ' O ' ' A' ' 16' ' ' VAL . 39.7 mm -150.08 83.07 6.25 Favored Pre-proline 0 N--CA 1.425 -1.722 0 N-CA-C 106.522 -1.658 . . . . 0.0 106.522 174.579 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.605 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 3.8 Cg_endo -91.56 -179.06 1.27 Allowed 'Trans proline' 0 N--CA 1.424 -2.612 0 C-N-CA 125.019 3.813 . . . . 0.0 109.961 178.838 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.435 ' HZ2' ' C ' ' A' ' 20' ' ' VAL . 0.0 OUTLIER -64.2 -29.26 70.38 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.943 179.912 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.442 HG23 ' O ' ' A' ' 18' ' ' PRO . 20.7 t . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.234 -0.889 . . . . 0.0 111.143 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.52 -0.203 0 CA-C-O 121.523 0.678 . . . . 0.0 109.519 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.701 HG12 HD12 ' A' ' 9' ' ' LEU . 9.2 t -79.31 -30.02 13.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 114.814 -1.084 . . . . 0.0 110.638 179.599 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.458 ' CD2' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -42.14 -25.38 0.07 Allowed 'General case' 0 CA--C 1.528 0.13 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.752 179.942 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.458 ' N ' ' CD2' ' A' ' 6' ' ' PHE . . . -66.02 -38.61 94.25 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.725 -0.75 . . . . 0.0 111.605 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.409 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -80.8 -51.99 8.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.67 0.272 . . . . 0.0 110.41 179.41 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.701 HD12 HG12 ' A' ' 5' ' ' VAL . 2.9 mp -51.96 -38.47 56.64 Favored 'General case' 0 CA--C 1.529 0.156 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.897 179.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.579 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -50.75 -21.45 1.64 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.183 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.47 ' O ' ' N ' ' A' ' 15' ' ' ARG . 1.7 ptm180 -88.77 -41.39 12.56 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.551 -179.183 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.477 HG13 ' N ' ' A' ' 13' ' ' LEU . 3.7 pt -54.62 -35.46 32.38 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.178 0 C-N-CA 120.369 -0.533 . . . . 0.0 110.817 -179.637 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.579 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.05 -26.98 67.75 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 177.879 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.633 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -93.96 -17.02 42.33 Favored Glycine 0 N--CA 1.444 -0.806 0 CA-C-N 115.187 -0.915 . . . . 0.0 111.532 178.273 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.47 ' N ' ' O ' ' A' ' 11' ' ' ARG . 2.5 mpt_? -100.35 26.58 6.46 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 120.956 0.408 . . . . 0.0 110.716 179.718 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.622 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.3 p -112.19 -50.42 5.9 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.02 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 179.67 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.622 HD13 ' O ' ' A' ' 16' ' ' VAL . 40.4 mm -150.15 83.82 5.97 Favored Pre-proline 0 N--CA 1.425 -1.703 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 174.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.633 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.8 Cg_endo -91.37 -179.18 1.34 Allowed 'Trans proline' 0 N--CA 1.422 -2.684 0 C-N-CA 124.904 3.736 . . . . 0.0 109.808 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.55 -29.46 70.72 Favored 'General case' 0 C--N 1.299 -1.604 0 CA-C-N 115.152 -0.931 . . . . 0.0 111.001 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 18' ' ' PRO . 21.5 t . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.287 -0.863 . . . . 0.0 111.092 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.518 -0.253 0 CA-C-O 121.577 0.703 . . . . 0.0 109.398 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.638 HG12 HD12 ' A' ' 9' ' ' LEU . 5.5 t -76.47 -30.0 19.09 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.448 0 CA-C-N 114.658 -1.155 . . . . 0.0 110.394 179.406 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.451 ' CD2' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -41.56 -25.61 0.05 Allowed 'General case' 0 C--O 1.232 0.138 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.738 179.936 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.451 ' N ' ' CD2' ' A' ' 6' ' ' PHE . . . -68.89 -42.01 80.18 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.359 179.045 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.464 ' N ' ' O ' ' A' ' 5' ' ' VAL . 2.0 mpt_? -71.03 -54.36 11.46 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 179.088 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.638 HD12 HG12 ' A' ' 5' ' ' VAL . 2.3 mp -50.58 -33.57 22.47 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 120.966 0.412 . . . . 0.0 110.71 179.646 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.549 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.61 -21.44 1.01 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.917 -0.583 . . . . 0.0 112.076 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.521 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.2 ptm180 -88.73 -42.43 11.95 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.326 -179.265 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.464 HG13 ' N ' ' A' ' 13' ' ' LEU . 3.8 pt -54.19 -34.38 27.07 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.181 0 C-N-CA 120.376 -0.529 . . . . 0.0 110.927 -179.685 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.564 ' O ' HG12 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -66.39 -28.89 68.99 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 178.023 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.638 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.67 -15.95 44.33 Favored Glycine 0 N--CA 1.445 -0.76 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.59 178.271 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.521 ' N ' ' O ' ' A' ' 11' ' ' ARG . 9.1 mpt_? -100.71 26.69 6.55 Favored 'General case' 0 N--CA 1.465 0.316 0 C-N-CA 122.768 0.427 . . . . 0.0 110.642 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.627 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.2 p -111.77 -50.41 6.05 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.994 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.627 HD13 ' O ' ' A' ' 16' ' ' VAL . 42.4 mm -150.2 83.51 6.04 Favored Pre-proline 0 N--CA 1.425 -1.685 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 174.61 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.638 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.5 Cg_endo -91.35 -179.15 1.34 Allowed 'Trans proline' 0 N--CA 1.423 -2.653 0 C-N-CA 125.002 3.802 . . . . 0.0 109.95 178.782 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.01 -26.95 69.09 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 115.135 -0.939 . . . . 0.0 111.135 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.495 HG23 ' O ' ' A' ' 18' ' ' PRO . 18.6 t . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.279 -0.867 . . . . 0.0 111.174 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.52 -0.193 0 CA-C-O 121.467 0.651 . . . . 0.0 109.483 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.726 HG12 HD12 ' A' ' 9' ' ' LEU . 9.3 t -78.04 -30.33 16.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 114.827 -1.079 . . . . 0.0 110.47 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.448 ' CD1' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -41.8 -25.28 0.05 Allowed 'General case' 0 CA--C 1.529 0.138 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.78 -179.978 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.448 ' N ' ' CD1' ' A' ' 6' ' ' PHE . . . -64.18 -40.25 97.85 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.721 -0.752 . . . . 0.0 111.476 179.124 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -79.72 -51.14 9.59 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.751 0.31 . . . . 0.0 110.364 179.277 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.726 HD12 HG12 ' A' ' 5' ' ' VAL . 1.4 mp -51.32 -38.28 52.16 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-O 121.09 0.471 . . . . 0.0 110.507 179.515 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.546 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.7 -21.12 0.55 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.949 179.567 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.481 ' O ' ' CD ' ' A' ' 15' ' ' ARG . 1.3 ptm180 -88.17 -42.31 12.41 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.235 -179.394 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.478 HG13 ' N ' ' A' ' 13' ' ' LEU . 5.1 pt -55.53 -34.68 35.66 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.17 0 C-N-CA 120.329 -0.549 . . . . 0.0 110.734 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.591 ' O ' HG12 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -66.38 -27.25 67.72 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 178.053 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.626 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.06 -16.74 43.15 Favored Glycine 0 N--CA 1.443 -0.834 0 CA-C-N 115.276 -0.875 . . . . 0.0 111.303 178.197 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.481 ' CD ' ' O ' ' A' ' 11' ' ' ARG . 1.7 mpt_? -100.22 26.91 6.04 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.004 0.43 . . . . 0.0 110.528 179.602 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.631 ' O ' HD13 ' A' ' 17' ' ' ILE . 9.1 p -111.45 -49.82 6.22 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.038 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.631 HD13 ' O ' ' A' ' 16' ' ' VAL . 40.5 mm -150.2 83.27 6.12 Favored Pre-proline 0 N--CA 1.424 -1.738 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 174.514 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.626 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.1 Cg_endo -91.39 -179.05 1.31 Allowed 'Trans proline' 0 N--CA 1.424 -2.616 0 C-N-CA 124.916 3.744 . . . . 0.0 109.801 178.696 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.39 -30.24 69.96 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.006 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 17.2 t . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.234 -0.889 . . . . 0.0 111.283 179.892 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.518 -0.281 0 CA-C-O 121.587 0.708 . . . . 0.0 109.354 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.821 HG12 HD12 ' A' ' 9' ' ' LEU . 5.5 t -74.64 -30.08 24.43 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.428 0 CA-C-N 114.621 -1.172 . . . . 0.0 110.279 179.237 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -42.78 -25.45 0.09 Allowed 'General case' 0 C--O 1.232 0.141 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.375 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -69.77 -40.67 75.57 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.816 -0.707 . . . . 0.0 111.388 178.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.461 ' N ' ' O ' ' A' ' 5' ' ' VAL . 1.0 OUTLIER -72.43 -54.14 10.19 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.772 0.32 . . . . 0.0 110.389 179.262 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.821 HD12 HG12 ' A' ' 5' ' ' VAL . 1.7 mp -53.8 -35.03 60.95 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 121.057 0.456 . . . . 0.0 110.718 179.623 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.623 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -47.72 -21.6 0.41 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.759 -0.655 . . . . 0.0 112.209 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.458 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.2 ptm180 -89.1 -41.54 12.23 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-N 116.603 -0.272 . . . . 0.0 111.469 -179.574 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.459 HG13 ' N ' ' A' ' 13' ' ' LEU . 4.9 pt -54.87 -34.73 31.57 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.234 0 C-N-CA 120.497 -0.481 . . . . 0.0 110.82 -179.7 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.623 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -65.3 -27.16 68.43 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.811 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.606 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -93.65 -19.38 34.9 Favored Glycine 0 N--CA 1.444 -0.768 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.506 178.166 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.458 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.7 mpt_? -100.16 26.28 6.64 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 120.863 0.363 . . . . 0.0 110.638 179.571 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.61 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.5 p -112.07 -49.63 6.0 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.064 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.61 HD13 ' O ' ' A' ' 16' ' ' VAL . 38.7 mm -149.74 83.19 6.4 Favored Pre-proline 0 N--CA 1.424 -1.748 0 N-CA-C 106.51 -1.663 . . . . 0.0 106.51 174.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.606 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.0 Cg_endo -91.58 -178.94 1.24 Allowed 'Trans proline' 0 N--CA 1.423 -2.618 0 C-N-CA 125.048 3.832 . . . . 0.0 109.746 178.692 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.92 -30.56 68.0 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.845 179.786 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.189 -0.91 . . . . 0.0 111.182 179.984 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.521 -0.153 0 CA-C-O 121.398 0.618 . . . . 0.0 109.798 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.608 HG12 HD12 ' A' ' 9' ' ' LEU . 15.0 t -72.82 -23.81 20.83 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.425 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.282 179.323 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -41.54 -25.24 0.04 OUTLIER 'General case' 0 C--N 1.333 -0.132 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.633 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.417 ' N ' ' C ' ' A' ' 5' ' ' VAL . . . -67.22 -41.03 92.33 Favored Glycine 0 N--CA 1.45 -0.423 0 CA-C-N 115.577 -0.738 . . . . 0.0 111.68 179.217 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.432 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -73.62 -54.74 7.46 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 179.251 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.608 HD12 HG12 ' A' ' 5' ' ' VAL . 2.8 mp -52.44 -34.53 49.17 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 120.982 0.42 . . . . 0.0 110.741 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.567 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -50.28 -21.51 1.41 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.989 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.501 ' O ' ' N ' ' A' ' 15' ' ' ARG . 3.1 ptm180 -88.68 -42.78 11.77 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.392 -179.311 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.485 HG13 ' N ' ' A' ' 13' ' ' LEU . 4.8 pt -53.39 -35.89 25.71 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.194 0 C-N-CA 120.364 -0.534 . . . . 0.0 110.823 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.567 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -65.03 -28.73 69.69 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 178.133 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.632 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.6 -16.16 43.75 Favored Glycine 0 N--CA 1.445 -0.763 0 CA-C-N 115.269 -0.878 . . . . 0.0 111.672 178.412 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.501 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.8 mpt_? -100.46 26.69 6.4 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 122.721 0.408 . . . . 0.0 110.733 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.618 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.1 p -111.92 -50.22 6.01 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.015 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.618 HD13 ' O ' ' A' ' 16' ' ' VAL . 42.6 mm -150.21 83.5 6.04 Favored Pre-proline 0 N--CA 1.424 -1.731 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 174.715 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.632 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.9 Cg_endo -91.36 -179.09 1.32 Allowed 'Trans proline' 0 N--CA 1.423 -2.629 0 C-N-CA 124.98 3.787 . . . . 0.0 109.754 178.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.61 -29.54 70.78 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.983 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 18' ' ' PRO . 20.8 t . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.297 -0.859 . . . . 0.0 111.195 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.519 -0.242 0 CA-C-O 121.53 0.681 . . . . 0.0 109.507 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.739 HG12 HD12 ' A' ' 9' ' ' LEU . 6.2 t -75.53 -29.2 20.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.402 179.384 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -41.53 -25.67 0.05 Allowed 'General case' 0 C--N 1.333 -0.121 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.661 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -65.18 -40.55 96.86 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.383 179.179 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.464 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -75.85 -52.55 10.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.789 0.328 . . . . 0.0 110.14 179.136 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.739 HD12 HG12 ' A' ' 5' ' ' VAL . 5.1 mp -52.43 -38.53 59.39 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.006 0.431 . . . . 0.0 110.618 179.609 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.561 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.3 -21.18 0.78 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.981 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.519 ' O ' ' N ' ' A' ' 15' ' ' ARG . 2.2 ptm180 -88.13 -42.08 12.59 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.338 -179.311 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.459 HG13 ' N ' ' A' ' 13' ' ' LEU . 4.5 pt -55.36 -34.79 34.83 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.218 0 C-N-CA 120.35 -0.54 . . . . 0.0 110.838 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.561 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.45 -27.73 68.04 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 178.089 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.632 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.7 -17.22 39.35 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.303 178.014 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.519 ' N ' ' O ' ' A' ' 11' ' ' ARG . 9.2 mpt_? -100.87 26.41 6.94 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 122.693 0.397 . . . . 0.0 110.866 179.816 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.608 ' O ' HD13 ' A' ' 17' ' ' ILE . 8.2 p -112.34 -50.32 5.85 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.059 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.608 HD13 ' O ' ' A' ' 16' ' ' VAL . 44.4 mm -150.29 83.78 5.91 Favored Pre-proline 0 N--CA 1.424 -1.743 0 N-CA-C 106.517 -1.66 . . . . 0.0 106.517 174.816 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.632 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.0 Cg_endo -91.24 -179.28 1.39 Allowed 'Trans proline' 0 N--CA 1.422 -2.702 0 C-N-CA 124.836 3.691 . . . . 0.0 109.569 178.662 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.23 -28.73 69.56 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 115.116 -0.947 . . . . 0.0 111.051 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.416 HG23 ' O ' ' A' ' 18' ' ' PRO . 20.1 t . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.245 -0.883 . . . . 0.0 111.232 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.517 -0.304 0 CA-C-O 121.65 0.738 . . . . 0.0 109.357 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.721 HG12 HD12 ' A' ' 9' ' ' LEU . 4.8 t -74.34 -32.19 30.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 114.652 -1.158 . . . . 0.0 110.315 179.352 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -42.14 -26.0 0.09 Allowed 'General case' 0 CA--C 1.528 0.112 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.583 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -71.72 -41.65 55.98 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.742 -0.742 . . . . 0.0 111.595 179.339 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.445 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -71.69 -52.07 19.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.676 0.274 . . . . 0.0 110.462 179.359 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.721 HD12 HG12 ' A' ' 5' ' ' VAL . 3.2 mp -55.1 -33.52 62.9 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.165 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.539 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.18 -21.53 0.5 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.137 -0.483 . . . . 0.0 112.097 179.839 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.505 ' O ' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.5 -44.67 10.53 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.022 -179.579 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.479 ' HA ' ' HB2' ' A' ' 15' ' ' ARG . 2.5 pt -54.76 -32.17 25.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 C-N-CA 120.552 -0.459 . . . . 0.0 111.163 -179.751 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.539 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -67.74 -29.25 68.43 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 178.201 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.577 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.96 -13.81 48.32 Favored Glycine 0 N--CA 1.445 -0.746 0 C-N-CA 120.478 -0.868 . . . . 0.0 111.458 178.137 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.505 ' N ' ' O ' ' A' ' 11' ' ' ARG . 0.4 OUTLIER -100.39 26.99 6.05 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 121.069 0.461 . . . . 0.0 110.775 -179.942 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.615 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.4 p -111.61 -49.36 6.2 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.032 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 179.491 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.615 HD13 ' O ' ' A' ' 16' ' ' VAL . 39.9 mm -150.03 83.63 6.09 Favored Pre-proline 0 N--CA 1.424 -1.741 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 174.375 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.577 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.4 Cg_endo -91.19 -179.17 1.39 Allowed 'Trans proline' 0 N--CA 1.424 -2.575 0 C-N-CA 125.001 3.801 . . . . 0.0 109.695 178.756 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.21 -29.58 69.28 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 115.238 -0.892 . . . . 0.0 110.811 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.5 t . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.276 -0.869 . . . . 0.0 111.226 179.8 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 CA--C 1.519 -0.217 0 CA-C-O 121.45 0.643 . . . . 0.0 109.47 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.449 ' O ' ' N ' ' A' ' 8' ' ' ARG . 10.5 t -81.0 -27.91 11.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.604 179.459 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.474 ' CD2' ' N ' ' A' ' 7' ' ' GLY . 0.1 OUTLIER -41.49 -25.44 0.05 OUTLIER 'General case' 0 C--O 1.231 0.128 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.738 -179.942 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.474 ' N ' ' CD2' ' A' ' 6' ' ' PHE . . . -69.05 -40.82 83.3 Favored Glycine 0 N--CA 1.45 -0.387 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.586 179.318 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.449 ' N ' ' O ' ' A' ' 5' ' ' VAL . 1.6 mpt_? -74.68 -47.18 33.13 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.878 0.371 . . . . 0.0 110.146 179.296 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.507 ' O ' HG13 ' A' ' 12' ' ' ILE . 1.0 OUTLIER -52.24 -60.25 3.44 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.993 179.709 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.604 ' HA ' HD11 ' A' ' 13' ' ' LEU . . . -44.64 -24.27 0.18 Allowed 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.963 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.475 ' NH2' HG22 ' A' ' 12' ' ' ILE . 0.0 OUTLIER -88.56 -48.24 7.72 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.808 -179.897 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.507 HG13 ' O ' ' A' ' 9' ' ' LEU . 1.1 pp -58.81 -36.94 63.52 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.204 0 C-N-CA 120.416 -0.514 . . . . 0.0 111.447 -179.617 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.604 HD11 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -62.36 -34.63 77.06 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 178.482 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.584 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -71.7 -12.9 74.62 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.079 -1.057 . . . . 0.0 111.034 177.75 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.45 ' HD2' ' N ' ' A' ' 15' ' ' ARG . 0.9 OUTLIER -99.67 27.35 5.43 Favored 'General case' 0 N--CA 1.465 0.319 0 C-N-CA 123.016 0.527 . . . . 0.0 110.51 179.646 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.592 ' O ' HD13 ' A' ' 17' ' ' ILE . 1.9 p -111.26 -49.01 6.37 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.934 0 N-CA-C 107.164 -1.421 . . . . 0.0 107.164 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.592 HD13 ' O ' ' A' ' 16' ' ' VAL . 44.2 mm -150.41 83.2 6.03 Favored Pre-proline 0 N--CA 1.423 -1.789 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 174.316 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.584 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.0 Cg_endo -91.53 -179.1 1.28 Allowed 'Trans proline' 0 N--CA 1.423 -2.675 0 C-N-CA 125.071 3.847 . . . . 0.0 109.633 178.622 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.16 -29.0 68.58 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.901 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.277 -0.868 . . . . 0.0 111.211 179.799 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.52 -0.193 0 CA-C-O 121.428 0.632 . . . . 0.0 109.408 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.676 HG12 HD12 ' A' ' 9' ' ' LEU . 11.6 t -72.5 -22.87 20.68 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.493 0 CA-C-N 114.852 -1.067 . . . . 0.0 109.94 178.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -41.51 -25.28 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.573 179.652 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 5' ' ' VAL . . . -71.64 -41.37 57.2 Favored Glycine 0 N--CA 1.45 -0.373 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.674 179.268 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.446 ' N ' ' O ' ' A' ' 5' ' ' VAL . 2.9 mmm180 -68.21 -54.1 20.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.88 0.371 . . . . 0.0 110.055 179.249 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.676 HD12 HG12 ' A' ' 5' ' ' VAL . 5.3 mp -56.18 -31.63 63.59 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.854 179.77 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.554 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -47.3 -21.53 0.3 Allowed 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.036 -0.529 . . . . 0.0 112.082 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.499 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.7 ptm180 -88.7 -42.78 11.76 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 116.536 -0.302 . . . . 0.0 111.252 -179.46 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.469 HG13 ' N ' ' A' ' 13' ' ' LEU . 4.4 pt -54.64 -33.92 28.44 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.209 0 C-N-CA 120.465 -0.494 . . . . 0.0 110.858 -179.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.554 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.62 -28.68 68.69 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 178.056 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.604 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.52 -14.13 48.53 Favored Glycine 0 N--CA 1.445 -0.742 0 CA-C-N 115.253 -0.885 . . . . 0.0 111.678 178.315 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.499 ' N ' ' O ' ' A' ' 11' ' ' ARG . 9.2 mpt_? -100.2 26.87 6.07 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 120.999 0.428 . . . . 0.0 110.688 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.62 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.4 p -111.88 -49.48 6.08 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.047 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 179.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.62 HD13 ' O ' ' A' ' 16' ' ' VAL . 40.7 mm -149.86 82.95 6.42 Favored Pre-proline 0 N--CA 1.422 -1.827 0 N-CA-C 106.574 -1.639 . . . . 0.0 106.574 174.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.604 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.7 Cg_endo -91.48 -179.01 1.28 Allowed 'Trans proline' 0 N--CA 1.423 -2.675 0 C-N-CA 125.091 3.861 . . . . 0.0 109.667 178.702 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.451 ' HZ2' ' C ' ' A' ' 20' ' ' VAL . 0.0 OUTLIER -66.76 -27.23 67.43 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.948 179.908 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.451 ' C ' ' HZ2' ' A' ' 19' ' ' LYS . 16.2 t . . . . . 0 C--O 1.25 1.1 0 CA-C-O 118.274 -0.869 . . . . 0.0 111.103 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.52 -0.208 0 CA-C-O 121.465 0.65 . . . . 0.0 109.388 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.442 ' O ' ' N ' ' A' ' 8' ' ' ARG . 9.3 t -73.3 -21.27 18.8 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.561 0 CA-C-N 114.877 -1.056 . . . . 0.0 109.999 178.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -41.15 -25.21 0.03 OUTLIER 'General case' 0 CA--C 1.529 0.145 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.694 179.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.422 ' N ' ' O ' ' A' ' 5' ' ' VAL . . . -62.75 -40.22 98.93 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.686 -0.769 . . . . 0.0 111.407 179.131 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.442 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.4 OUTLIER -74.61 -54.89 6.59 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 179.114 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.436 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 3.3 mp -52.02 -36.44 50.11 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.943 0.401 . . . . 0.0 110.745 179.597 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.556 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.86 -21.49 1.16 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.903 -0.59 . . . . 0.0 112.165 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.535 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.2 ptm180 -88.73 -42.42 11.96 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.453 -179.331 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.481 HG13 ' N ' ' A' ' 13' ' ' LEU . 2.8 pt -54.78 -33.79 28.85 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.221 0 C-N-CA 120.421 -0.512 . . . . 0.0 110.791 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.556 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.25 -29.27 69.48 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 177.971 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.636 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.25 -15.98 42.37 Favored Glycine 0 N--CA 1.444 -0.782 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.669 178.313 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.535 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.3 mpt_? -100.23 26.61 6.36 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 121.008 0.432 . . . . 0.0 110.677 179.694 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.623 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.4 p -112.02 -50.27 5.97 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 179.691 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.623 HD13 ' O ' ' A' ' 16' ' ' VAL . 42.1 mm -150.27 83.75 5.93 Favored Pre-proline 0 N--CA 1.425 -1.7 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 174.855 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.636 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.3 Cg_endo -91.26 -179.28 1.39 Allowed 'Trans proline' 0 N--CA 1.423 -2.642 0 C-N-CA 124.893 3.728 . . . . 0.0 109.658 178.603 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.24 -28.69 69.9 Favored 'General case' 0 C--N 1.301 -1.541 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.964 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.45 HG23 ' O ' ' A' ' 18' ' ' PRO . 18.5 t . . . . . 0 C--O 1.25 1.091 0 CA-C-O 118.235 -0.888 . . . . 0.0 111.185 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.52 -0.198 0 CA-C-O 121.431 0.634 . . . . 0.0 109.708 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.59 HG12 HD12 ' A' ' 9' ' ' LEU . 11.3 t -72.79 -28.07 26.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 114.933 -1.031 . . . . 0.0 110.209 179.269 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -41.78 -25.37 0.06 Allowed 'General case' 0 C--O 1.232 0.14 0 CA-C-N 115.406 -0.816 . . . . 0.0 110.695 179.683 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -67.98 -41.09 88.48 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.6 179.167 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.441 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -75.21 -59.47 2.73 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 110.393 -0.225 . . . . 0.0 110.393 179.25 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.59 HD12 HG12 ' A' ' 5' ' ' VAL . 1.0 OUTLIER -43.51 -30.88 0.62 Allowed 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 121.08 0.467 . . . . 0.0 111.04 179.506 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.562 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.89 -21.29 1.12 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.672 -0.695 . . . . 0.0 112.112 179.64 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.484 ' O ' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.4 -43.64 11.34 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 116.684 -0.234 . . . . 0.0 111.22 -179.146 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.472 ' N ' ' HG2' ' A' ' 11' ' ' ARG . 5.4 pt -54.79 -33.43 28.05 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 C-N-CA 120.429 -0.508 . . . . 0.0 111.101 -179.454 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.562 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -67.39 -28.86 68.28 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 178.08 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.6 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.98 -13.6 52.35 Favored Glycine 0 N--CA 1.444 -0.77 0 CA-C-N 115.2 -0.909 . . . . 0.0 111.783 178.473 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.484 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.4 mpt_? -100.18 26.76 6.18 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 120.963 0.411 . . . . 0.0 110.788 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.615 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.2 p -111.84 -49.29 6.12 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.037 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 179.624 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.615 HD13 ' O ' ' A' ' 16' ' ' VAL . 42.1 mm -150.04 83.33 6.18 Favored Pre-proline 0 N--CA 1.424 -1.762 0 N-CA-C 106.402 -1.703 . . . . 0.0 106.402 174.539 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.6 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.9 Cg_endo -91.55 -179.38 1.32 Allowed 'Trans proline' 0 N--CA 1.422 -2.715 0 C-N-CA 125.026 3.817 . . . . 0.0 109.797 178.744 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.46 -28.46 69.23 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 115.153 -0.93 . . . . 0.0 111.074 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.401 HG23 ' O ' ' A' ' 18' ' ' PRO . 19.6 t . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.218 -0.896 . . . . 0.0 111.093 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.5 m . . . . . 0 CA--C 1.518 -0.275 0 CA-C-O 121.525 0.678 . . . . 0.0 109.405 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.78 HG12 HD12 ' A' ' 9' ' ' LEU . 10.1 t -74.64 -33.49 32.04 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.462 0 CA-C-N 114.816 -1.084 . . . . 0.0 110.194 179.177 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -43.11 -25.65 0.12 Allowed 'General case' 0 C--O 1.231 0.123 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.404 179.666 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -67.28 -37.87 91.18 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.512 179.248 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.465 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -83.67 -43.54 15.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.79 0.329 . . . . 0.0 110.206 179.181 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.78 HD12 HG12 ' A' ' 5' ' ' VAL . 0.8 OUTLIER -55.05 -58.44 7.63 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.818 179.655 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.627 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.73 -21.91 0.7 Allowed 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.405 -0.361 . . . . 0.0 111.701 179.709 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.699 HH21 HG22 ' A' ' 12' ' ' ILE . 0.0 OUTLIER -88.88 -44.88 10.14 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.116 -179.488 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.699 HG22 HH21 ' A' ' 11' ' ' ARG . 1.8 pp -55.2 -42.8 67.67 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.253 0 C-N-CA 120.405 -0.518 . . . . 0.0 110.927 -179.613 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.627 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -57.66 -34.71 69.66 Favored 'General case' 0 CA--C 1.515 -0.378 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 177.912 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.581 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -62.75 -20.97 62.52 Favored Glycine 0 N--CA 1.446 -0.697 0 C-N-CA 120.118 -1.039 . . . . 0.0 110.676 177.619 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.406 ' NE ' ' HG2' ' A' ' 11' ' ' ARG . 2.2 mpt_? -99.85 27.13 5.67 Favored 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 123.118 0.567 . . . . 0.0 110.082 178.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.503 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 0.3 OUTLIER -111.21 -49.47 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.918 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 -179.947 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.503 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 37.0 mm -150.24 82.67 6.3 Favored Pre-proline 0 N--CA 1.425 -1.684 0 N-CA-C 106.54 -1.652 . . . . 0.0 106.54 174.191 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.581 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.3 Cg_endo -91.82 -178.86 1.17 Allowed 'Trans proline' 0 N--CA 1.423 -2.631 0 C-N-CA 125.251 3.967 . . . . 0.0 109.899 178.611 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.08 -28.5 66.57 Favored 'General case' 0 C--N 1.301 -1.519 0 CA-C-N 115.148 -0.933 . . . . 0.0 111.012 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 18.8 t . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.274 -0.869 . . . . 0.0 111.294 179.899 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.519 -0.217 0 CA-C-O 121.568 0.699 . . . . 0.0 109.333 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.442 ' O ' ' N ' ' A' ' 8' ' ' ARG . 6.6 t -76.08 -21.3 15.5 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 CA-C-N 114.758 -1.11 . . . . 0.0 110.085 178.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -41.17 -25.3 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.121 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.705 179.829 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 5' ' ' VAL . . . -63.37 -40.67 99.17 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.791 -0.718 . . . . 0.0 111.425 179.255 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.442 ' N ' ' O ' ' A' ' 5' ' ' VAL . 2.0 mpt_? -73.9 -54.9 6.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.803 0.335 . . . . 0.0 110.156 179.189 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.8 mp -52.25 -42.1 63.35 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.907 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.548 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.93 -21.6 0.69 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.016 -0.538 . . . . 0.0 112.288 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.534 ' O ' ' N ' ' A' ' 15' ' ' ARG . 1.4 ptm180 -88.93 -41.09 12.62 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-N 116.666 -0.243 . . . . 0.0 111.339 -179.514 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.491 HG13 ' N ' ' A' ' 13' ' ' LEU . 2.4 pt -54.91 -34.24 30.57 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.211 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.814 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.548 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -65.97 -28.49 68.94 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 178.032 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.626 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.43 -17.64 35.84 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.484 178.161 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.534 ' N ' ' O ' ' A' ' 11' ' ' ARG . 2.4 mpt_? -100.81 26.72 6.57 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 122.794 0.438 . . . . 0.0 110.623 179.673 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.602 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.4 p -111.89 -49.95 6.04 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.052 0 N-CA-C 107.741 -1.207 . . . . 0.0 107.741 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.602 HD13 ' O ' ' A' ' 16' ' ' VAL . 41.6 mm -149.98 82.99 6.33 Favored Pre-proline 0 N--CA 1.426 -1.663 0 N-CA-C 106.486 -1.672 . . . . 0.0 106.486 174.634 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.626 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.1 Cg_endo -91.71 -179.0 1.22 Allowed 'Trans proline' 0 N--CA 1.424 -2.615 0 C-N-CA 125.212 3.941 . . . . 0.0 110.03 178.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.16 -28.39 69.72 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 115.021 -0.99 . . . . 0.0 111.148 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.444 HG23 ' O ' ' A' ' 18' ' ' PRO . 16.6 t . . . . . 0 C--O 1.249 1.032 0 CA-C-O 118.274 -0.87 . . . . 0.0 111.154 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.521 -0.17 0 CA-C-O 121.571 0.701 . . . . 0.0 109.262 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.426 ' O ' ' N ' ' A' ' 7' ' ' GLY . 8.3 t -73.9 -21.25 18.02 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.499 0 CA-C-N 114.739 -1.119 . . . . 0.0 109.968 178.827 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.439 ' O ' ' HB2' ' A' ' 10' ' ' ALA . 0.5 OUTLIER -41.01 -25.11 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.72 179.954 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 5' ' ' VAL . . . -60.74 -38.43 95.17 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.845 -0.693 . . . . 0.0 111.58 179.193 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.94 -54.34 6.13 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.03 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.44 ' HA ' HG12 ' A' ' 12' ' ' ILE . 4.8 mp -55.34 -22.77 20.63 Favored 'General case' 0 CA--C 1.528 0.132 0 CA-C-O 121.017 0.437 . . . . 0.0 110.424 179.028 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.717 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -63.07 -21.14 65.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.373 179.763 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.443 ' O ' ' N ' ' A' ' 14' ' ' GLY . 0.0 OUTLIER -89.41 -40.96 12.37 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.597 -179.472 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.49 HG13 ' N ' ' A' ' 13' ' ' LEU . 1.6 pt -53.79 -36.61 30.28 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.171 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.979 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.717 HD21 ' HA ' ' A' ' 10' ' ' ALA . 1.5 pp -65.95 -24.34 66.79 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 177.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.643 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -92.23 -19.79 37.83 Favored Glycine 0 N--CA 1.444 -0.816 0 CA-C-N 115.102 -0.953 . . . . 0.0 111.603 178.31 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.439 ' CD ' ' O ' ' A' ' 11' ' ' ARG . 2.3 mpt_? -100.74 25.87 7.43 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 120.836 0.35 . . . . 0.0 110.947 179.614 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.622 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.6 p -112.42 -50.35 5.82 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.11 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.758 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.622 HD13 ' O ' ' A' ' 16' ' ' VAL . 31.9 mm -149.79 83.27 6.35 Favored Pre-proline 0 N--CA 1.423 -1.825 0 N-CA-C 106.578 -1.638 . . . . 0.0 106.578 175.446 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.643 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 3.6 Cg_endo -91.32 -178.94 1.31 Allowed 'Trans proline' 0 N--CA 1.424 -2.58 0 C-N-CA 125.049 3.833 . . . . 0.0 109.793 178.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -62.34 -23.07 66.57 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 115.227 -0.897 . . . . 0.0 111.164 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 2.6 t . . . . . 0 C--O 1.25 1.098 0 CA-C-O 118.152 -0.928 . . . . 0.0 110.848 -179.913 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.52 -0.188 0 CA-C-O 121.444 0.64 . . . . 0.0 109.578 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.674 HG12 HD12 ' A' ' 9' ' ' LEU . 14.1 t -74.65 -25.3 18.96 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.482 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.028 178.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -41.36 -25.47 0.04 OUTLIER 'General case' 0 C--N 1.333 -0.109 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.674 179.708 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.42 ' N ' ' C ' ' A' ' 5' ' ' VAL . . . -65.29 -40.54 96.64 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.556 179.34 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.432 ' N ' ' O ' ' A' ' 5' ' ' VAL . 1.8 mpt_? -78.23 -46.4 20.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.837 0.351 . . . . 0.0 110.459 179.368 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.674 HD12 HG12 ' A' ' 5' ' ' VAL . 1.6 mp -56.22 -60.58 3.3 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.903 179.803 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.646 ' HA ' HD11 ' A' ' 13' ' ' LEU . . . -44.44 -22.47 0.07 Allowed 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.195 -0.457 . . . . 0.0 112.056 179.74 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.723 ' NH2' HG22 ' A' ' 12' ' ' ILE . 0.0 OUTLIER -88.57 -46.14 9.32 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.645 -179.861 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.723 HG22 ' NH2' ' A' ' 11' ' ' ARG . 1.1 pp -57.48 -36.53 53.8 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.248 0 C-N-CA 120.52 -0.472 . . . . 0.0 111.149 -179.844 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.646 HD11 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -62.11 -35.35 78.45 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 178.198 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.588 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -70.6 -16.65 74.15 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.102 -1.047 . . . . 0.0 110.87 177.64 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.443 ' HD3' ' HG2' ' A' ' 11' ' ' ARG . 1.4 mpt_? -100.02 27.38 5.59 Favored 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 123.088 0.555 . . . . 0.0 110.491 179.566 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.567 ' O ' HD13 ' A' ' 17' ' ' ILE . 1.0 OUTLIER -111.21 -48.82 6.38 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.972 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 179.822 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.567 HD13 ' O ' ' A' ' 16' ' ' VAL . 44.1 mm -150.52 82.8 6.1 Favored Pre-proline 0 N--CA 1.424 -1.748 0 N-CA-C 106.568 -1.641 . . . . 0.0 106.568 174.257 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.588 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.7 Cg_endo -91.7 -178.9 1.2 Allowed 'Trans proline' 0 N--CA 1.423 -2.632 0 C-N-CA 125.135 3.89 . . . . 0.0 109.856 178.619 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.86 -28.9 67.94 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.197 -0.91 . . . . 0.0 110.912 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 16.6 t . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.217 -0.897 . . . . 0.0 111.266 179.819 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 13.3 m . . . . . 0 CA--C 1.519 -0.22 0 CA-C-O 121.579 0.704 . . . . 0.0 109.425 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.438 ' O ' ' N ' ' A' ' 8' ' ' ARG . 8.9 t -80.09 -24.68 11.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.472 179.387 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 7' ' ' GLY . 0.1 OUTLIER -41.36 -25.47 0.04 OUTLIER 'General case' 0 CA--C 1.527 0.073 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.657 179.84 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.446 ' N ' ' CD1' ' A' ' 6' ' ' PHE . . . -63.84 -41.37 98.83 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.666 -0.778 . . . . 0.0 111.426 179.169 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.438 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -76.66 -45.27 30.5 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.889 0.376 . . . . 0.0 110.165 179.201 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.474 ' O ' HG13 ' A' ' 12' ' ' ILE . 0.7 OUTLIER -55.35 -54.96 37.06 Favored 'General case' 0 CA--C 1.529 0.163 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.819 179.668 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.627 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -47.64 -21.88 0.43 Allowed 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 112.083 179.81 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.481 ' O ' ' HD3' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.61 -45.22 10.04 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.861 -179.655 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.474 HG13 ' O ' ' A' ' 9' ' ' LEU . 1.1 pt -53.97 -35.63 28.88 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.211 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.882 -179.711 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.627 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -63.42 -35.65 81.13 Favored 'General case' 0 CA--C 1.513 -0.473 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 177.793 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.591 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -69.56 -16.89 72.25 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 120.006 -1.092 . . . . 0.0 110.758 177.61 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.481 ' HD3' ' O ' ' A' ' 11' ' ' ARG . 9.8 mpt_? -99.7 27.06 5.64 Favored 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 123.054 0.542 . . . . 0.0 110.496 179.313 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.554 ' O ' HD13 ' A' ' 17' ' ' ILE . 0.8 OUTLIER -111.42 -49.09 6.3 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.918 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 179.748 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.554 HD13 ' O ' ' A' ' 16' ' ' VAL . 44.5 mm -150.51 83.16 5.98 Favored Pre-proline 0 N--CA 1.423 -1.796 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 174.292 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.591 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.3 Cg_endo -91.5 -179.27 1.32 Allowed 'Trans proline' 0 N--CA 1.423 -2.675 0 C-N-CA 125.029 3.82 . . . . 0.0 109.597 178.515 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.425 ' HZ2' ' C ' ' A' ' 20' ' ' VAL . 0.0 OUTLIER -65.75 -29.7 70.25 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 115.307 -0.861 . . . . 0.0 110.818 179.856 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.425 ' C ' ' HZ2' ' A' ' 19' ' ' LYS . 37.2 t . . . . . 0 C--O 1.25 1.098 0 CA-C-O 118.204 -0.903 . . . . 0.0 111.253 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.522 -0.131 0 CA-C-O 121.473 0.654 . . . . 0.0 109.325 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.423 ' C ' ' N ' ' A' ' 7' ' ' GLY . 9.1 t -73.23 -21.4 18.94 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.489 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.048 179.049 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.435 ' O ' ' HB2' ' A' ' 10' ' ' ALA . 0.5 OUTLIER -41.33 -24.98 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.244 -0.889 . . . . 0.0 110.747 179.885 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.423 ' N ' ' C ' ' A' ' 5' ' ' VAL . . . -65.39 -40.76 96.57 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.714 -0.755 . . . . 0.0 111.514 179.079 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.422 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -72.65 -54.31 9.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.815 0.341 . . . . 0.0 110.165 179.223 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.427 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 3.2 mp -56.71 -32.94 66.0 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.814 179.648 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.561 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.46 -21.58 0.58 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.923 -0.581 . . . . 0.0 112.008 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.519 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.9 ptm180 -88.76 -43.02 11.58 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.273 -179.43 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.463 HG13 ' N ' ' A' ' 13' ' ' LEU . 3.8 pt -54.58 -33.75 27.75 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.188 0 C-N-CA 120.47 -0.492 . . . . 0.0 110.949 -179.652 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.561 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.07 -28.42 68.82 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 177.967 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.638 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.96 -16.71 37.62 Favored Glycine 0 N--CA 1.446 -0.671 0 CA-C-N 115.256 -0.884 . . . . 0.0 111.507 178.287 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.519 ' N ' ' O ' ' A' ' 11' ' ' ARG . 9.5 mpt_? -100.38 26.72 6.33 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.967 0.413 . . . . 0.0 110.551 179.654 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.623 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.6 p -111.83 -50.05 6.06 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.0 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 179.745 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.623 HD13 ' O ' ' A' ' 16' ' ' VAL . 44.1 mm -150.28 83.75 5.92 Favored Pre-proline 0 N--CA 1.427 -1.625 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 174.44 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.638 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.8 Cg_endo -91.28 -179.07 1.34 Allowed 'Trans proline' 0 N--CA 1.423 -2.625 0 C-N-CA 124.909 3.74 . . . . 0.0 109.559 178.747 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.1 -27.53 68.82 Favored 'General case' 0 C--N 1.3 -1.565 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.994 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 18' ' ' PRO . 19.2 t . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.235 -0.888 . . . . 0.0 111.156 179.821 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 2.7 m . . . . . 0 CA--C 1.519 -0.224 0 CA-C-O 121.572 0.701 . . . . 0.0 109.575 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.467 ' O ' ' N ' ' A' ' 8' ' ' ARG . 8.2 t -76.68 -30.9 19.19 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.438 0 CA-C-N 114.701 -1.136 . . . . 0.0 110.521 179.526 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.454 ' CD2' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -41.78 -25.52 0.06 Allowed 'General case' 0 CA--C 1.528 0.128 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.72 -179.975 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.454 ' N ' ' CD2' ' A' ' 6' ' ' PHE . . . -65.34 -39.39 95.86 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.454 179.018 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.467 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.5 OUTLIER -80.01 -46.29 16.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.975 0.417 . . . . 0.0 110.058 179.209 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.47 ' O ' HG13 ' A' ' 12' ' ' ILE . 0.5 OUTLIER -52.52 -59.58 4.27 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.255 179.945 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.576 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -43.58 -24.66 0.12 Allowed 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 116.293 -0.412 . . . . 0.0 112.089 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.499 ' O ' ' HD2' ' A' ' 15' ' ' ARG . 0.4 OUTLIER -88.57 -45.93 9.49 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.051 -179.807 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.47 HG13 ' O ' ' A' ' 9' ' ' LEU . 1.1 pp -56.25 -35.82 44.03 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.212 0 C-N-CA 120.446 -0.501 . . . . 0.0 111.113 -179.662 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.576 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -64.22 -33.56 76.08 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 178.128 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.585 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -73.22 -14.35 79.15 Favored Glycine 0 N--CA 1.444 -0.779 0 C-N-CA 120.117 -1.04 . . . . 0.0 110.827 177.537 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.499 ' HD2' ' O ' ' A' ' 11' ' ' ARG . 0.6 OUTLIER -99.88 27.04 5.74 Favored 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 123.03 0.532 . . . . 0.0 110.401 179.493 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.547 ' O ' HD13 ' A' ' 17' ' ' ILE . 1.4 p -111.46 -48.89 6.28 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.926 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 179.824 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.547 HD13 ' O ' ' A' ' 16' ' ' VAL . 43.3 mm -150.38 82.85 6.16 Favored Pre-proline 0 N--CA 1.423 -1.783 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 174.395 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.585 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.9 Cg_endo -91.69 -178.93 1.21 Allowed 'Trans proline' 0 N--CA 1.425 -2.544 0 C-N-CA 125.211 3.94 . . . . 0.0 109.942 178.771 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.47 -28.65 69.81 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.102 -0.954 . . . . 0.0 111.068 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 18' ' ' PRO . 19.3 t . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.264 -0.875 . . . . 0.0 111.254 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.8 m . . . . . 0 CA--C 1.52 -0.206 0 CA-C-O 121.521 0.677 . . . . 0.0 109.659 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.528 HG12 HD12 ' A' ' 9' ' ' LEU . 6.3 t -80.39 -27.09 11.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.677 179.578 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.459 ' CD1' ' N ' ' A' ' 7' ' ' GLY . 0.1 OUTLIER -42.9 -25.29 0.09 Allowed 'General case' 0 C--O 1.231 0.12 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.519 179.828 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.459 ' N ' ' CD1' ' A' ' 6' ' ' PHE . . . -72.48 -37.46 58.46 Favored Glycine 0 N--CA 1.45 -0.41 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.651 179.372 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.476 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -73.11 -59.76 2.56 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.649 0.262 . . . . 0.0 110.354 179.345 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.528 HD12 HG12 ' A' ' 5' ' ' VAL . 0.4 OUTLIER -48.08 -30.8 4.79 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 120.97 0.415 . . . . 0.0 110.875 179.638 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.586 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.96 -21.57 1.25 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.836 -0.62 . . . . 0.0 112.185 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.485 ' O ' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.98 -43.38 11.18 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 116.707 -0.224 . . . . 0.0 111.186 -179.417 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.477 ' N ' ' HG2' ' A' ' 11' ' ' ARG . 3.1 pt -54.27 -33.56 25.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 C-N-CA 120.475 -0.49 . . . . 0.0 111.085 -179.521 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.586 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.05 -28.55 68.93 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 177.908 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.63 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.78 -17.16 39.31 Favored Glycine 0 N--CA 1.444 -0.782 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.635 178.351 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.485 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.7 mpt_? -100.46 26.74 6.35 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 120.949 0.404 . . . . 0.0 110.809 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.615 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.1 p -111.6 -49.84 6.16 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.082 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 179.789 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.615 HD13 ' O ' ' A' ' 16' ' ' VAL . 42.4 mm -150.2 83.23 6.13 Favored Pre-proline 0 N--CA 1.424 -1.754 0 N-CA-C 106.565 -1.642 . . . . 0.0 106.565 174.595 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.63 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.5 Cg_endo -91.32 -179.0 1.32 Allowed 'Trans proline' 0 N--CA 1.423 -2.659 0 C-N-CA 124.983 3.789 . . . . 0.0 109.777 178.768 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.58 -29.8 69.94 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 115.141 -0.936 . . . . 0.0 110.949 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 18.4 t . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.247 -0.882 . . . . 0.0 111.239 179.971 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 2.5 m . . . . . 0 CA--C 1.52 -0.19 0 CA-C-O 121.576 0.703 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.908 HG12 HD12 ' A' ' 9' ' ' LEU . 6.6 t -78.72 -31.49 15.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 114.689 -1.141 . . . . 0.0 110.644 179.53 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.458 ' CD1' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -42.47 -25.61 0.09 Allowed 'General case' 0 CA--C 1.528 0.102 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.731 179.993 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . 0.458 ' N ' ' CD1' ' A' ' 6' ' ' PHE . . . -70.83 -38.58 65.72 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.768 -0.73 . . . . 0.0 111.587 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . 0.463 ' N ' ' O ' ' A' ' 5' ' ' VAL . 9.3 mmm180 -75.92 -52.52 10.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.857 0.36 . . . . 0.0 110.217 179.25 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.908 HD12 HG12 ' A' ' 5' ' ' VAL . 0.7 OUTLIER -50.1 -38.35 38.3 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.063 179.833 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.58 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -46.57 -21.53 0.19 Allowed 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.215 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . 0.477 ' HG2' ' N ' ' A' ' 12' ' ' ILE . 0.0 OUTLIER -88.44 -43.77 11.22 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.877 -179.398 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . 0.477 ' N ' ' HG2' ' A' ' 11' ' ' ARG . 2.7 pt -57.32 -32.3 40.59 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.178 0 C-N-CA 120.454 -0.498 . . . . 0.0 111.011 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.658 ' O ' HG12 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -68.41 -28.03 66.73 Favored 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 178.188 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.605 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -90.55 -15.01 57.63 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.435 -0.888 . . . . 0.0 111.07 177.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.455 ' HD3' ' CG ' ' A' ' 11' ' ' ARG . 0.7 OUTLIER -100.35 26.93 6.1 Favored 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 122.626 0.371 . . . . 0.0 110.938 179.841 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.658 HG12 ' O ' ' A' ' 13' ' ' LEU . 8.6 p -111.63 -48.92 6.21 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.015 0 N-CA-C 107.391 -1.337 . . . . 0.0 107.391 179.679 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.628 HD13 ' O ' ' A' ' 16' ' ' VAL . 39.7 mm -150.08 83.07 6.25 Favored Pre-proline 0 N--CA 1.425 -1.722 0 N-CA-C 106.522 -1.658 . . . . 0.0 106.522 174.579 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.605 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 3.8 Cg_endo -91.56 -179.06 1.27 Allowed 'Trans proline' 0 N--CA 1.424 -2.612 0 C-N-CA 125.019 3.813 . . . . 0.0 109.961 178.838 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.435 ' HZ2' ' C ' ' A' ' 20' ' ' VAL . 0.0 OUTLIER -64.2 -29.26 70.38 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.943 179.912 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.442 HG23 ' O ' ' A' ' 18' ' ' PRO . 20.7 t . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.234 -0.889 . . . . 0.0 111.143 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.647 ' HA2' HG23 ' A' ' 5' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.2 0 N-CA-C 112.51 -0.236 . . . . 0.0 112.51 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.639 ' N ' HD22 ' A' ' 2' ' ' LEU . 2.1 mm? 64.07 80.91 0.22 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.93 0.395 . . . . 0.0 110.47 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 106.34 -37.01 4.03 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.807 -0.711 . . . . 0.0 111.984 -179.448 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -82.87 -34.64 26.7 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.523 0.678 . . . . 0.0 109.519 178.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.701 HG12 HD12 ' A' ' 9' ' ' LEU . 9.2 t -79.31 -30.02 13.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 114.814 -1.084 . . . . 0.0 110.638 179.599 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.458 ' CD2' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -42.14 -25.38 0.07 Allowed 'General case' 0 CA--C 1.528 0.13 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.752 179.942 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.458 ' N ' ' CD2' ' A' ' 6' ' ' PHE . . . -66.02 -38.61 94.25 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.725 -0.75 . . . . 0.0 111.605 179.209 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.409 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -80.8 -51.99 8.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.67 0.272 . . . . 0.0 110.41 179.41 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.701 HD12 HG12 ' A' ' 5' ' ' VAL . 2.9 mp -51.96 -38.47 56.64 Favored 'General case' 0 CA--C 1.529 0.156 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.897 179.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.579 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -50.75 -21.45 1.64 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.183 179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.47 ' O ' ' N ' ' A' ' 15' ' ' ARG . 1.7 ptm180 -88.77 -41.39 12.56 Favored 'General case' 0 N--CA 1.452 -0.374 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.551 -179.183 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.477 HG13 ' N ' ' A' ' 13' ' ' LEU . 3.7 pt -54.62 -35.46 32.38 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.178 0 C-N-CA 120.369 -0.533 . . . . 0.0 110.817 -179.637 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.579 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.05 -26.98 67.75 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 177.879 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.633 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -93.96 -17.02 42.33 Favored Glycine 0 N--CA 1.444 -0.806 0 CA-C-N 115.187 -0.915 . . . . 0.0 111.532 178.273 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.47 ' N ' ' O ' ' A' ' 11' ' ' ARG . 2.5 mpt_? -100.35 26.58 6.46 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 120.956 0.408 . . . . 0.0 110.716 179.718 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.622 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.3 p -112.19 -50.42 5.9 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.02 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 179.67 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.622 HD13 ' O ' ' A' ' 16' ' ' VAL . 40.4 mm -150.15 83.82 5.97 Favored Pre-proline 0 N--CA 1.425 -1.703 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 174.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.633 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.8 Cg_endo -91.37 -179.18 1.34 Allowed 'Trans proline' 0 N--CA 1.422 -2.684 0 C-N-CA 124.904 3.736 . . . . 0.0 109.808 178.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.55 -29.46 70.72 Favored 'General case' 0 C--N 1.299 -1.604 0 CA-C-N 115.152 -0.931 . . . . 0.0 111.001 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 18' ' ' PRO . 21.5 t . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.287 -0.863 . . . . 0.0 111.092 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.564 ' HA2' HG23 ' A' ' 5' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.174 0 N-CA-C 112.463 -0.255 . . . . 0.0 112.463 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.2 mm? 62.61 85.8 0.12 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.96 0.409 . . . . 0.0 110.231 -179.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.408 ' O ' ' CD2' ' A' ' 6' ' ' PHE . . . 98.68 -33.96 5.68 Favored Glycine 0 N--CA 1.448 -0.517 0 C-N-CA 120.764 -0.731 . . . . 0.0 111.678 -179.117 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -83.14 -37.58 23.55 Favored 'General case' 0 CA--C 1.518 -0.253 0 CA-C-O 121.577 0.703 . . . . 0.0 109.398 178.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.638 HG12 HD12 ' A' ' 9' ' ' LEU . 5.5 t -76.47 -30.0 19.09 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.448 0 CA-C-N 114.658 -1.155 . . . . 0.0 110.394 179.406 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.451 ' CD2' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -41.56 -25.61 0.05 Allowed 'General case' 0 C--O 1.232 0.138 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.738 179.936 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.451 ' N ' ' CD2' ' A' ' 6' ' ' PHE . . . -68.89 -42.01 80.18 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.359 179.045 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.464 ' N ' ' O ' ' A' ' 5' ' ' VAL . 2.0 mpt_? -71.03 -54.36 11.46 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 179.088 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.638 HD12 HG12 ' A' ' 5' ' ' VAL . 2.3 mp -50.58 -33.57 22.47 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 120.966 0.412 . . . . 0.0 110.71 179.646 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.549 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.61 -21.44 1.01 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.917 -0.583 . . . . 0.0 112.076 179.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.521 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.2 ptm180 -88.73 -42.43 11.95 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.326 -179.265 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.464 HG13 ' N ' ' A' ' 13' ' ' LEU . 3.8 pt -54.19 -34.38 27.07 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.181 0 C-N-CA 120.376 -0.529 . . . . 0.0 110.927 -179.685 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.564 ' O ' HG12 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -66.39 -28.89 68.99 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 178.023 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.638 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.67 -15.95 44.33 Favored Glycine 0 N--CA 1.445 -0.76 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.59 178.271 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.521 ' N ' ' O ' ' A' ' 11' ' ' ARG . 9.1 mpt_? -100.71 26.69 6.55 Favored 'General case' 0 N--CA 1.465 0.316 0 C-N-CA 122.768 0.427 . . . . 0.0 110.642 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.627 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.2 p -111.77 -50.41 6.05 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.994 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.627 HD13 ' O ' ' A' ' 16' ' ' VAL . 42.4 mm -150.2 83.51 6.04 Favored Pre-proline 0 N--CA 1.425 -1.685 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 174.61 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.638 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.5 Cg_endo -91.35 -179.15 1.34 Allowed 'Trans proline' 0 N--CA 1.423 -2.653 0 C-N-CA 125.002 3.802 . . . . 0.0 109.95 178.782 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.01 -26.95 69.09 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 115.135 -0.939 . . . . 0.0 111.135 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.495 HG23 ' O ' ' A' ' 18' ' ' PRO . 18.6 t . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.279 -0.867 . . . . 0.0 111.174 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.634 ' HA2' HG23 ' A' ' 5' ' ' VAL . . . . . . . . 0 N--CA 1.49 2.284 0 N-CA-C 112.477 -0.249 . . . . 0.0 112.477 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 2.6 mt 67.86 79.54 0.22 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.902 0.382 . . . . 0.0 110.439 -179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 106.64 -35.61 4.93 Favored Glycine 0 N--CA 1.45 -0.407 0 C-N-CA 120.837 -0.697 . . . . 0.0 111.867 -179.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -82.8 -34.8 26.87 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.467 0.651 . . . . 0.0 109.483 178.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.726 HG12 HD12 ' A' ' 9' ' ' LEU . 9.3 t -78.04 -30.33 16.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-N 114.827 -1.079 . . . . 0.0 110.47 179.389 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.448 ' CD1' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -41.8 -25.28 0.05 Allowed 'General case' 0 CA--C 1.529 0.138 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.78 -179.978 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.448 ' N ' ' CD1' ' A' ' 6' ' ' PHE . . . -64.18 -40.25 97.85 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.721 -0.752 . . . . 0.0 111.476 179.124 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -79.72 -51.14 9.59 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.751 0.31 . . . . 0.0 110.364 179.277 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.726 HD12 HG12 ' A' ' 5' ' ' VAL . 1.4 mp -51.32 -38.28 52.16 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-O 121.09 0.471 . . . . 0.0 110.507 179.515 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.546 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.7 -21.12 0.55 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.949 179.567 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.481 ' O ' ' CD ' ' A' ' 15' ' ' ARG . 1.3 ptm180 -88.17 -42.31 12.41 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.235 -179.394 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.478 HG13 ' N ' ' A' ' 13' ' ' LEU . 5.1 pt -55.53 -34.68 35.66 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.17 0 C-N-CA 120.329 -0.549 . . . . 0.0 110.734 179.835 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.591 ' O ' HG12 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -66.38 -27.25 67.72 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 178.053 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.626 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.06 -16.74 43.15 Favored Glycine 0 N--CA 1.443 -0.834 0 CA-C-N 115.276 -0.875 . . . . 0.0 111.303 178.197 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.481 ' CD ' ' O ' ' A' ' 11' ' ' ARG . 1.7 mpt_? -100.22 26.91 6.04 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.004 0.43 . . . . 0.0 110.528 179.602 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.631 ' O ' HD13 ' A' ' 17' ' ' ILE . 9.1 p -111.45 -49.82 6.22 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.038 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 179.796 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.631 HD13 ' O ' ' A' ' 16' ' ' VAL . 40.5 mm -150.2 83.27 6.12 Favored Pre-proline 0 N--CA 1.424 -1.738 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 174.514 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.626 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.1 Cg_endo -91.39 -179.05 1.31 Allowed 'Trans proline' 0 N--CA 1.424 -2.616 0 C-N-CA 124.916 3.744 . . . . 0.0 109.801 178.696 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.39 -30.24 69.96 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.006 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 17.2 t . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.234 -0.889 . . . . 0.0 111.283 179.892 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.656 ' HA2' HG23 ' A' ' 5' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.213 0 N-CA-C 112.543 -0.223 . . . . 0.0 112.543 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.566 HD22 ' N ' ' A' ' 2' ' ' LEU . 2.3 mm? 64.37 75.93 0.36 Allowed 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.989 0.423 . . . . 0.0 110.303 -179.81 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 108.72 -34.56 5.49 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.685 -179.244 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -82.96 -38.01 23.3 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-O 121.587 0.708 . . . . 0.0 109.354 178.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.821 HG12 HD12 ' A' ' 9' ' ' LEU . 5.5 t -74.64 -30.08 24.43 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.428 0 CA-C-N 114.621 -1.172 . . . . 0.0 110.279 179.237 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -42.78 -25.45 0.09 Allowed 'General case' 0 C--O 1.232 0.141 0 CA-C-N 115.676 -0.693 . . . . 0.0 110.375 179.818 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -69.77 -40.67 75.57 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.816 -0.707 . . . . 0.0 111.388 178.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.461 ' N ' ' O ' ' A' ' 5' ' ' VAL . 1.0 OUTLIER -72.43 -54.14 10.19 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.772 0.32 . . . . 0.0 110.389 179.262 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.821 HD12 HG12 ' A' ' 5' ' ' VAL . 1.7 mp -53.8 -35.03 60.95 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 121.057 0.456 . . . . 0.0 110.718 179.623 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.623 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -47.72 -21.6 0.41 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.759 -0.655 . . . . 0.0 112.209 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.458 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.2 ptm180 -89.1 -41.54 12.23 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-N 116.603 -0.272 . . . . 0.0 111.469 -179.574 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.459 HG13 ' N ' ' A' ' 13' ' ' LEU . 4.9 pt -54.87 -34.73 31.57 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.234 0 C-N-CA 120.497 -0.481 . . . . 0.0 110.82 -179.7 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.623 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -65.3 -27.16 68.43 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.811 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.606 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -93.65 -19.38 34.9 Favored Glycine 0 N--CA 1.444 -0.768 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.506 178.166 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.458 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.7 mpt_? -100.16 26.28 6.64 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 120.863 0.363 . . . . 0.0 110.638 179.571 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.61 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.5 p -112.07 -49.63 6.0 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.064 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.61 HD13 ' O ' ' A' ' 16' ' ' VAL . 38.7 mm -149.74 83.19 6.4 Favored Pre-proline 0 N--CA 1.424 -1.748 0 N-CA-C 106.51 -1.663 . . . . 0.0 106.51 174.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.606 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.0 Cg_endo -91.58 -178.94 1.24 Allowed 'Trans proline' 0 N--CA 1.423 -2.618 0 C-N-CA 125.048 3.832 . . . . 0.0 109.746 178.692 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.92 -30.56 68.0 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.845 179.786 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.189 -0.91 . . . . 0.0 111.182 179.984 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.401 ' O ' ' CD2' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.24 0 N-CA-C 112.405 -0.278 . . . . 0.0 112.405 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.522 ' H ' HG23 ' A' ' 5' ' ' VAL . 0.1 OUTLIER 176.85 -70.11 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.916 0.389 . . . . 0.0 110.438 -179.967 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -99.38 -18.06 24.9 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.221 179.475 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -82.79 -25.8 32.39 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 121.398 0.618 . . . . 0.0 109.798 179.064 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.608 HG12 HD12 ' A' ' 9' ' ' LEU . 15.0 t -72.82 -23.81 20.83 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.425 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.282 179.323 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -41.54 -25.24 0.04 OUTLIER 'General case' 0 C--N 1.333 -0.132 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.633 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.417 ' N ' ' C ' ' A' ' 5' ' ' VAL . . . -67.22 -41.03 92.33 Favored Glycine 0 N--CA 1.45 -0.423 0 CA-C-N 115.577 -0.738 . . . . 0.0 111.68 179.217 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.432 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -73.62 -54.74 7.46 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 179.251 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.608 HD12 HG12 ' A' ' 5' ' ' VAL . 2.8 mp -52.44 -34.53 49.17 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 120.982 0.42 . . . . 0.0 110.741 179.565 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.567 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -50.28 -21.51 1.41 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.989 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.501 ' O ' ' N ' ' A' ' 15' ' ' ARG . 3.1 ptm180 -88.68 -42.78 11.77 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.392 -179.311 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.485 HG13 ' N ' ' A' ' 13' ' ' LEU . 4.8 pt -53.39 -35.89 25.71 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.194 0 C-N-CA 120.364 -0.534 . . . . 0.0 110.823 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.567 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -65.03 -28.73 69.69 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 178.133 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.632 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.6 -16.16 43.75 Favored Glycine 0 N--CA 1.445 -0.763 0 CA-C-N 115.269 -0.878 . . . . 0.0 111.672 178.412 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.501 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.8 mpt_? -100.46 26.69 6.4 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 122.721 0.408 . . . . 0.0 110.733 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.618 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.1 p -111.92 -50.22 6.01 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.015 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 179.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.618 HD13 ' O ' ' A' ' 16' ' ' VAL . 42.6 mm -150.21 83.5 6.04 Favored Pre-proline 0 N--CA 1.424 -1.731 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 174.715 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.632 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.9 Cg_endo -91.36 -179.09 1.32 Allowed 'Trans proline' 0 N--CA 1.423 -2.629 0 C-N-CA 124.98 3.787 . . . . 0.0 109.754 178.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.61 -29.54 70.78 Favored 'General case' 0 C--N 1.3 -1.551 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.983 -179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 18' ' ' PRO . 20.8 t . . . . . 0 C--O 1.249 1.039 0 CA-C-O 118.297 -0.859 . . . . 0.0 111.195 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.48 ' HA2' HG23 ' A' ' 5' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.227 0 N-CA-C 112.473 -0.251 . . . . 0.0 112.473 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.55 ' N ' HD22 ' A' ' 2' ' ' LEU . 2.0 mm? 65.54 87.43 0.12 Allowed 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.994 0.426 . . . . 0.0 110.232 -179.819 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 98.43 -35.6 4.5 Favored Glycine 0 N--CA 1.449 -0.478 0 C-N-CA 120.802 -0.713 . . . . 0.0 111.69 -179.149 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -83.18 -36.61 24.56 Favored 'General case' 0 CA--C 1.519 -0.242 0 CA-C-O 121.53 0.681 . . . . 0.0 109.507 178.797 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.739 HG12 HD12 ' A' ' 9' ' ' LEU . 6.2 t -75.53 -29.2 20.6 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.402 179.384 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -41.53 -25.67 0.05 Allowed 'General case' 0 C--N 1.333 -0.121 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.661 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -65.18 -40.55 96.86 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.383 179.179 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.464 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -75.85 -52.55 10.11 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.789 0.328 . . . . 0.0 110.14 179.136 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.739 HD12 HG12 ' A' ' 5' ' ' VAL . 5.1 mp -52.43 -38.53 59.39 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 121.006 0.431 . . . . 0.0 110.618 179.609 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.561 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.3 -21.18 0.78 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.981 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.519 ' O ' ' N ' ' A' ' 15' ' ' ARG . 2.2 ptm180 -88.13 -42.08 12.59 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.338 -179.311 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.459 HG13 ' N ' ' A' ' 13' ' ' LEU . 4.5 pt -55.36 -34.79 34.83 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.218 0 C-N-CA 120.35 -0.54 . . . . 0.0 110.838 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.561 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.45 -27.73 68.04 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 178.089 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.632 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.7 -17.22 39.35 Favored Glycine 0 N--CA 1.445 -0.726 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.303 178.014 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.519 ' N ' ' O ' ' A' ' 11' ' ' ARG . 9.2 mpt_? -100.87 26.41 6.94 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 122.693 0.397 . . . . 0.0 110.866 179.816 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.608 ' O ' HD13 ' A' ' 17' ' ' ILE . 8.2 p -112.34 -50.32 5.85 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.059 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.608 HD13 ' O ' ' A' ' 16' ' ' VAL . 44.4 mm -150.29 83.78 5.91 Favored Pre-proline 0 N--CA 1.424 -1.743 0 N-CA-C 106.517 -1.66 . . . . 0.0 106.517 174.816 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.632 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.0 Cg_endo -91.24 -179.28 1.39 Allowed 'Trans proline' 0 N--CA 1.422 -2.702 0 C-N-CA 124.836 3.691 . . . . 0.0 109.569 178.662 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.23 -28.73 69.56 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 115.116 -0.947 . . . . 0.0 111.051 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.416 HG23 ' O ' ' A' ' 18' ' ' PRO . 20.1 t . . . . . 0 C--O 1.249 1.071 0 CA-C-O 118.245 -0.883 . . . . 0.0 111.232 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.561 ' HA2' HG23 ' A' ' 5' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 112.461 -0.255 . . . . 0.0 112.461 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.615 ' N ' HD22 ' A' ' 2' ' ' LEU . 2.5 mm? 62.2 86.16 0.11 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.922 0.391 . . . . 0.0 110.3 -179.829 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 98.91 -34.07 5.64 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.972 -179.45 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -83.0 -39.33 21.45 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-O 121.65 0.738 . . . . 0.0 109.357 178.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.721 HG12 HD12 ' A' ' 9' ' ' LEU . 4.8 t -74.34 -32.19 30.51 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 114.652 -1.158 . . . . 0.0 110.315 179.352 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -42.14 -26.0 0.09 Allowed 'General case' 0 CA--C 1.528 0.112 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.583 179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -71.72 -41.65 55.98 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.742 -0.742 . . . . 0.0 111.595 179.339 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.445 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -71.69 -52.07 19.71 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.676 0.274 . . . . 0.0 110.462 179.359 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.721 HD12 HG12 ' A' ' 5' ' ' VAL . 3.2 mp -55.1 -33.52 62.9 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.165 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.539 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.18 -21.53 0.5 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.137 -0.483 . . . . 0.0 112.097 179.839 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.505 ' O ' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.5 -44.67 10.53 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.022 -179.579 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.479 ' HA ' ' HB2' ' A' ' 15' ' ' ARG . 2.5 pt -54.76 -32.17 25.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 C-N-CA 120.552 -0.459 . . . . 0.0 111.163 -179.751 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.539 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -67.74 -29.25 68.43 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 178.201 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.577 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.96 -13.81 48.32 Favored Glycine 0 N--CA 1.445 -0.746 0 C-N-CA 120.478 -0.868 . . . . 0.0 111.458 178.137 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.505 ' N ' ' O ' ' A' ' 11' ' ' ARG . 0.4 OUTLIER -100.39 26.99 6.05 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 121.069 0.461 . . . . 0.0 110.775 -179.942 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.615 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.4 p -111.61 -49.36 6.2 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.032 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 179.491 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.615 HD13 ' O ' ' A' ' 16' ' ' VAL . 39.9 mm -150.03 83.63 6.09 Favored Pre-proline 0 N--CA 1.424 -1.741 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 174.375 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.577 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.4 Cg_endo -91.19 -179.17 1.39 Allowed 'Trans proline' 0 N--CA 1.424 -2.575 0 C-N-CA 125.001 3.801 . . . . 0.0 109.695 178.756 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.21 -29.58 69.28 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 115.238 -0.892 . . . . 0.0 110.811 179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.5 t . . . . . 0 C--O 1.249 1.072 0 CA-C-O 118.276 -0.869 . . . . 0.0 111.226 179.8 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.61 ' HA2' HG23 ' A' ' 5' ' ' VAL . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.543 ' N ' HD22 ' A' ' 2' ' ' LEU . 2.6 mm? 64.06 84.69 0.15 Allowed 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.018 0.437 . . . . 0.0 110.412 -179.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.405 ' O ' ' CD2' ' A' ' 6' ' ' PHE . . . 100.5 -36.29 4.25 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.851 -0.69 . . . . 0.0 111.789 -179.363 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -82.73 -33.87 27.36 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.45 0.643 . . . . 0.0 109.47 178.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.61 HG23 ' HA2' ' A' ' 1' ' ' GLY . 10.5 t -81.0 -27.91 11.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.604 179.459 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.474 ' CD2' ' N ' ' A' ' 7' ' ' GLY . 0.1 OUTLIER -41.49 -25.44 0.05 OUTLIER 'General case' 0 C--O 1.231 0.128 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.738 -179.942 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.474 ' N ' ' CD2' ' A' ' 6' ' ' PHE . . . -69.05 -40.82 83.3 Favored Glycine 0 N--CA 1.45 -0.387 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.586 179.318 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.449 ' N ' ' O ' ' A' ' 5' ' ' VAL . 1.6 mpt_? -74.68 -47.18 33.13 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.878 0.371 . . . . 0.0 110.146 179.296 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.507 ' O ' HG13 ' A' ' 12' ' ' ILE . 1.0 OUTLIER -52.24 -60.25 3.44 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.993 179.709 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.604 ' HA ' HD11 ' A' ' 13' ' ' LEU . . . -44.64 -24.27 0.18 Allowed 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.963 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.475 ' NH2' HG22 ' A' ' 12' ' ' ILE . 0.0 OUTLIER -88.56 -48.24 7.72 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.808 -179.897 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.507 HG13 ' O ' ' A' ' 9' ' ' LEU . 1.1 pp -58.81 -36.94 63.52 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.204 0 C-N-CA 120.416 -0.514 . . . . 0.0 111.447 -179.617 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.604 HD11 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -62.36 -34.63 77.06 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 178.482 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.584 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -71.7 -12.9 74.62 Favored Glycine 0 N--CA 1.446 -0.693 0 C-N-CA 120.079 -1.057 . . . . 0.0 111.034 177.75 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.45 ' N ' ' HD2' ' A' ' 15' ' ' ARG . 0.9 OUTLIER -99.67 27.35 5.43 Favored 'General case' 0 N--CA 1.465 0.319 0 C-N-CA 123.016 0.527 . . . . 0.0 110.51 179.646 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.592 ' O ' HD13 ' A' ' 17' ' ' ILE . 1.9 p -111.26 -49.01 6.37 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.934 0 N-CA-C 107.164 -1.421 . . . . 0.0 107.164 179.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.592 HD13 ' O ' ' A' ' 16' ' ' VAL . 44.2 mm -150.41 83.2 6.03 Favored Pre-proline 0 N--CA 1.423 -1.789 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 174.316 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.584 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.0 Cg_endo -91.53 -179.1 1.28 Allowed 'Trans proline' 0 N--CA 1.423 -2.675 0 C-N-CA 125.071 3.847 . . . . 0.0 109.633 178.622 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.16 -29.0 68.58 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.901 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 C--O 1.249 1.078 0 CA-C-O 118.277 -0.868 . . . . 0.0 111.211 179.799 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.539 ' O ' HD23 ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.489 2.197 0 N-CA-C 112.476 -0.25 . . . . 0.0 112.476 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.539 HD23 ' O ' ' A' ' 1' ' ' GLY . 0.2 OUTLIER 167.33 76.63 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.251 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.91 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 96.27 -29.09 10.69 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.652 -0.785 . . . . 0.0 111.619 -178.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -82.58 -30.42 29.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 121.428 0.632 . . . . 0.0 109.408 178.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.676 HG12 HD12 ' A' ' 9' ' ' LEU . 11.6 t -72.5 -22.87 20.68 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.493 0 CA-C-N 114.852 -1.067 . . . . 0.0 109.94 178.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -41.51 -25.28 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.573 179.652 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 5' ' ' VAL . . . -71.64 -41.37 57.2 Favored Glycine 0 N--CA 1.45 -0.373 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.674 179.268 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.446 ' N ' ' O ' ' A' ' 5' ' ' VAL . 2.9 mmm180 -68.21 -54.1 20.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.88 0.371 . . . . 0.0 110.055 179.249 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.676 HD12 HG12 ' A' ' 5' ' ' VAL . 5.3 mp -56.18 -31.63 63.59 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.854 179.77 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.554 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -47.3 -21.53 0.3 Allowed 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.036 -0.529 . . . . 0.0 112.082 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.499 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.7 ptm180 -88.7 -42.78 11.76 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 116.536 -0.302 . . . . 0.0 111.252 -179.46 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.469 HG13 ' N ' ' A' ' 13' ' ' LEU . 4.4 pt -54.64 -33.92 28.44 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.209 0 C-N-CA 120.465 -0.494 . . . . 0.0 110.858 -179.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.554 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.62 -28.68 68.69 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 178.056 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.604 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.52 -14.13 48.53 Favored Glycine 0 N--CA 1.445 -0.742 0 CA-C-N 115.253 -0.885 . . . . 0.0 111.678 178.315 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.499 ' N ' ' O ' ' A' ' 11' ' ' ARG . 9.2 mpt_? -100.2 26.87 6.07 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 120.999 0.428 . . . . 0.0 110.688 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.62 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.4 p -111.88 -49.48 6.08 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.047 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 179.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.62 HD13 ' O ' ' A' ' 16' ' ' VAL . 40.7 mm -149.86 82.95 6.42 Favored Pre-proline 0 N--CA 1.422 -1.827 0 N-CA-C 106.574 -1.639 . . . . 0.0 106.574 174.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.604 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.7 Cg_endo -91.48 -179.01 1.28 Allowed 'Trans proline' 0 N--CA 1.423 -2.675 0 C-N-CA 125.091 3.861 . . . . 0.0 109.667 178.702 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.451 ' HZ2' ' C ' ' A' ' 20' ' ' VAL . 0.0 OUTLIER -66.76 -27.23 67.43 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.948 179.908 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.451 ' C ' ' HZ2' ' A' ' 19' ' ' LYS . 16.2 t . . . . . 0 C--O 1.25 1.1 0 CA-C-O 118.274 -0.869 . . . . 0.0 111.103 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.542 ' O ' HD23 ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.241 0 N-CA-C 112.471 -0.252 . . . . 0.0 112.471 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.542 HD23 ' O ' ' A' ' 1' ' ' GLY . 0.2 OUTLIER 166.05 74.74 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -179.882 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 97.74 -28.86 12.45 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.592 -0.813 . . . . 0.0 111.444 -178.78 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -82.79 -29.09 29.84 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.465 0.65 . . . . 0.0 109.388 178.656 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.442 ' O ' ' N ' ' A' ' 8' ' ' ARG . 9.3 t -73.3 -21.27 18.8 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.561 0 CA-C-N 114.877 -1.056 . . . . 0.0 109.999 178.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -41.15 -25.21 0.03 OUTLIER 'General case' 0 CA--C 1.529 0.145 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.694 179.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.422 ' N ' ' O ' ' A' ' 5' ' ' VAL . . . -62.75 -40.22 98.93 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.686 -0.769 . . . . 0.0 111.407 179.131 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.442 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.4 OUTLIER -74.61 -54.89 6.59 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 179.114 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.436 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 3.3 mp -52.02 -36.44 50.11 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.943 0.401 . . . . 0.0 110.745 179.597 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.556 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.86 -21.49 1.16 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.903 -0.59 . . . . 0.0 112.165 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.535 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.2 ptm180 -88.73 -42.42 11.96 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-N 116.457 -0.338 . . . . 0.0 111.453 -179.331 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.481 HG13 ' N ' ' A' ' 13' ' ' LEU . 2.8 pt -54.78 -33.79 28.85 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.221 0 C-N-CA 120.421 -0.512 . . . . 0.0 110.791 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.556 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.25 -29.27 69.48 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 177.971 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.636 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.25 -15.98 42.37 Favored Glycine 0 N--CA 1.444 -0.782 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.669 178.313 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.535 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.3 mpt_? -100.23 26.61 6.36 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 121.008 0.432 . . . . 0.0 110.677 179.694 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.623 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.4 p -112.02 -50.27 5.97 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.028 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 179.691 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.623 HD13 ' O ' ' A' ' 16' ' ' VAL . 42.1 mm -150.27 83.75 5.93 Favored Pre-proline 0 N--CA 1.425 -1.7 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 174.855 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.636 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.3 Cg_endo -91.26 -179.28 1.39 Allowed 'Trans proline' 0 N--CA 1.423 -2.642 0 C-N-CA 124.893 3.728 . . . . 0.0 109.658 178.603 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.24 -28.69 69.9 Favored 'General case' 0 C--N 1.301 -1.541 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.964 -179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.45 HG23 ' O ' ' A' ' 18' ' ' PRO . 18.5 t . . . . . 0 C--O 1.25 1.091 0 CA-C-O 118.235 -0.888 . . . . 0.0 111.185 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.168 0 N-CA-C 112.611 -0.195 . . . . 0.0 112.611 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 17.7 mt -161.73 -76.47 0.05 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.878 0.37 . . . . 0.0 110.259 179.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -87.56 -16.14 60.7 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.838 -0.696 . . . . 0.0 112.35 179.496 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -82.76 -33.23 27.46 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-O 121.431 0.634 . . . . 0.0 109.708 179.187 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.59 HG12 HD12 ' A' ' 9' ' ' LEU . 11.3 t -72.79 -28.07 26.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 114.933 -1.031 . . . . 0.0 110.209 179.269 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -41.78 -25.37 0.06 Allowed 'General case' 0 C--O 1.232 0.14 0 CA-C-N 115.406 -0.816 . . . . 0.0 110.695 179.683 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -67.98 -41.09 88.48 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.6 179.167 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.441 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -75.21 -59.47 2.73 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 110.393 -0.225 . . . . 0.0 110.393 179.25 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.59 HD12 HG12 ' A' ' 5' ' ' VAL . 1.0 OUTLIER -43.51 -30.88 0.62 Allowed 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 121.08 0.467 . . . . 0.0 111.04 179.506 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.562 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.89 -21.29 1.12 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.672 -0.695 . . . . 0.0 112.112 179.64 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.484 ' O ' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.4 -43.64 11.34 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 116.684 -0.234 . . . . 0.0 111.22 -179.146 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.472 ' N ' ' HG2' ' A' ' 11' ' ' ARG . 5.4 pt -54.79 -33.43 28.05 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 C-N-CA 120.429 -0.508 . . . . 0.0 111.101 -179.454 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.562 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -67.39 -28.86 68.28 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 178.08 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.6 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.98 -13.6 52.35 Favored Glycine 0 N--CA 1.444 -0.77 0 CA-C-N 115.2 -0.909 . . . . 0.0 111.783 178.473 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.484 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.4 mpt_? -100.18 26.76 6.18 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 120.963 0.411 . . . . 0.0 110.788 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.615 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.2 p -111.84 -49.29 6.12 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.037 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 179.624 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.615 HD13 ' O ' ' A' ' 16' ' ' VAL . 42.1 mm -150.04 83.33 6.18 Favored Pre-proline 0 N--CA 1.424 -1.762 0 N-CA-C 106.402 -1.703 . . . . 0.0 106.402 174.539 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.6 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.9 Cg_endo -91.55 -179.38 1.32 Allowed 'Trans proline' 0 N--CA 1.422 -2.715 0 C-N-CA 125.026 3.817 . . . . 0.0 109.797 178.744 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.46 -28.46 69.23 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 115.153 -0.93 . . . . 0.0 111.074 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.401 HG23 ' O ' ' A' ' 18' ' ' PRO . 19.6 t . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.218 -0.896 . . . . 0.0 111.093 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.605 ' HA2' HG23 ' A' ' 5' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.205 0 N-CA-C 112.413 -0.275 . . . . 0.0 112.413 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.472 HD22 ' N ' ' A' ' 2' ' ' LEU . 2.8 mm? 61.99 85.83 0.12 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.904 0.383 . . . . 0.0 110.297 -179.716 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 99.16 -34.77 5.14 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.753 -0.737 . . . . 0.0 111.945 -179.269 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.5 m -82.78 -37.85 23.98 Favored 'General case' 0 CA--C 1.518 -0.275 0 CA-C-O 121.525 0.678 . . . . 0.0 109.405 178.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.78 HG12 HD12 ' A' ' 9' ' ' LEU . 10.1 t -74.64 -33.49 32.04 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.462 0 CA-C-N 114.816 -1.084 . . . . 0.0 110.194 179.177 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -43.11 -25.65 0.12 Allowed 'General case' 0 C--O 1.231 0.123 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.404 179.666 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -67.28 -37.87 91.18 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.512 179.248 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.465 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -83.67 -43.54 15.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.79 0.329 . . . . 0.0 110.206 179.181 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.78 HD12 HG12 ' A' ' 5' ' ' VAL . 0.8 OUTLIER -55.05 -58.44 7.63 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.818 179.655 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.627 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.73 -21.91 0.7 Allowed 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.405 -0.361 . . . . 0.0 111.701 179.709 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.699 HH21 HG22 ' A' ' 12' ' ' ILE . 0.0 OUTLIER -88.88 -44.88 10.14 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.116 -179.488 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.699 HG22 HH21 ' A' ' 11' ' ' ARG . 1.8 pp -55.2 -42.8 67.67 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.253 0 C-N-CA 120.405 -0.518 . . . . 0.0 110.927 -179.613 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.627 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -57.66 -34.71 69.66 Favored 'General case' 0 CA--C 1.515 -0.378 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 177.912 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.581 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -62.75 -20.97 62.52 Favored Glycine 0 N--CA 1.446 -0.697 0 C-N-CA 120.118 -1.039 . . . . 0.0 110.676 177.619 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.406 ' NE ' ' HG2' ' A' ' 11' ' ' ARG . 2.2 mpt_? -99.85 27.13 5.67 Favored 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 123.118 0.567 . . . . 0.0 110.082 178.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.503 ' CG1' ' N ' ' A' ' 17' ' ' ILE . 0.3 OUTLIER -111.21 -49.47 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.918 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 -179.947 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.503 ' N ' ' CG1' ' A' ' 16' ' ' VAL . 37.0 mm -150.24 82.67 6.3 Favored Pre-proline 0 N--CA 1.425 -1.684 0 N-CA-C 106.54 -1.652 . . . . 0.0 106.54 174.191 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.581 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.3 Cg_endo -91.82 -178.86 1.17 Allowed 'Trans proline' 0 N--CA 1.423 -2.631 0 C-N-CA 125.251 3.967 . . . . 0.0 109.899 178.611 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.08 -28.5 66.57 Favored 'General case' 0 C--N 1.301 -1.519 0 CA-C-N 115.148 -0.933 . . . . 0.0 111.012 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 18.8 t . . . . . 0 C--O 1.249 1.053 0 CA-C-O 118.274 -0.869 . . . . 0.0 111.294 179.899 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.581 ' O ' HD23 ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.489 2.172 0 N-CA-C 112.553 -0.219 . . . . 0.0 112.553 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.581 HD23 ' O ' ' A' ' 1' ' ' GLY . 0.2 OUTLIER 164.98 80.22 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 -179.924 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.402 ' O ' ' CD2' ' A' ' 6' ' ' PHE . . . 95.85 -28.4 12.72 Favored Glycine 0 N--CA 1.45 -0.39 0 C-N-CA 120.64 -0.79 . . . . 0.0 111.785 -179.028 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -82.77 -30.79 28.68 Favored 'General case' 0 CA--C 1.519 -0.217 0 CA-C-O 121.568 0.699 . . . . 0.0 109.333 178.782 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.442 ' O ' ' N ' ' A' ' 8' ' ' ARG . 6.6 t -76.08 -21.3 15.5 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 CA-C-N 114.758 -1.11 . . . . 0.0 110.085 178.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.402 ' CD2' ' O ' ' A' ' 3' ' ' GLY . 0.5 OUTLIER -41.17 -25.3 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.121 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.705 179.829 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 5' ' ' VAL . . . -63.37 -40.67 99.17 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.791 -0.718 . . . . 0.0 111.425 179.255 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.442 ' N ' ' O ' ' A' ' 5' ' ' VAL . 2.0 mpt_? -73.9 -54.9 6.93 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.803 0.335 . . . . 0.0 110.156 179.189 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.8 mp -52.25 -42.1 63.35 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.907 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.548 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.93 -21.6 0.69 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.016 -0.538 . . . . 0.0 112.288 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.534 ' O ' ' N ' ' A' ' 15' ' ' ARG . 1.4 ptm180 -88.93 -41.09 12.62 Favored 'General case' 0 N--CA 1.45 -0.435 0 CA-C-N 116.666 -0.243 . . . . 0.0 111.339 -179.514 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.491 HG13 ' N ' ' A' ' 13' ' ' LEU . 2.4 pt -54.91 -34.24 30.57 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.211 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.814 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.548 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -65.97 -28.49 68.94 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 178.032 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.626 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.43 -17.64 35.84 Favored Glycine 0 N--CA 1.445 -0.719 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.484 178.161 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.534 ' N ' ' O ' ' A' ' 11' ' ' ARG . 2.4 mpt_? -100.81 26.72 6.57 Favored 'General case' 0 N--CA 1.466 0.336 0 C-N-CA 122.794 0.438 . . . . 0.0 110.623 179.673 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.602 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.4 p -111.89 -49.95 6.04 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.052 0 N-CA-C 107.741 -1.207 . . . . 0.0 107.741 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.602 HD13 ' O ' ' A' ' 16' ' ' VAL . 41.6 mm -149.98 82.99 6.33 Favored Pre-proline 0 N--CA 1.426 -1.663 0 N-CA-C 106.486 -1.672 . . . . 0.0 106.486 174.634 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.626 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.1 Cg_endo -91.71 -179.0 1.22 Allowed 'Trans proline' 0 N--CA 1.424 -2.615 0 C-N-CA 125.212 3.941 . . . . 0.0 110.03 178.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.16 -28.39 69.72 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 115.021 -0.99 . . . . 0.0 111.148 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.444 HG23 ' O ' ' A' ' 18' ' ' PRO . 16.6 t . . . . . 0 C--O 1.249 1.032 0 CA-C-O 118.274 -0.87 . . . . 0.0 111.154 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.542 ' O ' HD23 ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.489 2.226 0 N-CA-C 112.398 -0.281 . . . . 0.0 112.398 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.542 HD23 ' O ' ' A' ' 1' ' ' GLY . 0.2 OUTLIER 166.5 76.22 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 -179.947 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 98.03 -29.51 11.09 Favored Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.381 -178.802 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -82.66 -29.02 30.29 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.571 0.701 . . . . 0.0 109.262 178.472 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.426 ' O ' ' N ' ' A' ' 7' ' ' GLY . 8.3 t -73.9 -21.25 18.02 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.499 0 CA-C-N 114.739 -1.119 . . . . 0.0 109.968 178.827 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.439 ' O ' ' HB2' ' A' ' 10' ' ' ALA . 0.5 OUTLIER -41.01 -25.11 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.72 179.954 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 5' ' ' VAL . . . -60.74 -38.43 95.17 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.845 -0.693 . . . . 0.0 111.58 179.193 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.94 -54.34 6.13 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.03 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.44 ' HA ' HG12 ' A' ' 12' ' ' ILE . 4.8 mp -55.34 -22.77 20.63 Favored 'General case' 0 CA--C 1.528 0.132 0 CA-C-O 121.017 0.437 . . . . 0.0 110.424 179.028 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.717 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -63.07 -21.14 65.97 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.373 179.763 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.443 ' O ' ' N ' ' A' ' 14' ' ' GLY . 0.0 OUTLIER -89.41 -40.96 12.37 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.597 -179.472 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.49 HG13 ' N ' ' A' ' 13' ' ' LEU . 1.6 pt -53.79 -36.61 30.28 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.171 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.979 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.717 HD21 ' HA ' ' A' ' 10' ' ' ALA . 1.5 pp -65.95 -24.34 66.79 Favored 'General case' 0 C--N 1.328 -0.338 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 177.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.643 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -92.23 -19.79 37.83 Favored Glycine 0 N--CA 1.444 -0.816 0 CA-C-N 115.102 -0.953 . . . . 0.0 111.603 178.31 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.439 ' CD ' ' O ' ' A' ' 11' ' ' ARG . 2.3 mpt_? -100.74 25.87 7.43 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 120.836 0.35 . . . . 0.0 110.947 179.614 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.622 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.6 p -112.42 -50.35 5.82 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.11 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.758 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.622 HD13 ' O ' ' A' ' 16' ' ' VAL . 31.9 mm -149.79 83.27 6.35 Favored Pre-proline 0 N--CA 1.423 -1.825 0 N-CA-C 106.578 -1.638 . . . . 0.0 106.578 175.446 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.643 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 3.6 Cg_endo -91.32 -178.94 1.31 Allowed 'Trans proline' 0 N--CA 1.424 -2.58 0 C-N-CA 125.049 3.833 . . . . 0.0 109.793 178.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -62.34 -23.07 66.57 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 115.227 -0.897 . . . . 0.0 111.164 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 2.6 t . . . . . 0 C--O 1.25 1.098 0 CA-C-O 118.152 -0.928 . . . . 0.0 110.848 -179.913 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.434 ' O ' ' HG ' ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.489 2.208 0 N-CA-C 112.444 -0.262 . . . . 0.0 112.444 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.434 ' HG ' ' O ' ' A' ' 1' ' ' GLY . 16.9 mt -163.41 -75.14 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.938 0.399 . . . . 0.0 110.152 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -89.29 -17.84 54.51 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.881 -0.676 . . . . 0.0 112.188 179.203 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -82.48 -28.8 30.96 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.444 0.64 . . . . 0.0 109.578 179.005 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.674 HG12 HD12 ' A' ' 9' ' ' LEU . 14.1 t -74.65 -25.3 18.96 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.482 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.028 178.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -41.36 -25.47 0.04 OUTLIER 'General case' 0 C--N 1.333 -0.109 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.674 179.708 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.42 ' N ' ' C ' ' A' ' 5' ' ' VAL . . . -65.29 -40.54 96.64 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.556 179.34 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.432 ' N ' ' O ' ' A' ' 5' ' ' VAL . 1.8 mpt_? -78.23 -46.4 20.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.837 0.351 . . . . 0.0 110.459 179.368 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.674 HD12 HG12 ' A' ' 5' ' ' VAL . 1.6 mp -56.22 -60.58 3.3 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.903 179.803 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.646 ' HA ' HD11 ' A' ' 13' ' ' LEU . . . -44.44 -22.47 0.07 Allowed 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.195 -0.457 . . . . 0.0 112.056 179.74 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.723 ' NH2' HG22 ' A' ' 12' ' ' ILE . 0.0 OUTLIER -88.57 -46.14 9.32 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.645 -179.861 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.723 HG22 ' NH2' ' A' ' 11' ' ' ARG . 1.1 pp -57.48 -36.53 53.8 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.248 0 C-N-CA 120.52 -0.472 . . . . 0.0 111.149 -179.844 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.646 HD11 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -62.11 -35.35 78.45 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 178.198 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.588 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -70.6 -16.65 74.15 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.102 -1.047 . . . . 0.0 110.87 177.64 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.443 ' HD3' ' HG2' ' A' ' 11' ' ' ARG . 1.4 mpt_? -100.02 27.38 5.59 Favored 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 123.088 0.555 . . . . 0.0 110.491 179.566 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.567 ' O ' HD13 ' A' ' 17' ' ' ILE . 1.0 OUTLIER -111.21 -48.82 6.38 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.972 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 179.822 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.567 HD13 ' O ' ' A' ' 16' ' ' VAL . 44.1 mm -150.52 82.8 6.1 Favored Pre-proline 0 N--CA 1.424 -1.748 0 N-CA-C 106.568 -1.641 . . . . 0.0 106.568 174.257 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.588 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.7 Cg_endo -91.7 -178.9 1.2 Allowed 'Trans proline' 0 N--CA 1.423 -2.632 0 C-N-CA 125.135 3.89 . . . . 0.0 109.856 178.619 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -67.86 -28.9 67.94 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.197 -0.91 . . . . 0.0 110.912 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 16.6 t . . . . . 0 C--O 1.249 1.042 0 CA-C-O 118.217 -0.897 . . . . 0.0 111.266 179.819 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.618 ' HA3' HG23 ' A' ' 5' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.184 0 N-CA-C 112.573 -0.211 . . . . 0.0 112.573 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 72.16 84.84 0.12 Allowed 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.965 0.412 . . . . 0.0 110.19 -179.652 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.418 ' O ' ' CD1' ' A' ' 6' ' ' PHE . . . 100.67 -34.58 5.47 Favored Glycine 0 N--CA 1.449 -0.451 0 C-N-CA 120.797 -0.716 . . . . 0.0 111.743 -179.224 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 13.3 m -82.82 -34.69 26.84 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.579 0.704 . . . . 0.0 109.425 178.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.618 HG23 ' HA3' ' A' ' 1' ' ' GLY . 8.9 t -80.09 -24.68 11.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.472 179.387 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.446 ' CD1' ' N ' ' A' ' 7' ' ' GLY . 0.1 OUTLIER -41.36 -25.47 0.04 OUTLIER 'General case' 0 CA--C 1.527 0.073 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.657 179.84 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.446 ' N ' ' CD1' ' A' ' 6' ' ' PHE . . . -63.84 -41.37 98.83 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.666 -0.778 . . . . 0.0 111.426 179.169 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.438 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -76.66 -45.27 30.5 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.889 0.376 . . . . 0.0 110.165 179.201 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.474 ' O ' HG13 ' A' ' 12' ' ' ILE . 0.7 OUTLIER -55.35 -54.96 37.06 Favored 'General case' 0 CA--C 1.529 0.163 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.819 179.668 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.627 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -47.64 -21.88 0.43 Allowed 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 112.083 179.81 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.481 ' O ' ' HD3' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.61 -45.22 10.04 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.861 -179.655 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.474 HG13 ' O ' ' A' ' 9' ' ' LEU . 1.1 pt -53.97 -35.63 28.88 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.211 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.882 -179.711 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.627 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -63.42 -35.65 81.13 Favored 'General case' 0 CA--C 1.513 -0.473 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 177.793 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.591 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -69.56 -16.89 72.25 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 120.006 -1.092 . . . . 0.0 110.758 177.61 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.481 ' HD3' ' O ' ' A' ' 11' ' ' ARG . 9.8 mpt_? -99.7 27.06 5.64 Favored 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 123.054 0.542 . . . . 0.0 110.496 179.313 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.554 ' O ' HD13 ' A' ' 17' ' ' ILE . 0.8 OUTLIER -111.42 -49.09 6.3 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.918 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 179.748 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.554 HD13 ' O ' ' A' ' 16' ' ' VAL . 44.5 mm -150.51 83.16 5.98 Favored Pre-proline 0 N--CA 1.423 -1.796 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 174.292 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.591 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 5.3 Cg_endo -91.5 -179.27 1.32 Allowed 'Trans proline' 0 N--CA 1.423 -2.675 0 C-N-CA 125.029 3.82 . . . . 0.0 109.597 178.515 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.425 ' HZ2' ' C ' ' A' ' 20' ' ' VAL . 0.0 OUTLIER -65.75 -29.7 70.25 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 115.307 -0.861 . . . . 0.0 110.818 179.856 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.425 ' C ' ' HZ2' ' A' ' 19' ' ' LYS . 37.2 t . . . . . 0 C--O 1.25 1.098 0 CA-C-O 118.204 -0.903 . . . . 0.0 111.253 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.577 ' O ' HD23 ' A' ' 2' ' ' LEU . . . . . . . . 0 N--CA 1.489 2.207 0 N-CA-C 112.507 -0.237 . . . . 0.0 112.507 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.577 HD23 ' O ' ' A' ' 1' ' ' GLY . 0.2 OUTLIER 164.2 72.39 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 109.56 -0.533 . . . . 0.0 109.56 -179.881 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 97.62 -28.24 15.17 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.176 -178.535 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -82.91 -27.03 30.93 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.473 0.654 . . . . 0.0 109.325 178.448 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.462 ' CG2' ' CA ' ' A' ' 1' ' ' GLY . 9.1 t -73.23 -21.4 18.94 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.489 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.048 179.049 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.435 ' O ' ' HB2' ' A' ' 10' ' ' ALA . 0.5 OUTLIER -41.33 -24.98 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.244 -0.889 . . . . 0.0 110.747 179.885 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.423 ' N ' ' C ' ' A' ' 5' ' ' VAL . . . -65.39 -40.76 96.57 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.714 -0.755 . . . . 0.0 111.514 179.079 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.422 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -72.65 -54.31 9.39 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.815 0.341 . . . . 0.0 110.165 179.223 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.427 ' O ' ' CD2' ' A' ' 13' ' ' LEU . 3.2 mp -56.71 -32.94 66.0 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.814 179.648 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.561 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -48.46 -21.58 0.58 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.923 -0.581 . . . . 0.0 112.008 179.803 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.519 ' O ' ' N ' ' A' ' 15' ' ' ARG . 4.9 ptm180 -88.76 -43.02 11.58 Favored 'General case' 0 N--CA 1.45 -0.453 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.273 -179.43 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.463 HG13 ' N ' ' A' ' 13' ' ' LEU . 3.8 pt -54.58 -33.75 27.75 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.188 0 C-N-CA 120.47 -0.492 . . . . 0.0 110.949 -179.652 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.561 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.07 -28.42 68.82 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 177.967 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.638 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -95.96 -16.71 37.62 Favored Glycine 0 N--CA 1.446 -0.671 0 CA-C-N 115.256 -0.884 . . . . 0.0 111.507 178.287 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.519 ' N ' ' O ' ' A' ' 11' ' ' ARG . 9.5 mpt_? -100.38 26.72 6.33 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.967 0.413 . . . . 0.0 110.551 179.654 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.623 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.6 p -111.83 -50.05 6.06 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.0 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 179.745 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.623 HD13 ' O ' ' A' ' 16' ' ' VAL . 44.1 mm -150.28 83.75 5.92 Favored Pre-proline 0 N--CA 1.427 -1.625 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 174.44 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.638 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.8 Cg_endo -91.28 -179.07 1.34 Allowed 'Trans proline' 0 N--CA 1.423 -2.625 0 C-N-CA 124.909 3.74 . . . . 0.0 109.559 178.747 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.1 -27.53 68.82 Favored 'General case' 0 C--N 1.3 -1.565 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.994 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 18' ' ' PRO . 19.2 t . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.235 -0.888 . . . . 0.0 111.156 179.821 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.611 ' HA2' HG23 ' A' ' 5' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.189 0 N-CA-C 112.503 -0.239 . . . . 0.0 112.503 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.617 ' N ' HD22 ' A' ' 2' ' ' LEU . 2.4 mm? 65.36 83.39 0.17 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.967 0.413 . . . . 0.0 110.178 -179.749 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 100.03 -33.67 6.11 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.861 -0.685 . . . . 0.0 111.752 -179.218 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 2.7 m -82.98 -36.55 24.98 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.572 0.701 . . . . 0.0 109.575 178.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.611 HG23 ' HA2' ' A' ' 1' ' ' GLY . 8.2 t -76.68 -30.9 19.19 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.438 0 CA-C-N 114.701 -1.136 . . . . 0.0 110.521 179.526 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.454 ' CD2' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -41.78 -25.52 0.06 Allowed 'General case' 0 CA--C 1.528 0.128 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.72 -179.975 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.454 ' N ' ' CD2' ' A' ' 6' ' ' PHE . . . -65.34 -39.39 95.86 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.677 -0.773 . . . . 0.0 111.454 179.018 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.467 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.5 OUTLIER -80.01 -46.29 16.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.975 0.417 . . . . 0.0 110.058 179.209 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.47 ' O ' HG13 ' A' ' 12' ' ' ILE . 0.5 OUTLIER -52.52 -59.58 4.27 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.255 179.945 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.576 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -43.58 -24.66 0.12 Allowed 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 116.293 -0.412 . . . . 0.0 112.089 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.499 ' O ' ' HD2' ' A' ' 15' ' ' ARG . 0.4 OUTLIER -88.57 -45.93 9.49 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.051 -179.807 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.47 HG13 ' O ' ' A' ' 9' ' ' LEU . 1.1 pp -56.25 -35.82 44.03 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.212 0 C-N-CA 120.446 -0.501 . . . . 0.0 111.113 -179.662 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.576 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -64.22 -33.56 76.08 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 178.128 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.585 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -73.22 -14.35 79.15 Favored Glycine 0 N--CA 1.444 -0.779 0 C-N-CA 120.117 -1.04 . . . . 0.0 110.827 177.537 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.499 ' HD2' ' O ' ' A' ' 11' ' ' ARG . 0.6 OUTLIER -99.88 27.04 5.74 Favored 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 123.03 0.532 . . . . 0.0 110.401 179.493 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.547 ' O ' HD13 ' A' ' 17' ' ' ILE . 1.4 p -111.46 -48.89 6.28 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.926 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 179.824 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.547 HD13 ' O ' ' A' ' 16' ' ' VAL . 43.3 mm -150.38 82.85 6.16 Favored Pre-proline 0 N--CA 1.423 -1.783 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 174.395 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.585 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.9 Cg_endo -91.69 -178.93 1.21 Allowed 'Trans proline' 0 N--CA 1.425 -2.544 0 C-N-CA 125.211 3.94 . . . . 0.0 109.942 178.771 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.47 -28.65 69.81 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.102 -0.954 . . . . 0.0 111.068 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 18' ' ' PRO . 19.3 t . . . . . 0 C--O 1.249 1.035 0 CA-C-O 118.264 -0.875 . . . . 0.0 111.254 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.181 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.6 mt 69.69 -66.37 0.27 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.83 0.348 . . . . 0.0 110.642 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.419 ' O ' ' CD1' ' A' ' 6' ' ' PHE . . . -91.49 -24.26 26.6 Favored Glycine 0 N--CA 1.45 -0.418 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.292 179.578 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 1.8 m -83.01 -33.17 26.6 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.521 0.677 . . . . 0.0 109.659 179.019 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.528 HG12 HD12 ' A' ' 9' ' ' LEU . 6.3 t -80.39 -27.09 11.63 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.677 179.578 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.459 ' CD1' ' N ' ' A' ' 7' ' ' GLY . 0.1 OUTLIER -42.9 -25.29 0.09 Allowed 'General case' 0 C--O 1.231 0.12 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.519 179.828 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.459 ' N ' ' CD1' ' A' ' 6' ' ' PHE . . . -72.48 -37.46 58.46 Favored Glycine 0 N--CA 1.45 -0.41 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.651 179.372 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.476 ' N ' ' O ' ' A' ' 5' ' ' VAL . 0.0 OUTLIER -73.11 -59.76 2.56 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.649 0.262 . . . . 0.0 110.354 179.345 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.528 HD12 HG12 ' A' ' 5' ' ' VAL . 0.4 OUTLIER -48.08 -30.8 4.79 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 120.97 0.415 . . . . 0.0 110.875 179.638 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.586 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -49.96 -21.57 1.25 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.836 -0.62 . . . . 0.0 112.185 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.485 ' O ' ' N ' ' A' ' 15' ' ' ARG . 0.0 OUTLIER -88.98 -43.38 11.18 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 116.707 -0.224 . . . . 0.0 111.186 -179.417 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.477 ' N ' ' HG2' ' A' ' 11' ' ' ARG . 3.1 pt -54.27 -33.56 25.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 C-N-CA 120.475 -0.49 . . . . 0.0 111.085 -179.521 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.586 HD21 ' HA ' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -66.05 -28.55 68.93 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 177.908 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.63 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -94.78 -17.16 39.31 Favored Glycine 0 N--CA 1.444 -0.782 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.635 178.351 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.485 ' N ' ' O ' ' A' ' 11' ' ' ARG . 1.7 mpt_? -100.46 26.74 6.35 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 120.949 0.404 . . . . 0.0 110.809 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.615 ' O ' HD13 ' A' ' 17' ' ' ILE . 7.1 p -111.6 -49.84 6.16 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.082 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 179.789 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.615 HD13 ' O ' ' A' ' 16' ' ' VAL . 42.4 mm -150.2 83.23 6.13 Favored Pre-proline 0 N--CA 1.424 -1.754 0 N-CA-C 106.565 -1.642 . . . . 0.0 106.565 174.595 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.63 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 4.5 Cg_endo -91.32 -179.0 1.32 Allowed 'Trans proline' 0 N--CA 1.423 -2.659 0 C-N-CA 124.983 3.789 . . . . 0.0 109.777 178.768 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.58 -29.8 69.94 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 115.141 -0.936 . . . . 0.0 110.949 179.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 18.4 t . . . . . 0 C--O 1.249 1.03 0 CA-C-O 118.247 -0.882 . . . . 0.0 111.239 179.971 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.61 ' HA2' HG23 ' A' ' 5' ' ' VAL . . . . . . . . 0 N--CA 1.489 2.205 0 N-CA-C 112.49 -0.244 . . . . 0.0 112.49 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 4.2 mm? 62.49 86.15 0.12 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.856 0.36 . . . . 0.0 110.554 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 98.31 -33.76 5.76 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.776 -0.726 . . . . 0.0 111.925 -179.426 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 2.5 m -83.02 -36.88 24.63 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.576 0.703 . . . . 0.0 109.417 178.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.908 HG12 HD12 ' A' ' 9' ' ' LEU . 6.6 t -78.72 -31.49 15.39 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 114.689 -1.141 . . . . 0.0 110.644 179.53 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.458 ' CD1' ' N ' ' A' ' 7' ' ' GLY . 0.0 OUTLIER -42.47 -25.61 0.09 Allowed 'General case' 0 CA--C 1.528 0.102 0 CA-C-N 115.671 -0.695 . . . . 0.0 110.731 179.993 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . 0.458 ' N ' ' CD1' ' A' ' 6' ' ' PHE . . . -70.83 -38.58 65.72 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.768 -0.73 . . . . 0.0 111.587 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . 0.463 ' N ' ' O ' ' A' ' 5' ' ' VAL . 9.3 mmm180 -75.92 -52.52 10.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.857 0.36 . . . . 0.0 110.217 179.25 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.908 HD12 HG12 ' A' ' 5' ' ' VAL . 0.7 OUTLIER -50.1 -38.35 38.3 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.063 179.833 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.58 ' HA ' HD21 ' A' ' 13' ' ' LEU . . . -46.57 -21.53 0.19 Allowed 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 115.943 -0.571 . . . . 0.0 112.215 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.477 ' HG2' ' N ' ' A' ' 12' ' ' ILE . 0.0 OUTLIER -88.44 -43.77 11.22 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.877 -179.398 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.477 ' N ' ' HG2' ' A' ' 11' ' ' ARG . 2.7 pt -57.32 -32.3 40.59 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.178 0 C-N-CA 120.454 -0.498 . . . . 0.0 111.011 -179.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.658 ' O ' HG12 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -68.41 -28.03 66.73 Favored 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 178.188 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.605 ' O ' ' HG3' ' A' ' 18' ' ' PRO . . . -90.55 -15.01 57.63 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.435 -0.888 . . . . 0.0 111.07 177.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.455 ' HD3' ' CG ' ' A' ' 11' ' ' ARG . 0.7 OUTLIER -100.35 26.93 6.1 Favored 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 122.626 0.371 . . . . 0.0 110.938 179.841 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.658 HG12 ' O ' ' A' ' 13' ' ' LEU . 8.6 p -111.63 -48.92 6.21 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.015 0 N-CA-C 107.391 -1.337 . . . . 0.0 107.391 179.679 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.628 HD13 ' O ' ' A' ' 16' ' ' VAL . 39.7 mm -150.08 83.07 6.25 Favored Pre-proline 0 N--CA 1.425 -1.722 0 N-CA-C 106.522 -1.658 . . . . 0.0 106.522 174.579 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.605 ' HG3' ' O ' ' A' ' 14' ' ' GLY . 3.8 Cg_endo -91.56 -179.06 1.27 Allowed 'Trans proline' 0 N--CA 1.424 -2.612 0 C-N-CA 125.019 3.813 . . . . 0.0 109.961 178.838 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.435 ' HZ2' ' C ' ' A' ' 20' ' ' VAL . 0.0 OUTLIER -64.2 -29.26 70.38 Favored 'General case' 0 C--N 1.301 -1.535 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.943 179.912 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.442 HG23 ' O ' ' A' ' 18' ' ' PRO . 20.7 t . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.234 -0.889 . . . . 0.0 111.143 179.984 . . . . . . . . 1 1 . 1 stop_ save_